<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2102</journal-id><journal-id journal-id-type="pmc-domain">pharmaceuticals</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10383774</article-id><article-id pub-id-type="pmcid-ver">PMC10383774.1</article-id><article-id pub-id-type="pmcaid">10383774</article-id><article-id pub-id-type="pmcaiid">10383774</article-id><article-id pub-id-type="pmid">37513965</article-id><article-id pub-id-type="doi">10.3390/ph16071054</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-16-01054</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Lekshmy</surname><given-names initials="M">Manju</given-names></name><xref rid="af1-pharmaceuticals-16-01054" ref-type="aff">1</xref><xref rid="fn1-pharmaceuticals-16-01054" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5197-0697</contrib-id><name name-style="western"><surname>Dhanya</surname><given-names initials="CR">Chandrasekharan Rajalekshmi</given-names></name><xref rid="af2-pharmaceuticals-16-01054" ref-type="aff">2</xref><xref rid="fn1-pharmaceuticals-16-01054" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-1217-947X</contrib-id><name name-style="western"><surname>Smrithi</surname><given-names initials="JS">Jayashree SatheeshKumar</given-names></name><xref rid="af3-pharmaceuticals-16-01054" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sindhurani</surname><given-names initials="JA">Janaki Anandavallyamma</given-names></name><xref rid="af4-pharmaceuticals-16-01054" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vandanamthadathil</surname><given-names initials="JJ">Jiji Joseph</given-names></name><xref rid="af5-pharmaceuticals-16-01054" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Veettil</surname><given-names initials="JT">Jayakrishnan Therthala</given-names></name><xref rid="af5-pharmaceuticals-16-01054" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8781-4581</contrib-id><name name-style="western"><surname>Anila</surname><given-names initials="L">Leelamma</given-names></name><xref rid="af4-pharmaceuticals-16-01054" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lathakumari</surname><given-names initials="VS">Vishnu Sasidharan</given-names></name><xref rid="af6-pharmaceuticals-16-01054" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nayar</surname><given-names initials="AM">Adhira M.</given-names></name><xref rid="af7-pharmaceuticals-16-01054" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4991-6899</contrib-id><name name-style="western"><surname>Madhavan</surname><given-names initials="M">Maya</given-names></name><xref rid="af8-pharmaceuticals-16-01054" ref-type="aff">8</xref><xref rid="c1-pharmaceuticals-16-01054" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Diamond</surname><given-names initials="G">Gill</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Zaccaro</surname><given-names initials="L">Laura</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Del Gatto</surname><given-names initials="A">Annarita</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Maayan</surname><given-names initials="G">Galia</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-16-01054"><label>1</label>Department of Botany and Biotechnology, St. Xavier&#8217;s College, Thumba, Thiruvananthapuram 695586, Kerala, India; <email>drlmanjuakathalam@gmail.com</email></aff><aff id="af2-pharmaceuticals-16-01054"><label>2</label>Department of Biochemistry, Government College Kariavattom, Thiruvananthapuram 695581, Kerala, India; <email>dhanyasbabu@gmail.com</email></aff><aff id="af3-pharmaceuticals-16-01054"><label>3</label>TATA Translational Cancer Research Centre, Tata Medical Centre, Kolkata 700156, West Bengal, India; <email>smrithi.js@ttcrc.tmckolkata.org</email> (J.S.S.); </aff><aff id="af4-pharmaceuticals-16-01054"><label>4</label>Department of Biochemistry, NSS College, Nilamel, Kollam 691535, Kerala, India; <email>sindhurani77@gmail.com</email></aff><aff id="af5-pharmaceuticals-16-01054"><label>5</label>Department of Zoology, Government Brennen College, Thalassery 670106, Kerala, India; <email>jijijoseph@brennencollege.ac.in</email> (J.J.V.); <email>jkbrennen@brennencollege.ac.in</email> (J.T.V.)</aff><aff id="af6-pharmaceuticals-16-01054"><label>6</label>Department of Biochemistry and Industrial Microbiology, Sree Narayana College for Women, Kollam 691001, Kerala, India; <email>vishnusncw@gmail.com</email></aff><aff id="af7-pharmaceuticals-16-01054"><label>7</label>Department of Zoology, Mahatma Gandhi College, Thiruvananthapuram 695004, Kerala, India; <email>adhira.m.nayar@mgcollegetvm.org</email></aff><aff id="af8-pharmaceuticals-16-01054"><label>8</label>Department of Biochemistry, Government College for Women, Thiruvananthapuram 695014, Kerala, India</aff><author-notes><corresp id="c1-pharmaceuticals-16-01054"><label>*</label>Correspondence: <email>drmayamadhavan@gmail.com</email></corresp><fn id="fn1-pharmaceuticals-16-01054"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>7</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2023</year></pub-date><volume>16</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">441862</issue-id><elocation-id>1054</elocation-id><history><date date-type="received"><day>10</day><month>4</month><year>2023</year></date><date date-type="rev-recd"><day>11</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>16</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>07</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>30</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-28 17:25:50.757"><day>28</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceuticals-16-01054.pdf"/><abstract><p>Breast and gynecologic cancers are significant global threats to women&#8217;s health and those living with the disease require lifelong physical, financial, and social support from their families, healthcare providers, and society as a whole. Cancer vaccines offer a promising means of inducing long-lasting immune response against the disease. Among various types of cancer vaccines available, peptide vaccines offer an effective strategy to elicit specific anti-tumor immune responses. Peptide vaccines have been developed based on tumor associated antigens (TAAs) and tumor specific neoantigens which can also be of viral origin. Molecular alterations in HER2 and non-HER2 genes are established to be involved in the pathogenesis of female-specific cancers and hence were exploited for the development of peptide vaccines against these diseases, most of which are in the latter stages of clinical trials. However, prophylactic vaccines for viral induced cancers, especially those against Human Papillomavirus (HPV) infection are well established. This review discusses therapeutic and prophylactic approaches for various types of female-specific cancers such as breast cancer and gynecologic cancers with special emphasis on peptide vaccines. We also present a pipeline for the design and evaluation of a multiepitope peptide vaccine that can be active against female-specific cancers.</p></abstract><kwd-group><kwd>female-specific cancers</kwd><kwd>peptide vaccine</kwd><kwd>HER2</kwd><kwd>non-HER2</kwd><kwd>HPV vaccine</kwd><kwd>prophylactic cancer vaccine</kwd><kwd>therapeutic cancer vaccine</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-16-01054"><title>1. Introduction</title><p>For many years, the gold standard in cancer treatment is conventional methods like radiation therapy, chemotherapy, and surgery [<xref rid="B1-pharmaceuticals-16-01054" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceuticals-16-01054" ref-type="bibr">2</xref>]. Consistent scientific effort has resulted in the development of a number of alternative potential treatment strategies to circumvent the therapeutic limitations of the current conventional methods [<xref rid="B2-pharmaceuticals-16-01054" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceuticals-16-01054" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-16-01054" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceuticals-16-01054" ref-type="bibr">5</xref>]. Cancer cells are unique in their ability to bypass the immune system for their survival [<xref rid="B6-pharmaceuticals-16-01054" ref-type="bibr">6</xref>]. Activating the immune system to recognize and tackle tumors is a potentially effective therapeutic strategy against cancer. Several immunotherapeutic modalities for cancer include monoclonal antibody therapy [<xref rid="B7-pharmaceuticals-16-01054" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceuticals-16-01054" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceuticals-16-01054" ref-type="bibr">9</xref>] immune checkpoint blockade (ICB) [<xref rid="B10-pharmaceuticals-16-01054" ref-type="bibr">10</xref>], chimeric antigen receptor (CAR) T cell therapy [<xref rid="B11-pharmaceuticals-16-01054" ref-type="bibr">11</xref>], oncolytic viral therapy [<xref rid="B12-pharmaceuticals-16-01054" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceuticals-16-01054" ref-type="bibr">13</xref>] natural killer (NK) cell therapy [<xref rid="B14-pharmaceuticals-16-01054" ref-type="bibr">14</xref>] and cancer vaccines [<xref rid="B13-pharmaceuticals-16-01054" ref-type="bibr">13</xref>,<xref rid="B15-pharmaceuticals-16-01054" ref-type="bibr">15</xref>]. Even though various immunotherapeutic approaches are available, cancer vaccines offer a promising method of inducing long-term immune response against cancer [<xref rid="B16-pharmaceuticals-16-01054" ref-type="bibr">16</xref>]. Among the various cancer vaccines available, peptide vaccines offer a promising strategy to elicit specific anti-tumor immune responses. This review focuses on immunotherapy, with special reference to peptide vaccines as therapeutic and prophylactic agents for treating cancers in women.</p></sec><sec id="sec2-pharmaceuticals-16-01054"><title>2. Female-Specific Cancers</title><p>The influence of cancer and its outcome on women needs special attention since it impacts the economic, emotional and social well-being of an individual extending to the society. Moreover, the enormous global discrepancies in female cancer survival make female-specific cancers a major public health concern [<xref rid="B17-pharmaceuticals-16-01054" ref-type="bibr">17</xref>]. A brief summary of the various aspects of female- specific cancers is depicted in <xref rid="pharmaceuticals-16-01054-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec3-pharmaceuticals-16-01054"><title>3. Cancer Vaccines</title><p>Advances in bioengineering and material science have helped the development of different types of cancer vaccines which can arrest tumor progression and prevent recurrence [<xref rid="B32-pharmaceuticals-16-01054" ref-type="bibr">32</xref>]. An efficient cancer vaccine should ideally be able to reinforce the body&#8217;s natural defenses against cancer by eliciting potent CD4+ and CD8+ T effector and memory response [<xref rid="B12-pharmaceuticals-16-01054" ref-type="bibr">12</xref>]. Cancer vaccines come in a variety of forms which include cell-based vaccines/whole tumor cells [<xref rid="B33-pharmaceuticals-16-01054" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceuticals-16-01054" ref-type="bibr">34</xref>], viral/bacterial-based vaccines [<xref rid="B34-pharmaceuticals-16-01054" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceuticals-16-01054" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceuticals-16-01054" ref-type="bibr">36</xref>], gene-based vaccines [<xref rid="B13-pharmaceuticals-16-01054" ref-type="bibr">13</xref>,<xref rid="B34-pharmaceuticals-16-01054" ref-type="bibr">34</xref>,<xref rid="B37-pharmaceuticals-16-01054" ref-type="bibr">37</xref>], and protein/peptide vaccines [<xref rid="B34-pharmaceuticals-16-01054" ref-type="bibr">34</xref>,<xref rid="B38-pharmaceuticals-16-01054" ref-type="bibr">38</xref>].</p><p>Cancer vaccines stimulate both cellular and humoral immune response by utilizing tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs), thus preventing tumor growth and killing tumor cells [<xref rid="B39-pharmaceuticals-16-01054" ref-type="bibr">39</xref>]. Traditional vaccine preparations that target TAAs are having low immunogenic capacity and risk of toxicity to normal cells [<xref rid="B40-pharmaceuticals-16-01054" ref-type="bibr">40</xref>]. TSAs or neoantigens, on the other hand, are only expressed by cancer cells and elicit strong immune responses because of the lack of immunological tolerance [<xref rid="B41-pharmaceuticals-16-01054" ref-type="bibr">41</xref>]. TSAs are highly specific and are used in the production and design of personalized vaccines [<xref rid="B40-pharmaceuticals-16-01054" ref-type="bibr">40</xref>]. The possibilities of various approaches in cancer vaccines with potential against female-specific cancers are summarized in <xref rid="pharmaceuticals-16-01054-f001" ref-type="fig">Figure 1</xref>.</p><p>Vaccines based on peptides have an advantage over other forms of therapy. Metastatic cancers that have spread to various parts of the body can be treated with peptide vaccines, and they are nontoxic compared to other treatment strategies [<xref rid="B42-pharmaceuticals-16-01054" ref-type="bibr">42</xref>]. Unlike other immunotherapeutic techniques like CAR T cell therapy which targets a cell surface antigen, peptide vaccines are using multiple epitopes positioned outside or inside of tumor cells [<xref rid="B43-pharmaceuticals-16-01054" ref-type="bibr">43</xref>]. By developing a peptide vaccine devoid of B cell epitopes, the risk of hypersensitivity could be avoided, and highly heterogeneous tumors could be effectively targeted by peptide-based vaccines [<xref rid="B44-pharmaceuticals-16-01054" ref-type="bibr">44</xref>]. Though the role of B cell epitopes in cancer vaccine design is underappreciated, recent investigations reveal the significance of multiepitope vaccines encompassing B cell epitopes along with T helper and cytotoxic T lymphocyte (CTL) epitopes in prophylaxis and therapy of cancer [<xref rid="B45-pharmaceuticals-16-01054" ref-type="bibr">45</xref>].</p></sec><sec id="sec4-pharmaceuticals-16-01054"><title>4. Peptide Vaccines</title><p>Peptide vaccines are composed of synthetic peptides which are highly immunogenic and elicit desired and specific adaptive immune response [<xref rid="B46-pharmaceuticals-16-01054" ref-type="bibr">46</xref>]. They come in a variety of forms, including multivalent long peptide vaccines, multi-peptide vaccines containing CTL and T helper-epitopes, peptide cocktail vaccines, hybrid peptide vaccines, personalized peptide vaccines, and peptide-pulsed dendritic cell vaccines [<xref rid="B47-pharmaceuticals-16-01054" ref-type="bibr">47</xref>]. The efficacy of peptide vaccines are widely studied against neurodegenerative diseases [<xref rid="B48-pharmaceuticals-16-01054" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceuticals-16-01054" ref-type="bibr">49</xref>], infectious diseases [<xref rid="B50-pharmaceuticals-16-01054" ref-type="bibr">50</xref>] like human immunodeficiency virus (HIV) [<xref rid="B51-pharmaceuticals-16-01054" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceuticals-16-01054" ref-type="bibr">52</xref>], hepatitis C virus [<xref rid="B53-pharmaceuticals-16-01054" ref-type="bibr">53</xref>], tuberculosis [<xref rid="B54-pharmaceuticals-16-01054" ref-type="bibr">54</xref>], foot and mouth disease [<xref rid="B55-pharmaceuticals-16-01054" ref-type="bibr">55</xref>], cancer [<xref rid="B6-pharmaceuticals-16-01054" ref-type="bibr">6</xref>], etc. The general aspects of peptide vaccines in the context of cancer therapy are summarized in <xref rid="pharmaceuticals-16-01054-f002" ref-type="fig">Figure 2</xref>.</p><p>The differential expression of TAAs and TSAs on normal cells and cancer cells are made use of in designing peptide-based cancer vaccines [<xref rid="B6-pharmaceuticals-16-01054" ref-type="bibr">6</xref>,<xref rid="B42-pharmaceuticals-16-01054" ref-type="bibr">42</xref>,<xref rid="B56-pharmaceuticals-16-01054" ref-type="bibr">56</xref>]. Synthetic long peptides (SLPs) consist of 25&#8211;35 amino acids that are derived from TAAs or TSAs from a major type of peptide-based cancer vaccines [<xref rid="B57-pharmaceuticals-16-01054" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceuticals-16-01054" ref-type="bibr">58</xref>]. Cancer vaccination trials with SLPs demonstrated inhibition of growth of transplanted tumors in mice [<xref rid="B59-pharmaceuticals-16-01054" ref-type="bibr">59</xref>]. Survivin-based vaccine, composed of a pool of three SLPs with eight CD4+ epitopes and six CD8+ epitopes, has shown to activate both CD4+ and CD8+ immune responses in mouse models for colorectal cancer. Fusion proteins made by combining Xcl1 with Ovalbumin SLP antigen and IgG1 Fc fragment were shown to elicit specific T cell response and sustained tumor control against the poorly immunogenic B16-OVA melanoma tumor [<xref rid="B60-pharmaceuticals-16-01054" ref-type="bibr">60</xref>].</p><p>Short peptides composed of 8&#8211;10 amino acids utilize Class I major histocompatibility complex (MHC) receptors and initiate CD8+ T cell response. Cancer neoepitope vaccine, based on MHC1 restricted short peptide, Nes2LR was reported to induce functional CD8+ T cell responses and prevent tumor growth in murine renal carcinoma model [<xref rid="B61-pharmaceuticals-16-01054" ref-type="bibr">61</xref>]</p><p>Recombinant overlapping peptides (ROPs) developed as a design strategy for peptide vaccines consist of a single-chain polypeptide with multiple epitopes. They can produce strong immunogenic responses in CD4+ and CD8+ T cells [<xref rid="B62-pharmaceuticals-16-01054" ref-type="bibr">62</xref>]. Immunoinformatics approaches were utilized to construct a multi-epitope peptide vaccine against breast cancer using immunogenic regions of the BORIS cancer-testis antigen containing multiple CTL epitopes. The selected regions were linked together by GPGPG linker followed by incorporation of T helper epitopes and the toll-like receptor (TLR)-4/MD-2 agonist. The resulting vaccine was reverse translated and then inserted into pcDNA3.1 to form the DNA vaccine [<xref rid="B63-pharmaceuticals-16-01054" ref-type="bibr">63</xref>]. Further investigations were carried out which revealed that co immunization of the multiepitope peptide vaccine and the resultant DNA vaccine significantly inhibited the growth of breast tumors, decreased tumor weight, inhibited metastasis, and enhanced survival time in murine mammary carcinoma [<xref rid="B64-pharmaceuticals-16-01054" ref-type="bibr">64</xref>].</p></sec><sec id="sec5-pharmaceuticals-16-01054"><title>5. Peptide Vaccines Developed for Female-Specific Cancers</title><sec id="sec5dot1-pharmaceuticals-16-01054"><title>5.1. Based on Genes Involved in Pathogenesis of Cancer</title><p>Accumulation of genetic and epigenetic alterations is well established to be involved in the process of carcinogenesis. The molecular alterations involved in pathogenesis of cancer include gene amplification, gene fusion, mutation and overexpression. Multiple studies have investigated the association of breast and gynecologic malignancies with overexpression and/or amplification of HER2 [<xref rid="B65-pharmaceuticals-16-01054" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceuticals-16-01054" ref-type="bibr">66</xref>,<xref rid="B67-pharmaceuticals-16-01054" ref-type="bibr">67</xref>,<xref rid="B68-pharmaceuticals-16-01054" ref-type="bibr">68</xref>,<xref rid="B69-pharmaceuticals-16-01054" ref-type="bibr">69</xref>,<xref rid="B70-pharmaceuticals-16-01054" ref-type="bibr">70</xref>,<xref rid="B71-pharmaceuticals-16-01054" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceuticals-16-01054" ref-type="bibr">72</xref>,<xref rid="B73-pharmaceuticals-16-01054" ref-type="bibr">73</xref>], as well as non-HER2 genes such as BRCA1/BRCA2, CHEK2, PTEN, MUCI, Tp53, MAGE, etc. [<xref rid="B23-pharmaceuticals-16-01054" ref-type="bibr">23</xref>,<xref rid="B74-pharmaceuticals-16-01054" ref-type="bibr">74</xref>,<xref rid="B75-pharmaceuticals-16-01054" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceuticals-16-01054" ref-type="bibr">76</xref>,<xref rid="B77-pharmaceuticals-16-01054" ref-type="bibr">77</xref>,<xref rid="B78-pharmaceuticals-16-01054" ref-type="bibr">78</xref>,<xref rid="B79-pharmaceuticals-16-01054" ref-type="bibr">79</xref>,<xref rid="B80-pharmaceuticals-16-01054" ref-type="bibr">80</xref>]. The alterations identified in these genes are used successfully to design peptide vaccines with therapeutic efficiency against female-specific cancers.</p><sec id="sec5dot1dot1-pharmaceuticals-16-01054"><title>5.1.1. HER2 Based Peptide Vaccines for Female-Specific Cancers</title><p>HER2 is a receptor tyrosine kinase which is found to be involved in cell proliferation and survival [<xref rid="B72-pharmaceuticals-16-01054" ref-type="bibr">72</xref>]. Several HER2 derived peptide vaccines have been designed and are in the latter stages of clinical trials. B cell or T cell peptide-based vaccines, liposome-based vaccines with B cell peptides, and mature dendritic cells (DCs) loaded with TAA/TSA are a few of the diverse approaches employed [<xref rid="B81-pharmaceuticals-16-01054" ref-type="bibr">81</xref>].</p><p>HER2, a well-studied TAA is validated as a therapeutic target in breast cancer for the development of therapeutic vaccines. The present status of development of vaccines for breast cancer based on HER2 is summarized in <xref rid="pharmaceuticals-16-01054-t002" ref-type="table">Table 2</xref>.</p><p>Systematic review and meta-analysis were carried out to investigate the outcomes of HER2 based peptide vaccines in breast cancer. Both Chamani et al. [<xref rid="B91-pharmaceuticals-16-01054" ref-type="bibr">91</xref>] and You et al. [<xref rid="B92-pharmaceuticals-16-01054" ref-type="bibr">92</xref>] have reported that E75 vaccine is effective and safe in breast cancer while You et al. reported that GP2 vaccine elicited a strong immune response [<xref rid="B92-pharmaceuticals-16-01054" ref-type="bibr">92</xref>].</p><p>Overexpression, gene amplification and gene mutation of HER2 has been found to occur in patients with gynecologic malignancies with possible therapeutic implications [<xref rid="B93-pharmaceuticals-16-01054" ref-type="bibr">93</xref>]. In one of the earlier studies, intradermal immunization with a peptide vaccine based on HER2/neu combined with granulocyte macrophage colony stimulating factor (GM-CSF) as an adjuvant induced CD4+ T helper-specific immunological response in patients with breast and ovarian cancer. Patients produced HER2 specific T cell responses which could migrate out of the peripheral circulation [<xref rid="B94-pharmaceuticals-16-01054" ref-type="bibr">94</xref>].</p><p>Autologous DCs pulsed with HER2/neu or MUC1-derived peptides can effectively induce antigen-specific T cells in patients with advanced breast and ovarian cancer. The immunizations were shown to be well tolerated with no side effects in a pilot study involving 10 participants. MUC1 peptide specific T cells were found in patients vaccinated with HER2/new-derived peptides [<xref rid="B95-pharmaceuticals-16-01054" ref-type="bibr">95</xref>]. The uptake of tumor cells by DCs that are involved in cross-priming [<xref rid="B96-pharmaceuticals-16-01054" ref-type="bibr">96</xref>] and induction of other tumor antigen-specific CTLs could be the possible mechanism for this observation.</p><p>HER2/neu-specific antibody immunity was assessed in 35 patients with breast and ovarian cancer after immunization with HER2 based-peptides and successful immune response was recorded in majority of the patients. Moreover, epitope spreading to p53 was observed in 20% of the vaccinated patients [<xref rid="B82-pharmaceuticals-16-01054" ref-type="bibr">82</xref>]<sup>.</sup></p><p>Monthly vaccination of 6 breast/ovarian cancer patients having HER2/neu-overexpressing tumors with HER2/neu-derived HLA-A2-peptide and GM-CSF as adjuvant, for six months was found to induce interferon-gamma (IFN-&#947;) secreting CD8+ T lymphocytes targeting HER2/neu. The minimal and transient nature of immune responses necessitated the need for CD4+ T cell support to maintain immunization [<xref rid="B97-pharmaceuticals-16-01054" ref-type="bibr">97</xref>].</p><p>In a Phase 1 study, 9 participants with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma were administered with 5 class I MHC-restricted synthetic peptides derived from multiple ovarian cancer-associated proteins, as well as a class II MHC-restricted synthetic helper peptide derived from tetanus toxoid protein. All of the peptides used were immunogenic, including HER2/neu 754&#8211;762 peptide which stimulated CD8+ T cell responses. Authors suggested that the low potency of immunogenicity in ovarian cancers requires additional immunomodulation [<xref rid="B98-pharmaceuticals-16-01054" ref-type="bibr">98</xref>].</p></sec><sec id="sec5dot1dot2-pharmaceuticals-16-01054"><title>5.1.2. Non-HER2 Based Peptide Vaccines for Female-Specific Cancers</title><p>Genes other than HER2 are also established to have a role in the pathogenesis of breast and gynecologic cancers. Mutations in MSH6, CHEK2, BRCA1, BRCA2, ATM, PMS2, PALB2, and MSH2 were found to occur more frequently than in any other gene in the analysis of breast and uterine cancer patients. The frequency of BRCA1, MLH1, MSH2, MSH6, PMS2, and PTEN mutations was higher in breast and uterine cancer than in breast cancer, whereas the frequency of ATM mutations was higher in breast and uterine cancer than in uterine cancer alone [<xref rid="B99-pharmaceuticals-16-01054" ref-type="bibr">99</xref>]. In 90% of mucinous ovarian carcinomas, KRAS, BRAF, and/or ERRB2 gene amplifications are present, demonstrating the therapeutic potency of RAS/MEK pathway in this subtype [<xref rid="B100-pharmaceuticals-16-01054" ref-type="bibr">100</xref>]. <xref rid="pharmaceuticals-16-01054-t003" ref-type="table">Table 3</xref> describes the state-of-the-art progress in the development of peptide vaccines designed against non-HER2 genes for female-specific cancers.</p></sec></sec><sec id="sec5dot2-pharmaceuticals-16-01054"><title>5.2. Based on Viruses Involved in Pathogenesis of Female-Specific Cancers</title><p>Viruses are known to interact with host factors creating a tumor microenvironment (TME) that facilitates tumorigenesis [<xref rid="B121-pharmaceuticals-16-01054" ref-type="bibr">121</xref>]. Viruses are a possible cause of 15% of all human cancers, which is a sizable proportion of the worldwide cancer burden [<xref rid="B122-pharmaceuticals-16-01054" ref-type="bibr">122</xref>]. Human papilloma virus (HPV), Epstein-Barr virus (EBV), Mouse mammary tumor virus (MMTV) and Bovine leukemia virus (BLV) are known to be involved in the pathogenesis of female-specific cancers including breast and gynecologic cancers [<xref rid="B123-pharmaceuticals-16-01054" ref-type="bibr">123</xref>].</p><sec id="sec5dot2dot1-pharmaceuticals-16-01054"><title>5.2.1. Human Papilloma Virus (HPV)</title><p>HPV is a double-stranded, circular DNA [<xref rid="B124-pharmaceuticals-16-01054" ref-type="bibr">124</xref>] and the most prevalent sexually transmitted virus. High-risk HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) are the leading causes of genital tract cancers, including cervical, vulvar, vaginal, penile, and anal cancers, and a subset of head and neck cancers [<xref rid="B125-pharmaceuticals-16-01054" ref-type="bibr">125</xref>]. Subtypes 16, 18, and 33 are associated with 29% of breast cancer. [<xref rid="B126-pharmaceuticals-16-01054" ref-type="bibr">126</xref>] Two viral proteins, E6 and E7, are critical in initiating oncogenesis in infected cells, resulting in unregulated proliferation, unrestrained telomerase activity, and ultimately, cervical cancer progression [<xref rid="B127-pharmaceuticals-16-01054" ref-type="bibr">127</xref>]. HPV oncoproteins E6 can inactivate tumor suppressor protein p53 and E7 can inactivate pRb [<xref rid="B128-pharmaceuticals-16-01054" ref-type="bibr">128</xref>] which leads to the development of cancer.</p><p>The discovery of the etiologic involvement of HPV in the development and progression of cancers, mainly cervical cancer, has led to intensive research on prophylactic strategies. Currently available prophylactic vaccines exploit the ability of HPV capsid protein L1 to form virus-like particles (VLP) which are similar to native virions [<xref rid="B129-pharmaceuticals-16-01054" ref-type="bibr">129</xref>]. They induce the production of neutralizing antibodies that bind to viral particles and block their entry into host cells and effectively prevent HPV infections [<xref rid="B130-pharmaceuticals-16-01054" ref-type="bibr">130</xref>]. VLPs lack a viral genome and are neither infectious nor carcinogenic. In addition, they can provoke a robust humoral immune response with high and persistent neutralizing antibodies [<xref rid="B131-pharmaceuticals-16-01054" ref-type="bibr">131</xref>].</p><p>Three prophylactic peptide vaccines are commercially available against HPV infection, all of them based on L1 VLP. They are Gardasil<sup>&#174;</sup>4, a quadrivalent vaccine [<xref rid="B132-pharmaceuticals-16-01054" ref-type="bibr">132</xref>], Cervarix&#8482;, a bivalent vaccine [<xref rid="B133-pharmaceuticals-16-01054" ref-type="bibr">133</xref>] and Gardasil<sup>&#174;</sup>9, a nonavalent vaccine [<xref rid="B133-pharmaceuticals-16-01054" ref-type="bibr">133</xref>]. These prophylactic vaccines induce strong immune responses and produce high titer of antibodies [<xref rid="B134-pharmaceuticals-16-01054" ref-type="bibr">134</xref>]. HPV prophylactic vaccine is an ineffective treatment for an already infected person [<xref rid="B135-pharmaceuticals-16-01054" ref-type="bibr">135</xref>], but they can protect up to 100% of females between the ages of 9 and 26 from cervical cancer caused by HPV [<xref rid="B136-pharmaceuticals-16-01054" ref-type="bibr">136</xref>]. <xref rid="pharmaceuticals-16-01054-t004" ref-type="table">Table 4</xref> enlists the currently available prophylactic peptide vaccines that could offer protection against HPV infection.</p><p>The clinical success of therapeutic cancer vaccines is very low due to the immunosuppressive nature of the TME. So, administration of cancer vaccine as a prophylactic measure in individuals at high risk of cancer or premalignant conditions will enhance the clinical efficacy [<xref rid="B152-pharmaceuticals-16-01054" ref-type="bibr">152</xref>].</p><p>Therapeutic vaccines for HPV are of four major categories such as live vector-based vaccines, peptide and protein-based vaccines, nucleic acid-based vaccines and whole cell vaccines [<xref rid="B153-pharmaceuticals-16-01054" ref-type="bibr">153</xref>]. peptide-based antigens are being extensively explored in the design of therapeutic vaccines against HPV infection.</p><p>In one of the initial studies, the impact of HPV16 E6 and E7 SLP vaccination on antigen-specific T cell response in cervical cancer patients was studied by Welters M J P et al. Patients were vaccinated with overlapping long peptides emulsified in Montanide ISA-51. Both CD4+ and CD8+ T cell responses to HPV16 E6 and E7 were observed [<xref rid="B154-pharmaceuticals-16-01054" ref-type="bibr">154</xref>].</p><p>In another study, women with HPV16 positive grade 3 vulvar intraepithelial neoplasia vaccinated with long peptides from the HPV16 viral oncoproteins E6 and E7 in incomplete Freund&#8217;s adjuvant showed strong interferon-&#947;&#8211;associated proliferative CD4+ T cell response and a broad response of CD8+ interferon-&#947; T cells. Positive outcomes appear to be linked to the activation of HPV16 specific immunity [<xref rid="B155-pharmaceuticals-16-01054" ref-type="bibr">155</xref>]. Studies indicated that mHSP110, a chaperone immunoadjuvant, enhanced the immune response to peptide vaccine based on HPV16 oncoprotein E7 derived CTL epitope E7 (49&#8211;57), inhibited tumor growth and prolonged survival time in mouse models for cervical cancer [<xref rid="B156-pharmaceuticals-16-01054" ref-type="bibr">156</xref>].</p><p>Cornelis et al. have reported that 20 women with high-grade vulvar intraepithelial neoplasia on receiving a synthetic peptide vaccine composed of 13 overlapping peptides with incomplete Freund adjuvant (mineral oil-based, Montanide ISA-51). In 9 individuals, the long-peptide vaccine completely regressed all lesions and eradicated HPV16. Clinical response was strongly linked with vaccine-induced T cell response [<xref rid="B157-pharmaceuticals-16-01054" ref-type="bibr">157</xref>,<xref rid="B158-pharmaceuticals-16-01054" ref-type="bibr">158</xref>].</p><p>A single administration of HPV vaccine having CpG oligodeoxynucleotides as an adjuvant and HPV16 E7 43&#8211;77 peptide as antigen was reported to elicit prophylactic and therapeutic effects on cervical cancer in mice models. Injection of vaccine increased cellular immunity mediated by CD4+ IFN-&#947;+ T cells and CD8+ IFN-&#947;+ T cells. Vaccine administration decreased numbers of immunosuppressive cells including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) [<xref rid="B159-pharmaceuticals-16-01054" ref-type="bibr">159</xref>]. Further studies were carried out with modified formulation of the vaccine in TC-1 grafted tumor. Subcutaneous injection of mannose-modified DCs-targeting liposomes loaded with HPV16 E7 peptide and CpG ODN vaccine stimulated powerful E7 specific CTL response and elevated the percentage of CD4+ T cells, CD8+ T cells and IFN-&#947; producing cells. Expression of IL-12, IFN-&#947;, TNF-&#945;, and IL-2 were significantly increased, while those of IL-4 and TGF-&#946; significantly decreased [<xref rid="B160-pharmaceuticals-16-01054" ref-type="bibr">160</xref>].</p><p>HPV16 E6/E7 synthetic overlapping long peptide vaccine was investigated for its therapeutic effect in high-grade cervical squamous intraepithelial lesions and was found to increase HPV16 specific T cell immunity which lasted up to one year [<xref rid="B161-pharmaceuticals-16-01054" ref-type="bibr">161</xref>] HPV16 SLP vaccination combined with Carboplatin and Paclitaxel chemotherapy was found to induce robust T cell response in a mouse tumor model and in patients with advanced cervical cancer [<xref rid="B162-pharmaceuticals-16-01054" ref-type="bibr">162</xref>]. Tri-therapy where HPV16 E7 SLP was administered, combined with Carboplatin/Paclitaxel followed by TLR9 agonist CpG resulted in regression of genital HPV16 tumors [<xref rid="B163-pharmaceuticals-16-01054" ref-type="bibr">163</xref>]. In 77 patients with advanced, recurrent, or metastatic cervical cancer undergoing Carboplatin/Paclitaxel chemotherapy, administration of ISA101, an SLP vaccine containing HPV E6/E7 showed type 1 T cell response and prolonged survival [<xref rid="B164-pharmaceuticals-16-01054" ref-type="bibr">164</xref>]. In a Phase I/II clinical study, immune responses of ISA101 vaccine with or without Polyethylene Glycol (PEG)ylated IFN-&#945; as combination therapy with Carboplatin and Paclitaxel were evaluated. Enhanced tumor-specific immunity was observed and addition of PEGylated IFN-&#945; enhanced the immune response [<xref rid="B165-pharmaceuticals-16-01054" ref-type="bibr">165</xref>].</p><p>A therapeutic vaccine for HPV called Pepcan (HPV16 E6 peptides combined with Candida skin testing reagent called Candin) was administered intradermally in 31 patients with high-grade squamous intraepithelial lesions and was reported to decrease the viral load in nine of the patients [<xref rid="B166-pharmaceuticals-16-01054" ref-type="bibr">166</xref>]. The Phase II clinical trial of Pepcan to the two treatment arms- Pepcan and Candin, in 99 patients with cervical high grade squamous intra-epitheial lesions was recently completed [<xref rid="B167-pharmaceuticals-16-01054" ref-type="bibr">167</xref>].</p><p>A bivalent therapeutic vaccine against HPV16/18 genotypes composed of a fusion protein containing the extra domain A of human fibronectin and HPV16/18 E7 viral antigens was developed by Arribillaga L et al. The vaccine induced E7-specific CTL response and eradicated pre-existing tumors [<xref rid="B168-pharmaceuticals-16-01054" ref-type="bibr">168</xref>]. Promising results have arrived from a Phase I clinical trial using the novel therapeutic vaccine, Hespecta (HPV E6 Peptide conjugated to Amplivant<sup>&#174;</sup>) which showed a T cell specific immune response [<xref rid="B169-pharmaceuticals-16-01054" ref-type="bibr">169</xref>].</p><p>HPV16 E5 has also been proven to be a promising target for cervical cancer therapy. Administration of E5 peptide-based on epitopes predicted by immunoinformatics in combination with CpG has induced strong cell-mediated immunity, decreased tumor volume and increased survival time in mice models [<xref rid="B170-pharmaceuticals-16-01054" ref-type="bibr">170</xref>].</p><p>Administration of different immunodominant epitopes of HPV in combination was found to elicit increased immune response. Studies report induction of Th1 immune response and high Granzyme B secretion which indicates CTL activity in mice receiving E7 and E5 peptides together when compared to those receiving the peptides individually [<xref rid="B171-pharmaceuticals-16-01054" ref-type="bibr">171</xref>].</p><p>A multiepitope vaccine consisting of linked segments of E5, E6 and E7 peptides (E765m) was developed and inserted into the major immune dominant region (MIR) of hepatitis B virus core antigen (HBc) to form HBc-E765m chimeric virus-like particles (cVLPs). E5-TC-1 tumor-bearing mice immunized with cVLPs elicited high E5-, E6- and E7- specific CTLs, IgG antibody responses and increased levels of IFN-&#947;, IL-4 and IL-5. Tumor growth was also suppressed, which indicated that the novel vaccine provides a promising platform for immunotherapy in HPV16-associated cervical intraepithelial neoplasia [<xref rid="B172-pharmaceuticals-16-01054" ref-type="bibr">172</xref>]. An SLP vaccine containing HPV16 E7 antigen in combination with TLR9 agonist CpG formulated in an oil-in-water emulsion was found to inhibit tumor growth and induce robust CD8+ T cell response in TC-1 murine model [<xref rid="B173-pharmaceuticals-16-01054" ref-type="bibr">173</xref>].</p><p>Strategies using nanoparticles have been employed for the design of therapeutic peptide vaccines against HPV infection. Tat-E7/pGM-CSF nanoparticles are a promising new strategy for boosting the efficacy of peptide-based cervical cancer vaccinations. The HIV-1 Tat cell-penetrating peptide was fused with the HPV16 E7 CTL epitope and GM-CSF. In prophylactic and therapeutic mouse models, the vaccination resulted in lower tumor growth and improved long-term survival and higher frequency of CD8+ memory T cells [<xref rid="B174-pharmaceuticals-16-01054" ref-type="bibr">174</xref>]. In another study, Rahimian et al. used a double emulsion solvent evaporation technique to create polymeric nanoparticles (NPs) based on hydrophilic polyester loaded with an SLP derived from HPV16 E7 oncoprotein and a TLR3 ligand. There was a substantial increase in HPV specific CD8+ T cells when the HPV SLP antigen encapsulated in nanoparticles was administered. These biodegradable polymeric nanoparticles are an efficient alternative for adjuvant in cancer vaccinations since they cause no adverse reactions on administration [<xref rid="B175-pharmaceuticals-16-01054" ref-type="bibr">175</xref>].</p><p>A therapeutic HPV nanovaccine candidate was created by Zhang et al. using poly [<sc>d, l</sc>-lactic-co-glycolic acid] (PLGA), to encapsulate HPV-16 E744&#8211;62. Adenosine triphosphate (ATP) was added to the design as a novel adjuvant element. The PLGA encapsulation improved antigen presentation to antigen presenting cells (APCs), triggered the immunological response, ATP induced DC maturation, and improved antigen recognition and uptake by DCs [<xref rid="B176-pharmaceuticals-16-01054" ref-type="bibr">176</xref>]. Another novel liposomal nanoparticle based therapeutic peptide vaccine PDS0101 composed of cationic lipid R-DOTAP and 6 HPV16 E6/E7 peptides was developed. The ongoing clinical trial is evaluating the efficacy of this multipeptide vaccine when used in conjunction with chemotherapy and radiation therapy in 35 patients with stage IB3-IVA cervical cancer [<xref rid="B177-pharmaceuticals-16-01054" ref-type="bibr">177</xref>]. Future directions for HPV therapeutic vaccine development include the production of new potent adjuvants, novel antigen targets, and an enrichment of preclinical models.</p></sec><sec id="sec5dot2dot2-pharmaceuticals-16-01054"><title>5.2.2. Mouse Mammary Tumor Virus (MMTV)</title><p>MMTV is a beta retrovirus that causes mammary cancers in both wild and laboratory mice [<xref rid="B178-pharmaceuticals-16-01054" ref-type="bibr">178</xref>] and has also been identified in 40% of human breast cancers [<xref rid="B179-pharmaceuticals-16-01054" ref-type="bibr">179</xref>]. It has been proposed earlier that the zoonotic transmission of MMTV from the mice, <italic toggle="yes">Mus musculus domesticus</italic> could account for the geographic differences in breast cancer incidence [<xref rid="B180-pharmaceuticals-16-01054" ref-type="bibr">180</xref>]. Stewart et al. has recently reported evidence for correlation of spikes in breast cancer incidence in Australia and New Zealand with mouse population outbreaks [<xref rid="B181-pharmaceuticals-16-01054" ref-type="bibr">181</xref>].</p><p>Ever since the involvement of MMTV with breast cancer was identified, investigations have been carried out to recognize TAA that can serve as potential vaccine targets. In one study using TgMMTV-neu mouse, three early-stage tumor antigens (PDHX, STK39, and OTUD6B) were identified by serological analysis of cDNA expression libraries (SEREX) screen that could serve as superior antigen targets for the inhibition of tumor growth [<xref rid="B182-pharmaceuticals-16-01054" ref-type="bibr">182</xref>]. MMTV-p14, the signal peptide of the MMTV envelope precursor, was found to be expressed on breast cancer cells. Protective vaccination using p14 with alum as an adjuvant revealed enhanced immune response which demonstrates p14 as a target for prophylactic vaccination in MMTV associated cancers [<xref rid="B183-pharmaceuticals-16-01054" ref-type="bibr">183</xref>]. Earlier, the feasibility of using MMTV-p14 for vaccination was demonstrated in Balb/c mice that harbor MMTV [<xref rid="B184-pharmaceuticals-16-01054" ref-type="bibr">184</xref>].</p><p>Proteins gp36 and gp52 which are part of the MMTV envelope were reported to be present in primary cultures of human breast cancer [<xref rid="B185-pharmaceuticals-16-01054" ref-type="bibr">185</xref>]. Protective efficacies of vaccines consisting of synthetic peptides based upon the primary sequence of gp52 were studied in mice models. Vaccinating Balb/c mice with surface accessible peptide region EP-3 of major viral envelope glycoprotein (gp52) of C3H-MuMTV was found to result in significant decrease in frequency of early onset tumors [<xref rid="B186-pharmaceuticals-16-01054" ref-type="bibr">186</xref>].</p></sec><sec id="sec5dot2dot3-pharmaceuticals-16-01054"><title>5.2.3. Epstein-Barr Virus (EBV)</title><p>EBV is a DNA virus that belongs to the gamma Herpesviridae family [<xref rid="B187-pharmaceuticals-16-01054" ref-type="bibr">187</xref>]. The presence of the EBV genome was identified in a large subset of breast cancers by polymerase chain reaction (PCR), Southern blot analysis and immunohistochemical detection of Epstein-Barr nuclear antigen 2 (EBNA-2) [<xref rid="B188-pharmaceuticals-16-01054" ref-type="bibr">188</xref>]. Activation of HER2/HER3 signaling cascade is known to be involved in the malignant transformation induced by EBV [<xref rid="B189-pharmaceuticals-16-01054" ref-type="bibr">189</xref>].</p><p>Statistical association of EBV infection with increased breast carcinoma was demonstrated by meta-analysis [<xref rid="B190-pharmaceuticals-16-01054" ref-type="bibr">190</xref>]. Breast tumors showed viral products like EBNA-1, BZLF1, BARF-1, BARF-0, BXLF-2 and BFRF-3 [<xref rid="B187-pharmaceuticals-16-01054" ref-type="bibr">187</xref>]. Epidemiological studies suggest that EBV increases the risk for breast cancer and this association is stronger in Asian countries than in European countries, though EBV infection is not involved in the progression of breast cancer. Also, there is an association between EBV and breast cancer in areas where nasopharyngeal carcinoma is endemic [<xref rid="B191-pharmaceuticals-16-01054" ref-type="bibr">191</xref>].</p><p>Studies conducted by Li W et al. on the immune response of mice to EBV latent membrane protein 2 (LMP2) multi-epitope antigen demonstrated that priming with DNA vaccine and boosting with peptide vaccine elicited a robust humoral immune response and efficient CTL activity [<xref rid="B192-pharmaceuticals-16-01054" ref-type="bibr">192</xref>]. In vivo studies have reported that LMP-1 vaccines suppress LMP-1 expressing tumor growth and metastasis in nasopharyngeal carcinoma animal models [<xref rid="B193-pharmaceuticals-16-01054" ref-type="bibr">193</xref>]. Studies also suggest a correlation between expression of EBV LMP-1 and aggressive ER-negative breast cancer [<xref rid="B194-pharmaceuticals-16-01054" ref-type="bibr">194</xref>]. This opens a possible avenue for the development of LMP-1-based peptide vaccine as a therapeutic strategy against breast cancer.</p><p>The use of immunoinformatics approaches has resulted in the prediction of potential T cell and B cell epitopes for nine antigenic EBV proteins. The integrative meta-analytical approach could model these epitopes as effective candidates for peptide vaccine development towards the treatment of EBV associated cancers [<xref rid="B195-pharmaceuticals-16-01054" ref-type="bibr">195</xref>]. A computational meta-analysis integrated with dynamics could predict a panel of epitopes including B cell epitopes and cytotoxic T cell epitopes. These peptides were then docked against the MHC molecules and the selected peptides were subjected to molecular dynamics simulation and stability analysis. The validated peptides are suggested to aid in the development of vaccines that could be effective against multiple diseases caused by EBV [<xref rid="B196-pharmaceuticals-16-01054" ref-type="bibr">196</xref>]. A multiepitope based polyvalent vaccine against EBV associated tumors was developed using immunoinformatics approach. Molecular docking of the vaccine construct against TLRs revealed that it could elicit humoral and cellular immune responses [<xref rid="B197-pharmaceuticals-16-01054" ref-type="bibr">197</xref>].</p></sec><sec id="sec5dot2dot4-pharmaceuticals-16-01054"><title>5.2.4. Bovine Leukemia Virus (BLV)</title><p>BLV is a delta retrovirus that most closely resembles human T cell lymphotropic virus 1 (HTLV-1) [<xref rid="B198-pharmaceuticals-16-01054" ref-type="bibr">198</xref>]. Association of breast cancer with exposure to BLV has been reported by Buehring G C et al. [<xref rid="B199-pharmaceuticals-16-01054" ref-type="bibr">199</xref>]. Literature search reveals a few investigations that have been carried out on development of peptide vaccines that could be effective against BLV associated tumors.</p><p>In one of the initial studies, Kabeya H et al. had reported that recombinant baculovirus (rgp51) and synthetic multiple antigenic peptides (MAP) of T helper, T cytotoxic, and B cell epitopes of BLV gp51 protected sheep from BLV [<xref rid="B200-pharmaceuticals-16-01054" ref-type="bibr">200</xref>].</p><p>Inoculation of mannan-coated liposome encapsulating 20-mer synthetic peptide of BLV envelope glycoprotein gp51 in BALB/c mice induced specific delayed-type hypersensitivity, lymphocyte proliferative responses, and weak cytotoxic lymphocyte response [<xref rid="B201-pharmaceuticals-16-01054" ref-type="bibr">201</xref>]. Glycoprotein gp51-peptide epitope covalently linked to a mutant bacteriophage carrier (mQ&#946;) using two different linker strategies, isothiocyanate and dinitrophenyl adipate were reported to elicit long-lasting neutralizing antibodies in mice [<xref rid="B202-pharmaceuticals-16-01054" ref-type="bibr">202</xref>].</p><p>A prophylactic multi-epitope vaccine against BLV was computationally developed for breast cancer. The vaccine construct consisted of five antigenic CTL and four helper T lymphocyte (HTL) epitopes linked by AAY and GPGPG, respectively. &#946;-defensin (TLR3 agonist) was added as an adjuvant using EAAAK linker. Immune simulation study confirmed that the designed vaccine could produce a higher response exhibited by helper T and cytotoxic T cell during vaccination. Also, NK and DCs demonstrated elevated macrophage activity [<xref rid="B203-pharmaceuticals-16-01054" ref-type="bibr">203</xref>].</p><p>An in silico approach was used to predict the reliable B and T helper cell epitopes of BLV that can be used for vaccine design. Immunogenic regions of linear and conformational epitopes were selected and the tertiary structure of the final epitope was modeled. The structures of both conformational epitopes were the same as that of the whole extracellular part of gp60 SU (surface glycoprotein of BLV, the major target for the host immunity against the virus) [<xref rid="B204-pharmaceuticals-16-01054" ref-type="bibr">204</xref>].</p></sec></sec></sec><sec id="sec6-pharmaceuticals-16-01054"><title>6. A Pipeline for the Design and Evaluation of Peptide Vaccine in Female-Specific Cancers</title><p>One of the initial steps in the design of a peptide vaccine is the identification of appropriate epitopes with immunogenicity. Immunoinformatics approaches can be effectively used for the prediction of epitopes in vaccine research. The multi-epitope vaccine construct is an acceptable choice for future research [<xref rid="B205-pharmaceuticals-16-01054" ref-type="bibr">205</xref>]. Epitopes can also be designed based on the sequence of TAA or TSA that are encoded by mutated cancer genes [<xref rid="B42-pharmaceuticals-16-01054" ref-type="bibr">42</xref>,<xref rid="B206-pharmaceuticals-16-01054" ref-type="bibr">206</xref>,<xref rid="B207-pharmaceuticals-16-01054" ref-type="bibr">207</xref>]. In the case of viral induced cancers, the viral antigens can serve as a guide for epitope-based vaccine design [<xref rid="B208-pharmaceuticals-16-01054" ref-type="bibr">208</xref>,<xref rid="B209-pharmaceuticals-16-01054" ref-type="bibr">209</xref>,<xref rid="B210-pharmaceuticals-16-01054" ref-type="bibr">210</xref>]. After an epitope is predicted, a multi-epitope vaccine can be designed. Then the allergenicity, antigenicity and physicochemical properties of the vaccine construct is analyzed [<xref rid="B211-pharmaceuticals-16-01054" ref-type="bibr">211</xref>]. It is followed by preclinical or in vitro studies in cell lines and/or in animal models/humanized animal models and various phases of clinical trials before the successful development of a commercial vaccine. A flow chart illustrating a model pipeline for the design and evaluation of peptide vaccine in female-specific cancers is shown in <xref rid="pharmaceuticals-16-01054-f003" ref-type="fig">Figure 3</xref>.</p></sec><sec id="sec7-pharmaceuticals-16-01054"><title>7. Delivery Systems for Peptide Vaccines</title><p>When used alone as vaccines, peptides do not elicit robust in vivo immune responses due to their rapid degradation at the injection site, lack of costimulatory effects and immune signals essential for APC activation [<xref rid="B42-pharmaceuticals-16-01054" ref-type="bibr">42</xref>]. In early phase clinical trials of peptide-based vaccines, overlapping long peptides were used along with adjuvants to boost immune response. For example, a vaccine made by combining HPV E6 and E7 peptides in Montanide ISA 51 adjuvant was well tolerated and induced the development of IFN-related T cell response in advanced cervical cancer patients [<xref rid="B212-pharmaceuticals-16-01054" ref-type="bibr">212</xref>]. So adjuvants and/or delivery systems are required to induce a satisfactory immune response and also protect the antigen from degradation and deliver it to the targeted cells. Delivery systems are self-adjuvating and they aid in the delivery of peptides to APCs to generate optimum T cell responses. Poly lactic-co-glycolic acid (PLGA) [<xref rid="B213-pharmaceuticals-16-01054" ref-type="bibr">213</xref>] and liposomes [<xref rid="B214-pharmaceuticals-16-01054" ref-type="bibr">214</xref>] are two drug delivery methods that have been studied for many years and have proven safety and efficacy for the treatment of cancer. Nanoparticles are an effective antigen presentation and delivery system for stimulating an optimal immune response [<xref rid="B215-pharmaceuticals-16-01054" ref-type="bibr">215</xref>]. The physical features of nanoparticles, such as size, shape, and surface characteristics can be easily modified to induce immunological responses against the associated antigen. Vaccines have been delivered via polymeric nanoparticles such as nanogels [<xref rid="B216-pharmaceuticals-16-01054" ref-type="bibr">216</xref>], dendrimers [<xref rid="B216-pharmaceuticals-16-01054" ref-type="bibr">216</xref>], hydrogels [<xref rid="B217-pharmaceuticals-16-01054" ref-type="bibr">217</xref>], and micelles [<xref rid="B218-pharmaceuticals-16-01054" ref-type="bibr">218</xref>] that have been conjugated with immune stimulants. Conjugation of peptides to inorganic nanoparticles like gold nanoparticles increases the stability and reproducibility of the conjugate [<xref rid="B219-pharmaceuticals-16-01054" ref-type="bibr">219</xref>]. A recent study by Firdaus et al. shows that a completely specified, natural, hydrophobic amino-acid-based polymer (Polyleucine) conjugated to peptide antigen works well for vaccine delivery mechanism [<xref rid="B220-pharmaceuticals-16-01054" ref-type="bibr">220</xref>]. VLPs can efficiently act as vehicles of antigens to APCs, where they are cross-presented in association with both MHC class I and class II molecules, eliciting both humoral and cellular immune responses [<xref rid="B221-pharmaceuticals-16-01054" ref-type="bibr">221</xref>]. Recently, adenovirus-inspired non-infectious VLP was shown to stimulate anti-tumor immune response in mouse modes of melanoma [<xref rid="B222-pharmaceuticals-16-01054" ref-type="bibr">222</xref>] present shortcomings of peptide vaccines necessitate additional research on more effective adjuvants, routes of administration, and novel delivery systems.</p></sec><sec id="sec8-pharmaceuticals-16-01054"><title>8. Limitations and Adverse Effects of Peptide Vaccines</title><p>Peptide vaccines provide a number of benefits, including simplicity of synthesis, low production costs, adaptability to antigens, and high specificity. However, they also have a number of drawbacks, including MHC constraints, poor immunogenic potency, and the necessity for an adjuvant. Even though stability and immunogenicity of peptide vaccines can be improved by conjugating them with adjuvants, the unwanted immune response elicited by the adjuvant is a challenge. The extent and diversity of MHC alleles in various populations and races also pose a barrier that a specific peptide may not induce much cell-mediated immunity in individuals with diverse MHC class I molecules. Since the vaccine must match the HLA in patients, a peptide vaccine for the entire human population cannot be designed due to the presence of HLA polymorphisms [<xref rid="B223-pharmaceuticals-16-01054" ref-type="bibr">223</xref>]. Even though peptides present on MHC-II molecules that are recognized by helper T cells could considerably improve efficacy, it is extremely difficult to predict the immunogenicity of MHC-II-restricted peptides due to their greater diversity and complexity than MHC-I-restricted peptides [<xref rid="B224-pharmaceuticals-16-01054" ref-type="bibr">224</xref>]. Short peptides may induce T cell tolerance since they can directly bind to MHC on non-professional APCs [<xref rid="B225-pharmaceuticals-16-01054" ref-type="bibr">225</xref>]. Also, the constrained conformation of short peptides will prevent them from folding into the three-dimensional structure that is required for proper immunogenicity [<xref rid="B226-pharmaceuticals-16-01054" ref-type="bibr">226</xref>,<xref rid="B227-pharmaceuticals-16-01054" ref-type="bibr">227</xref>]. Although algorithms for predicting T cell epitopes are widely employed, their accuracy and sensitivity are somewhat limited due to the fact that the spatial configuration of T cell epitopes changes when antigens bind to cell surface receptors. Consequently, false-positive and false-negative immune responses are possible [<xref rid="B228-pharmaceuticals-16-01054" ref-type="bibr">228</xref>]. Tumor-specific CD4+ T cell responses often target self-derived epitopes. This will hinder the immune system from realizing its entire potential in fighting against cancer, presenting another important challenge in peptide vaccine development [<xref rid="B229-pharmaceuticals-16-01054" ref-type="bibr">229</xref>].</p></sec><sec id="sec9-pharmaceuticals-16-01054"><title>9. Future Prospects</title><p>The increasing incidence of female-specific cancers across the globe remains a great challenge that needs to be addressed with therapeutic and prophylactic approaches. In the case of viral-induced female-specific cancers, the development of novel prophylactic vaccines is all the more important. Even though vaccinations against HPV are widely used, prophylactic strategies against retroviruses causing female-specific cancers, such as MMTV and BLV are not even in the nascent stages of development. The major concern regarding retroviruses is that they stably integrate into the host genome, enter long-term latency in some cells, and evade immune response making vaccination difficult [<xref rid="B230-pharmaceuticals-16-01054" ref-type="bibr">230</xref>].</p><p>Peptide-based vaccination approaches have several advantages over other forms of therapies in eliciting appropriate anti-tumor immune responses. This should be addressed in conjunction with the fact that the anticancer immune response of peptide vaccines can be attenuated by factors such as the complexity, continuous evolution of the TME and the influence of neoantigen-specific T cell immunity [<xref rid="B231-pharmaceuticals-16-01054" ref-type="bibr">231</xref>]. Also, due to their rapid degradation at the injection site, lack of costimulation, and lack of signals needed for APC activation, peptide vaccines may not induce robust immune reactions in vivo [<xref rid="B232-pharmaceuticals-16-01054" ref-type="bibr">232</xref>]. Thus more studies are warranted on the development of potent adjuvants or immunostimulators and efficient delivery systems that are capable of producing effective T cell responses.</p><p>The identification of optimal antigen targets, streamlining immunization regimens and exploring novel biomarkers that could predict the efficacy of vaccine response are all major domains that deserve additional attention in the near future [<xref rid="B42-pharmaceuticals-16-01054" ref-type="bibr">42</xref>]. Empirical research on the design and effectiveness of combining peptide-based cancer vaccination with other forms of existing therapy is also the need of the hour.</p><p>The concept of multi-epitope-based peptide vaccines is quite interesting for both therapeutic and prophylactic purposes. Advances in artificial intelligence should be effectively exploited for the development of new algorithms for the prediction of peptide-binding epitopes which would aid in the design of neoantigen-based cancer vaccines. Personalized peptide-based cancer vaccines, emerging as a promising strategy for eliciting a diversified antitumor immune response that is appropriate and useful to individual cancer patients, which is currently an expensive and time-consuming affair, also need more attention.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization and design of manuscript, M.M., Writing-Original draft preparation, M.M., M.L. and C.R.D., Preparation of Figures, C.R.D., Preparation of Tables, M.L. and J.S.S., Project Administration, J.A.S., Validation and formal analysis, J.J.V., Data curation, J.T.V., Visualization and supervision, L.A., Writing-Review and Editing, V.S.L., Resources and literature survey, A.M.N. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data is contained within the article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Nomenclature </title><array orientation="portrait"><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">AAHS</td><td align="left" valign="bottom" rowspan="1" colspan="1">Amorphous aluminum hydroxyphosphate sulfate</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">AE37, AE36, E75 and GP2 </td><td align="left" valign="bottom" rowspan="1" colspan="1">Immunogenic peptides from the HER2/neu</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">APC </td><td align="left" valign="bottom" rowspan="1" colspan="1">Antigen presenting cells</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">B16-OVA </td><td align="left" valign="bottom" rowspan="1" colspan="1">B16 Ovalbumin</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">BLV </td><td align="left" valign="bottom" rowspan="1" colspan="1">Bovine leukemia virus</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">BORIS </td><td align="left" valign="bottom" rowspan="1" colspan="1">Brother of Regulator of Imprinted Sites</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">BRCA1/BRCA2 </td><td align="left" valign="bottom" rowspan="1" colspan="1">Breast Cancer gene</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">CA-125 </td><td align="left" valign="bottom" rowspan="1" colspan="1">Cancer antigen 125</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">CAR T cell </td><td align="left" valign="bottom" rowspan="1" colspan="1">Chimeric antigen receptor T cell</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">CCL-Chemokine</td><td align="left" valign="bottom" rowspan="1" colspan="1">(C-C motif) ligand</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">CEA </td><td align="left" valign="bottom" rowspan="1" colspan="1">Carcinoembryonic antigen</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">CHEK2</td><td align="left" valign="bottom" rowspan="1" colspan="1">Checkpoint kinase 2</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">CIN </td><td align="left" valign="bottom" rowspan="1" colspan="1">Cervical squamous intraepithelial neoplasia</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">CpG-ODN </td><td align="left" valign="bottom" rowspan="1" colspan="1">Oligodeoxynucleotides of cytosine and guanine</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">CRP </td><td align="left" valign="bottom" rowspan="1" colspan="1">C-reactive protein</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">CTL</td><td align="left" valign="bottom" rowspan="1" colspan="1">Cytotoxic T lymphocyte</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">CTLA-4</td><td align="left" valign="bottom" rowspan="1" colspan="1">Cytotoxic T lymphocyte-associated antigen-4</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">cVLPs</td><td align="left" valign="bottom" rowspan="1" colspan="1">Chimeric virus-like particles</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">CXCL</td><td align="left" valign="bottom" rowspan="1" colspan="1">Chemokine (C-X-C motif) ligand</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">DCs </td><td align="left" valign="bottom" rowspan="1" colspan="1">Dendritic cells</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">dLOS (CIA06) </td><td align="left" valign="bottom" rowspan="1" colspan="1">A novel proprietary immune adjuvant</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">DTH </td><td align="left" valign="bottom" rowspan="1" colspan="1">Delayed type hypersensitivity</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">E1, E2, E3</td><td align="left" valign="bottom" rowspan="1" colspan="1">Epitope 1, 2, 3</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">EBNA-2 </td><td align="left" valign="bottom" rowspan="1" colspan="1">Epstein-Barr nuclear antigen 2</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">EBV </td><td align="left" valign="bottom" rowspan="1" colspan="1">Epstein-Barr virus.</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">ECD </td><td align="left" valign="bottom" rowspan="1" colspan="1">Extracellular domain</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">EGFR </td><td align="left" valign="bottom" rowspan="1" colspan="1">Epidermal growth factor receptor</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">ER </td><td align="left" valign="bottom" rowspan="1" colspan="1">Estrogen receptor;</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">ErbB2 </td><td align="left" valign="bottom" rowspan="1" colspan="1">Erythroblastic oncogene B</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">FR </td><td align="left" valign="bottom" rowspan="1" colspan="1">Folate receptor</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">GM-CSF </td><td align="left" valign="bottom" rowspan="1" colspan="1">Granulocyte-macrophage colony-stimulating factor</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">HBc</td><td align="left" valign="bottom" rowspan="1" colspan="1">Hepatitis B virus core antigen</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">HER 2 </td><td align="left" valign="bottom" rowspan="1" colspan="1">Human epidermal growth factor receptor 2</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">HIV </td><td align="left" valign="bottom" rowspan="1" colspan="1">Human immunodeficiency virus</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">HLA</td><td align="left" valign="bottom" rowspan="1" colspan="1">Human leukocyte antigens</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">HPV </td><td align="left" valign="bottom" rowspan="1" colspan="1">Human Papillomavirus</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">HSP </td><td align="left" valign="bottom" rowspan="1" colspan="1">Heat shock protein;</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">HTL </td><td align="left" valign="bottom" rowspan="1" colspan="1">Helper T lymphocyte</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">HTLV-1 </td><td align="left" valign="bottom" rowspan="1" colspan="1">Human T cell lymphotropic virus 1</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">ICB </td><td align="left" valign="bottom" rowspan="1" colspan="1">Immune checkpoint blockade</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">ICD </td><td align="left" valign="bottom" rowspan="1" colspan="1">Intracellular domain</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">IFN</td><td align="left" valign="bottom" rowspan="1" colspan="1">Interferon</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">IgG </td><td align="left" valign="bottom" rowspan="1" colspan="1">Immunoglobulin G</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">IL</td><td align="left" valign="bottom" rowspan="1" colspan="1">Interleukin</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">KLH-</td><td align="left" valign="bottom" rowspan="1" colspan="1">Keyhole limpet hemocyanin</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">LMP2 </td><td align="left" valign="bottom" rowspan="1" colspan="1">Latent membrane protein 2</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">MAGE </td><td align="left" valign="bottom" rowspan="1" colspan="1">Melanoma Antigen Gene</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">MAP </td><td align="left" valign="bottom" rowspan="1" colspan="1">Multiple antigenic peptides</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">MD</td><td align="left" valign="bottom" rowspan="1" colspan="1">Molecular dynamics</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">MDSCs </td><td align="left" valign="bottom" rowspan="1" colspan="1">Myeloid-derived suppressor cells</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">MHC </td><td align="left" valign="bottom" rowspan="1" colspan="1">Major histocompatibility complex</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">MIR </td><td align="left" valign="bottom" rowspan="1" colspan="1">Major immune dominant region</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">MMTV </td><td align="left" valign="bottom" rowspan="1" colspan="1">Mouse Mammary Tumour Virus</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">MUC1 </td><td align="left" valign="bottom" rowspan="1" colspan="1">Mucin1</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">NK </td><td align="left" valign="bottom" rowspan="1" colspan="1">Natural killer cell</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">NP</td><td align="left" valign="bottom" rowspan="1" colspan="1">Nanoparticle</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">NPBC </td><td align="left" valign="bottom" rowspan="1" colspan="1">Non-palpable breast cancer</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">NPS </td><td align="left" valign="bottom" rowspan="1" colspan="1">Nelipepimut-S</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">OLP </td><td align="left" valign="bottom" rowspan="1" colspan="1">Overlapping peptide</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">PCR </td><td align="left" valign="bottom" rowspan="1" colspan="1">Polymerase chain reaction</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">PEG </td><td align="left" valign="bottom" rowspan="1" colspan="1">Polyethylene Glycolylated</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">PEP-DC </td><td align="left" valign="bottom" rowspan="1" colspan="1">DCs pulsed with up to ten peptides</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Poly-ICLC</td><td align="left" valign="bottom" rowspan="1" colspan="1">Polyinosinic-polycytidylic acid</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">PLGA </td><td align="left" valign="bottom" rowspan="1" colspan="1">Poly lactic-co-glycolic acid</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">PTEN </td><td align="left" valign="bottom" rowspan="1" colspan="1">Phosphatase and TENsin homolog</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">RNF </td><td align="left" valign="bottom" rowspan="1" colspan="1">Ring finger protein; ROC-recurrent ovarian cancer</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">ROPs </td><td align="left" valign="bottom" rowspan="1" colspan="1">Recombinant overlapping peptides</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">SEREX </td><td align="left" valign="bottom" rowspan="1" colspan="1">Serological analysis of cDNA expression libraries</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">SLP </td><td align="left" valign="bottom" rowspan="1" colspan="1">Synthetic long peptide</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">SSA </td><td align="left" valign="bottom" rowspan="1" colspan="1">Serum amyloid A</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">STING </td><td align="left" valign="bottom" rowspan="1" colspan="1">Stimulator of interferon genes</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">TAAs </td><td align="left" valign="bottom" rowspan="1" colspan="1">Tumor associated antigens</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">TCR </td><td align="left" valign="bottom" rowspan="1" colspan="1">T-cell receptor</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">TGF</td><td align="left" valign="bottom" rowspan="1" colspan="1">Tumor growth factor</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Th</td><td align="left" valign="bottom" rowspan="1" colspan="1">helper T cells</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">TLR </td><td align="left" valign="bottom" rowspan="1" colspan="1">Toll-like receptor</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">TNBC </td><td align="left" valign="bottom" rowspan="1" colspan="1">Triple-negative breast cancer</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">TNF</td><td align="left" valign="bottom" rowspan="1" colspan="1">Tumor necrosis factor</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">TME </td><td align="left" valign="bottom" rowspan="1" colspan="1">Tumor microenvironment</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Tp53 </td><td align="left" valign="bottom" rowspan="1" colspan="1">Tumor protein 53</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">TSAs </td><td align="left" valign="bottom" rowspan="1" colspan="1">Tumor-specific antigens</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">TUBO </td><td align="left" valign="bottom" rowspan="1" colspan="1">Cell lines cloned from a BALB/c mouse mammary carcinoma</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">VLP</td><td align="left" valign="bottom" rowspan="1" colspan="1">Virus like particles.</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">wt p53 </td><td align="left" valign="bottom" rowspan="1" colspan="1">Wild type p53</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">WT1 </td><td align="left" valign="bottom" rowspan="1" colspan="1">Wilms&#8217; tumor 1</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-16-01054"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.-X.</given-names></name></person-group><article-title>Adapting conventional cancer treatment for immunotherapy</article-title><source>J. Mol. Med.</source><year>2016</year><volume>94</volume><fpage>489</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1007/s00109-016-1393-4</pub-id><pub-id pub-id-type="pmid">26910191</pub-id></element-citation></ref><ref id="B2-pharmaceuticals-16-01054"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoda</surname><given-names>M.</given-names></name></person-group><article-title>Potential Alternatives to Conventional Cancer Therapeutic Approaches: The Way Forward</article-title><source>Curr. Pharm. Biotechnol.</source><year>2021</year><volume>22</volume><fpage>1141</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.2174/1389201021666201016142408</pub-id><pub-id pub-id-type="pmid">33069195</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-16-01054"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuhle</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sood</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thielen</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Jatoi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Faubion</surname><given-names>S.S.</given-names></name></person-group><article-title>Menopausal hormone therapy in cancer survivors: A narrative review of the literature</article-title><source>Maturitas</source><year>2016</year><volume>92</volume><fpage>86</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.maturitas.2016.07.018</pub-id><pub-id pub-id-type="pmid">27621244</pub-id></element-citation></ref><ref id="B4-pharmaceuticals-16-01054"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da Silva</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Silva-de-Oliveira</surname><given-names>A.F.S.</given-names></name><name name-style="western"><surname>Andraus</surname><given-names>R.A.C.</given-names></name><name name-style="western"><surname>Maia</surname><given-names>L.P.</given-names></name></person-group><article-title>Effects of low level laser therapy in cancer cells&#8212;A systematic review of the literature</article-title><source>Lasers Med. Sci.</source><year>2020</year><volume>35</volume><fpage>523</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1007/s10103-019-02824-2</pub-id><pub-id pub-id-type="pmid">31209588</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-16-01054"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Schenkein</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Pietrusko</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rolfe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Linette</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Stec</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stagliano</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Ginsburg</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Symmans</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Pusztai</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Targeted Therapies for Cancer 2004</article-title><source>Am. J. Clin. Pathol.</source><year>2004</year><volume>122</volume><fpage>598</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1309/5CWPU41AFR1VYM3F</pub-id><pub-id pub-id-type="pmid">15487459</pub-id></element-citation></ref><ref id="B6-pharmaceuticals-16-01054"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stephens</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Burgess-Brown</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>2629</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.696791</pub-id><pub-id pub-id-type="pmcid">PMC8279810</pub-id><pub-id pub-id-type="pmid">34276688</pub-id></element-citation></ref><ref id="B7-pharmaceuticals-16-01054"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Asano</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>Y.</given-names></name></person-group><article-title>Development of a Novel Anti-Mouse CCR4 Monoclonal Antibody (C<sub>4</sub>Mab-1) by N-Terminal Peptide Immunization</article-title><source>Monoclon. Antibodies Immunodiagn. Immunother.</source><year>2022</year><volume>41</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1089/mab.2021.0064</pub-id><pub-id pub-id-type="pmid">35471046</pub-id></element-citation></ref><ref id="B8-pharmaceuticals-16-01054"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nezafat</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ghasemi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Javadi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Khoshnoud</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Omidinia</surname><given-names>E.</given-names></name></person-group><article-title>A novel multi-epitope peptide vaccine against cancer: An in silico approach</article-title><source>J. Theor. Biol.</source><year>2014</year><volume>349</volume><fpage>121</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2014.01.018</pub-id><pub-id pub-id-type="pmid">24512916</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-16-01054"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Campos</surname><given-names>N.S.P.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>G.C.P.</given-names></name><name name-style="western"><surname>Porto</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Chalbatani</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Lagreca</surname><given-names>G.</given-names></name><name name-style="western"><surname>Janji</surname><given-names>B.</given-names></name><name name-style="western"><surname>Suarez</surname><given-names>E.R.</given-names></name></person-group><article-title>Carbonic Anhydrase IX: A Renewed Target for Cancer Immunotherapy</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>1392</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14061392</pub-id><pub-id pub-id-type="pmid">35326544</pub-id><pub-id pub-id-type="pmcid">PMC8946730</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-16-01054"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hargadon</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C.J.</given-names></name></person-group><article-title>Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors</article-title><source>Int. Immunopharmacol.</source><year>2018</year><volume>62</volume><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2018.06.001</pub-id><pub-id pub-id-type="pmid">29990692</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-16-01054"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fry</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Mackall</surname><given-names>C.L.</given-names></name></person-group><article-title>T-cell adoptive immunotherapy for acute lymphoblastic leukemia</article-title><source>Hematology Am. Soc. Hematol. Educ. Program</source><year>2013</year><volume>2013</volume><fpage>348</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1182/asheducation-2013.1.348</pub-id><pub-id pub-id-type="pmid">24319203</pub-id><pub-id pub-id-type="pmcid">PMC7569491</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-16-01054"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlom</surname><given-names>J.</given-names></name></person-group><article-title>Therapeutic Cancer Vaccines: Current Status and Moving Forward</article-title><source>JNCI J. Natl. Cancer Inst.</source><year>2012</year><volume>104</volume><fpage>599</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1093/jnci/djs033</pub-id><pub-id pub-id-type="pmid">22395641</pub-id><pub-id pub-id-type="pmcid">PMC3328421</pub-id></element-citation></ref><ref id="B13-pharmaceuticals-16-01054"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatti-Mays</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Redman</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bilusic</surname><given-names>M.</given-names></name></person-group><article-title>Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations</article-title><source>Hum. Vaccines Immunother.</source><year>2017</year><volume>13</volume><fpage>2561</fpage><lpage>2574</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1364322</pub-id><pub-id pub-id-type="pmcid">PMC5703410</pub-id><pub-id pub-id-type="pmid">28857666</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-16-01054"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ollert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>J.</given-names></name></person-group><article-title>A Hot Topic: Cancer Immunotherapy and Natural Killer Cells</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>797</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23020797</pub-id><pub-id pub-id-type="pmid">35054985</pub-id><pub-id pub-id-type="pmcid">PMC8776043</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-16-01054"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cebon</surname><given-names>J.</given-names></name></person-group><article-title>Perspective: Cancer vaccines in the era of immune checkpoint blockade</article-title><source>Mamm. Genome</source><year>2018</year><volume>29</volume><fpage>703</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1007/s00335-018-9786-z</pub-id><pub-id pub-id-type="pmid">30446791</pub-id><pub-id pub-id-type="pmcid">PMC6267701</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-16-01054"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vandermeulen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pr&#233;at</surname><given-names>V.</given-names></name></person-group><article-title>Cancer DNA vaccines: Current preclinical and clinical developments and future perspectives</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2019</year><volume>38</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1186/s13046-019-1154-7</pub-id><pub-id pub-id-type="pmid">30953535</pub-id><pub-id pub-id-type="pmcid">PMC6449928</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-16-01054"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ginsburg</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Vanderpuye</surname><given-names>V.</given-names></name><name name-style="western"><surname>Eniu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kotha</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Sarker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huong</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Allemani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dvaladze</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The global burden of women&#8217;s cancers: A grand challenge in global health</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>847</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)31392-7</pub-id><pub-id pub-id-type="pmid">27814965</pub-id><pub-id pub-id-type="pmcid">PMC6191029</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-16-01054"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Torre</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J. Clin.</source><year>2018</year><volume>68</volume><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-16-01054"><label>19.</label><element-citation publication-type="webpage"><article-title>Diseases and Conditions-Mayo Clinic</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mayoclinic.org/diseases-conditions?customer_id=856-310-7743&amp;mc_id=google&amp;campaign=19807197113&amp;geo=1007828&amp;kw=mayoclinic&amp;ad=650933999493&amp;network=g&amp;sitetarget=&amp;adgroup=147643045435&amp;extension=&amp;target=kwd-98051161&amp;matchtype=e&amp;device=c&amp;account=8563107743&amp;invsrc=india&amp;placementsite=enterprise&amp;gclid=Cj0KCQjw_r6hBhDdARIsAMIDhV80obPMuAybSmabKG5o7bfYGuiMqecyuCzOrgx4PUm32MPsx2TZtYMaAuPCEALw_wcB" ext-link-type="uri">https://www.mayoclinic.org/diseases-conditions?customer_id=856-310-7743&amp;mc_id=google&amp;campaign=19807197113&amp;geo=1007828&amp;kw=mayoclinic&amp;ad=650933999493&amp;network=g&amp;sitetarget=&amp;adgroup=147643045435&amp;extension=&amp;target=kwd-98051161&amp;matchtype=e&amp;device=c&amp;account=8563107743&amp;invsrc=india&amp;placementsite=enterprise&amp;gclid=Cj0KCQjw_r6hBhDdARIsAMIDhV80obPMuAybSmabKG5o7bfYGuiMqecyuCzOrgx4PUm32MPsx2TZtYMaAuPCEALw_wcB</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-07">(accessed on 7 April 2023)</date-in-citation></element-citation></ref><ref id="B20-pharmaceuticals-16-01054"><label>20.</label><element-citation publication-type="webpage"><article-title>Cancer Types|Cancer Resources|American Cancer Society</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cancer.org/cancer.html" ext-link-type="uri">https://www.cancer.org/cancer.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-07">(accessed on 7 April 2023)</date-in-citation></element-citation></ref><ref id="B21-pharmaceuticals-16-01054"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alibek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kakpenova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mussabekova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sypabekova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karatayeva</surname><given-names>N.</given-names></name></person-group><article-title>Role of viruses in the development of breast cancer</article-title><source>Infect. Agents Cancer</source><year>2013</year><volume>8</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/1750-9378-8-32</pub-id><pub-id pub-id-type="pmcid">PMC3765990</pub-id><pub-id pub-id-type="pmid">24138789</pub-id></element-citation></ref><ref id="B22-pharmaceuticals-16-01054"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Long</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>H.</given-names></name></person-group><article-title>Association Between BRCA Status and P53 Status in Breast Cancer: A Meta-Analysis</article-title><source>Med. Sci. Monit.</source><year>2016</year><volume>22</volume><fpage>1939</fpage><lpage>1945</lpage><pub-id pub-id-type="doi">10.12659/MSM.896260</pub-id><pub-id pub-id-type="pmid">27272763</pub-id><pub-id pub-id-type="pmcid">PMC4917318</pub-id></element-citation></ref><ref id="B23-pharmaceuticals-16-01054"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Casadei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Coats</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Swisher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stray</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roach</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Mandell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Ciernikova</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer</article-title><source>JAMA</source><year>2006</year><volume>295</volume><fpage>1379</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1001/jama.295.12.1379</pub-id><pub-id pub-id-type="pmid">16551709</pub-id></element-citation></ref><ref id="B24-pharmaceuticals-16-01054"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>O&#8217;Hara</surname><given-names>A.J.</given-names></name></person-group><article-title>The genomics and genetics of endometrial cancer</article-title><source>Adv. Genom. Genet.</source><year>2012</year><volume>2012</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.2147/AGG.S28953</pub-id><pub-id pub-id-type="pmid">22888282</pub-id><pub-id pub-id-type="pmcid">PMC3415201</pub-id></element-citation></ref><ref id="B25-pharmaceuticals-16-01054"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharmin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zohura</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shimonty</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.-A.</given-names></name><name name-style="western"><surname>Parveen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sharmin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ahsan</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>A.B.M.M.K.</given-names></name><name name-style="western"><surname>Yasmin</surname><given-names>M.</given-names></name></person-group><article-title>Mutational profiles of marker genes of cervical carcinoma in Bangladeshi patients</article-title><source>BMC Cancer</source><year>2021</year><volume>21</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1186/s12885-021-07906-5</pub-id><pub-id pub-id-type="pmid">33736612</pub-id><pub-id pub-id-type="pmcid">PMC7977314</pub-id></element-citation></ref><ref id="B26-pharmaceuticals-16-01054"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamandani</surname><given-names>D.M.K.</given-names></name><name name-style="western"><surname>Sobti</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Shekari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huria</surname><given-names>A.</given-names></name></person-group><article-title>CPG Island methylation of TMS1/ASC and CASP8 genes in cervical cancer</article-title><source>Eur. J. Med. Res.</source><year>2009</year><volume>14</volume><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1186/2047-783X-14-2-71</pub-id><pub-id pub-id-type="pmcid">PMC3351963</pub-id><pub-id pub-id-type="pmid">19258216</pub-id></element-citation></ref><ref id="B27-pharmaceuticals-16-01054"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>L.</given-names></name></person-group><article-title>Downregulation of ERBB3 decreases the proliferation, migration and invasion of cervical cancer cells though the interaction with MTK 1</article-title><source>Oncol Lett.</source><year>2018</year><volume>16</volume><fpage>3453</fpage><lpage>3458</lpage><pub-id pub-id-type="doi">10.3892/ol.2018.9088</pub-id><pub-id pub-id-type="pmid">30127948</pub-id><pub-id pub-id-type="pmcid">PMC6096111</pub-id></element-citation></ref><ref id="B28-pharmaceuticals-16-01054"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toss</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tomasello</surname><given-names>C.</given-names></name><name name-style="western"><surname>Razzaboni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Contu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grandi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cagnacci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schilder</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Cortesi</surname><given-names>L.</given-names></name></person-group><article-title>Hereditary Ovarian Cancer: Not Only<italic toggle="yes">BRCA</italic>1 and 2 Genes</article-title><source>BioMed Res. Int.</source><year>2015</year><volume>2015</volume><fpage>341723</fpage><pub-id pub-id-type="doi">10.1155/2015/341723</pub-id><pub-id pub-id-type="pmid">26075229</pub-id><pub-id pub-id-type="pmcid">PMC4449870</pub-id></element-citation></ref><ref id="B29-pharmaceuticals-16-01054"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The AACR Project GENIE Consortium</collab><name name-style="western"><surname>Andr&#233;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Arnedos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baras</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Baselga</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bedard</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Bierkens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cerami</surname><given-names>E.</given-names></name><etal/></person-group><article-title>AACR Project GENIE: Powering Precision Medicine through an International Consortium</article-title><source>Cancer Discov.</source><year>2017</year><volume>7</volume><fpage>818</fpage><lpage>831</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.cd-17-0151</pub-id><pub-id pub-id-type="pmid">28572459</pub-id><pub-id pub-id-type="pmcid">PMC5611790</pub-id></element-citation></ref><ref id="B30-pharmaceuticals-16-01054"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Capria</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tahir</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fatehi</surname><given-names>M.</given-names></name></person-group><article-title>Vulva Cancer</article-title><source>Decision Making in Radiation Oncology</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2023</year><fpage>703</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1007/978-3-642-16333-3_6</pub-id></element-citation></ref><ref id="B31-pharmaceuticals-16-01054"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zi&#281;ba</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kowalik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zalewski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rusetska</surname><given-names>N.</given-names></name><name name-style="western"><surname>Goryca</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pia&#347;cik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Misiek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baku&#322;a-Zalewska</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kopczy&#324;ski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets</article-title><source>Gynecol. Oncol.</source><year>2018</year><volume>150</volume><fpage>552</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2018.06.026</pub-id><pub-id pub-id-type="pmid">29980281</pub-id></element-citation></ref><ref id="B32-pharmaceuticals-16-01054"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viswanath</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.-C.</given-names></name><name name-style="western"><surname>Huston</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Chua</surname><given-names>C.Y.X.</given-names></name><name name-style="western"><surname>Grattoni</surname><given-names>A.</given-names></name></person-group><article-title>Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines</article-title><source>Biomaterials</source><year>2022</year><volume>280</volume><fpage>121297</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121297</pub-id><pub-id pub-id-type="pmid">34902729</pub-id><pub-id pub-id-type="pmcid">PMC8725170</pub-id></element-citation></ref><ref id="B33-pharmaceuticals-16-01054"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin-Liberal</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Olza</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Hierro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gros</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rodon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tabernero</surname><given-names>J.</given-names></name></person-group><article-title>The expanding role of immunotherapy</article-title><source>Cancer Treat. Rev.</source><year>2017</year><volume>54</volume><fpage>74</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2017.01.008</pub-id><pub-id pub-id-type="pmid">28231560</pub-id></element-citation></ref><ref id="B34-pharmaceuticals-16-01054"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shibata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Egloff</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Uppaluri</surname><given-names>R.</given-names></name></person-group><article-title>Personalized cancer vaccination in head and neck cancer</article-title><source>Cancer Sci.</source><year>2021</year><volume>112</volume><fpage>978</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1111/cas.14784</pub-id><pub-id pub-id-type="pmid">33368875</pub-id><pub-id pub-id-type="pmcid">PMC7935792</pub-id></element-citation></ref><ref id="B35-pharmaceuticals-16-01054"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toussaint</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chauchet</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Polack</surname><given-names>B.</given-names></name><name name-style="western"><surname>Le Gou&#235;llec</surname><given-names>A.</given-names></name></person-group><article-title>Live-attenuated bacteria as a cancer vaccine vector</article-title><source>Expert Rev. Vaccines</source><year>2014</year><volume>12</volume><fpage>1139</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1586/14760584.2013.836914</pub-id><pub-id pub-id-type="pmid">24124876</pub-id></element-citation></ref><ref id="B36-pharmaceuticals-16-01054"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>G.N.</given-names></name></person-group><article-title>Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines</article-title><source>Cancer Cell</source><year>2018</year><volume>33</volume><fpage>599</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.03.011</pub-id><pub-id pub-id-type="pmid">29634947</pub-id><pub-id pub-id-type="pmcid">PMC5918693</pub-id></element-citation></ref><ref id="B37-pharmaceuticals-16-01054"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNamara</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Holl</surname><given-names>E.K.</given-names></name></person-group><article-title>RNA-Based Vaccines in Cancer Immunotherapy</article-title><source>J. Immunol. Res.</source><year>2015</year><volume>2015</volume><fpage>794528</fpage><pub-id pub-id-type="doi">10.1155/2015/794528</pub-id><pub-id pub-id-type="pmid">26665011</pub-id><pub-id pub-id-type="pmcid">PMC4668311</pub-id></element-citation></ref><ref id="B38-pharmaceuticals-16-01054"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obara</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kanehira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Katagiri</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takata</surname><given-names>R.</given-names></name></person-group><article-title>Present status and future perspective of peptide-based vaccine therapy for urological cancer</article-title><source>Cancer Sci.</source><year>2018</year><volume>109</volume><fpage>550</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1111/cas.13506</pub-id><pub-id pub-id-type="pmid">29345737</pub-id><pub-id pub-id-type="pmcid">PMC5834812</pub-id></element-citation></ref><ref id="B39-pharmaceuticals-16-01054"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>mRNA vaccine for cancer immunotherapy</article-title><source>Mol. Cancer</source><year>2021</year><volume>20</volume><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1186/s12943-021-01335-5</pub-id><pub-id pub-id-type="pmid">33632261</pub-id><pub-id pub-id-type="pmcid">PMC7905014</pub-id></element-citation></ref><ref id="B40-pharmaceuticals-16-01054"><label>40.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Nwonu</surname><given-names>E.J.</given-names></name></person-group><article-title>Approaches to cancer vaccination</article-title><source>Vaccinology and Methods in Vaccine Research</source><publisher-name>ACM</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2022</year><fpage>177</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/b978-0-323-91146-7.00003-2</pub-id></element-citation></ref><ref id="B41-pharmaceuticals-16-01054"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Yelensky</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jooss</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>T.A.</given-names></name></person-group><article-title>Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different</article-title><source>Trends Immunol.</source><year>2018</year><volume>39</volume><fpage>536</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/j.it.2018.04.005</pub-id><pub-id pub-id-type="pmid">29751996</pub-id><pub-id pub-id-type="pmcid">PMC7954132</pub-id></element-citation></ref><ref id="B42-pharmaceuticals-16-01054"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abd-Aziz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Poh</surname><given-names>C.L.</given-names></name></person-group><article-title>Development of Peptide-Based Vaccines for Cancer</article-title><source>J. Oncol.</source><year>2022</year><volume>2022</volume><fpage>9749363</fpage><pub-id pub-id-type="doi">10.1155/2022/9749363</pub-id><pub-id pub-id-type="pmid">35342400</pub-id><pub-id pub-id-type="pmcid">PMC8941562</pub-id></element-citation></ref><ref id="B43-pharmaceuticals-16-01054"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sotillo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Black</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Bagashev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oldridge</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sussman</surname><given-names>R.</given-names></name><name name-style="western"><surname>LaNauze</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ruella</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gazzara</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy</article-title><source>Cancer Discov.</source><year>2015</year><volume>5</volume><fpage>1282</fpage><lpage>1295</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-1020</pub-id><pub-id pub-id-type="pmid">26516065</pub-id><pub-id pub-id-type="pmcid">PMC4670800</pub-id></element-citation></ref><ref id="B44-pharmaceuticals-16-01054"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quakkelaar</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Fransen</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>van Maren</surname><given-names>W.W.C.</given-names></name><name name-style="western"><surname>Vaneman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Loof</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>van Heiningen</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Verbeek</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Ossendorp</surname><given-names>F.</given-names></name><name name-style="western"><surname>Melief</surname><given-names>C.J.M.</given-names></name></person-group><article-title>IgG-Mediated Anaphylaxis to a Synthetic Long Peptide Vaccine Containing a B Cell Epitope Can Be Avoided by Slow-Release Formulation</article-title><source>J. Immunol.</source><year>2014</year><volume>192</volume><fpage>5813</fpage><lpage>5820</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1302337</pub-id><pub-id pub-id-type="pmid">24813207</pub-id></element-citation></ref><ref id="B45-pharmaceuticals-16-01054"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nordin</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Norpi</surname><given-names>A.S.M.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Yusoff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Azmi</surname><given-names>F.</given-names></name></person-group><article-title>HER2/neu-Based Peptide Vaccination-Pulsed with B-Cell Epitope Induced Efficient Prophylactic and Therapeutic Antitumor Activities in TUBO Breast Cancer Mice Model</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>4958</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13194958</pub-id><pub-id pub-id-type="pmid">34638441</pub-id><pub-id pub-id-type="pmcid">PMC8507975</pub-id></element-citation></ref><ref id="B46-pharmaceuticals-16-01054"><label>46.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Marintcheva</surname><given-names>B.</given-names></name></person-group><article-title>Viruses as Tools for Vaccine Development</article-title><source>Harnessing the Power of Viruses</source><publisher-name>ACM</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2018</year><fpage>217</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/b978-0-12-810514-6.00008-8</pub-id></element-citation></ref><ref id="B47-pharmaceuticals-16-01054"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sasada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>K.</given-names></name></person-group><article-title>Next-generation peptide vaccines for advanced cancer</article-title><source>Cancer Sci.</source><year>2013</year><volume>104</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1111/cas.12050</pub-id><pub-id pub-id-type="pmid">23107418</pub-id><pub-id pub-id-type="pmcid">PMC7657262</pub-id></element-citation></ref><ref id="B48-pharmaceuticals-16-01054"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vassilakopoulou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Karachaliou</surname><given-names>C.-E.</given-names></name><name name-style="western"><surname>Evangelou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zikos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Livaniou</surname><given-names>E.</given-names></name></person-group><article-title>Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1278</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9111278</pub-id><pub-id pub-id-type="pmid">34835209</pub-id><pub-id pub-id-type="pmcid">PMC8622585</pub-id></element-citation></ref><ref id="B49-pharmaceuticals-16-01054"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vukicevic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fiorini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Siegert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carpintero</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rincon-Restrepo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lopez-Deber</surname><given-names>P.</given-names></name><name name-style="western"><surname>Piot</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ayer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rentero</surname><given-names>I.</given-names></name><name name-style="western"><surname>Babolin</surname><given-names>C.</given-names></name><etal/></person-group><article-title>An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer&#8217;s disease: Pyroglutamate amyloid beta</article-title><source>Brain Commun.</source><year>2022</year><volume>4</volume><fpage>fcac022</fpage><pub-id pub-id-type="doi">10.1093/braincomms/fcac022</pub-id><pub-id pub-id-type="pmid">35479516</pub-id><pub-id pub-id-type="pmcid">PMC9037369</pub-id></element-citation></ref><ref id="B50-pharmaceuticals-16-01054"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malonis</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Vergnolle</surname><given-names>O.</given-names></name></person-group><article-title>Peptide-Based Vaccines: Current Progress and Future Challenges</article-title><source>Chem. Rev.</source><year>2020</year><volume>120</volume><fpage>3210</fpage><lpage>3229</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.9b00472</pub-id><pub-id pub-id-type="pmid">31804810</pub-id><pub-id pub-id-type="pmcid">PMC7094793</pub-id></element-citation></ref><ref id="B51-pharmaceuticals-16-01054"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A D-peptide-based HIV gelatinous combination vaccine improves therapy in ART-delayed macaques of chronic infection</article-title><source>Nano Today</source><year>2022</year><volume>42</volume><fpage>101353</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2021.101353</pub-id></element-citation></ref><ref id="B52-pharmaceuticals-16-01054"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Combadi&#232;re</surname><given-names>B.</given-names></name><name name-style="western"><surname>Beaujean</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chaudesaigues</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vieillard</surname><given-names>V.</given-names></name></person-group><article-title>Peptide-Based Vaccination for Antibody Responses Against HIV</article-title><source>Vaccines</source><year>2019</year><volume>7</volume><elocation-id>105</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines7030105</pub-id><pub-id pub-id-type="pmid">31480779</pub-id><pub-id pub-id-type="pmcid">PMC6789779</pub-id></element-citation></ref><ref id="B53-pharmaceuticals-16-01054"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sumadi</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Jamil</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Auliyana</surname><given-names>N.</given-names></name><name name-style="western"><surname>H</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>K</surname><given-names>R.N.</given-names></name></person-group><article-title>Developing an Epitope-Based Peptide Vaccine for the Hepatitis C Virus Using an in Silico Approach</article-title><source>KnE Med.</source><year>2022</year><fpage>212</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.18502/kme.v2i3.11871</pub-id></element-citation></ref><ref id="B54-pharmaceuticals-16-01054"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name></person-group><article-title>Peptide-Based Vaccines for Tuberculosis</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>104</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.830497</pub-id><pub-id pub-id-type="pmcid">PMC8841753</pub-id><pub-id pub-id-type="pmid">35173740</pub-id></element-citation></ref><ref id="B55-pharmaceuticals-16-01054"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ca&#241;as-Arranz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Defaus</surname><given-names>S.</given-names></name><name name-style="western"><surname>de Le&#243;n</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Pulido</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ganges</surname><given-names>L.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sobrino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Andreu</surname><given-names>D.</given-names></name></person-group><article-title>Peptide-Based Vaccines: Foot-and-Mouth Disease Virus, a Paradigm in Animal Health</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>477</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9050477</pub-id><pub-id pub-id-type="pmid">34066901</pub-id><pub-id pub-id-type="pmcid">PMC8150788</pub-id></element-citation></ref><ref id="B56-pharmaceuticals-16-01054"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Peptide-based therapeutic cancer vaccine: Current trends in clinical application</article-title><source>Cell Prolif.</source><year>2021</year><volume>54</volume><fpage>e13025</fpage><pub-id pub-id-type="doi">10.1111/cpr.13025</pub-id><pub-id pub-id-type="pmid">33754407</pub-id><pub-id pub-id-type="pmcid">PMC8088465</pub-id></element-citation></ref><ref id="B57-pharmaceuticals-16-01054"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Speetjens</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Kuppen</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Welters</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Essahsah</surname><given-names>F.</given-names></name><name name-style="western"><surname>Brink</surname><given-names>A.M.E.V.v.D.</given-names></name><name name-style="western"><surname>Lantrua</surname><given-names>M.G.K.</given-names></name><name name-style="western"><surname>Valentijn</surname><given-names>A.R.P.</given-names></name><name name-style="western"><surname>Oostendorp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fathers</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Nijman</surname><given-names>H.W.</given-names></name><etal/></person-group><article-title>Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer</article-title><source>Clin. Cancer Res.</source><year>2009</year><volume>15</volume><fpage>1086</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2227</pub-id><pub-id pub-id-type="pmid">19188184</pub-id></element-citation></ref><ref id="B58-pharmaceuticals-16-01054"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Poelgeest</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Welters</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>van Esch</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Stynenbosch</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Kerpershoek</surname><given-names>G.</given-names></name><name name-style="western"><surname>van Persijn van Meerten</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>van den Hende</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#246;wik</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Berends-van der Meer</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Fathers</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial</article-title><source>J. Transl. Med.</source><year>2013</year><volume>11</volume><fpage>88</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-11-88</pub-id><pub-id pub-id-type="pmid">23557172</pub-id><pub-id pub-id-type="pmcid">PMC3623745</pub-id></element-citation></ref><ref id="B59-pharmaceuticals-16-01054"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rangan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Florenceau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fortun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Charpentier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dupr&#233;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Paolini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Beauvillain</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dupel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Latouche</surname><given-names>J.-B.</given-names></name><etal/></person-group><article-title>Cancer vaccines: Designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells</article-title><source>Oncoimmunology</source><year>2019</year><volume>8</volume><fpage>e1560919-10</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2018.1560919</pub-id><pub-id pub-id-type="pmid">30906653</pub-id><pub-id pub-id-type="pmcid">PMC6422379</pub-id></element-citation></ref><ref id="B60-pharmaceuticals-16-01054"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Botelho</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Tschumi</surname><given-names>B.O.</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Donda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>P.</given-names></name></person-group><article-title>Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>294</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00294</pub-id><pub-id pub-id-type="pmid">30863405</pub-id><pub-id pub-id-type="pmcid">PMC6399421</pub-id></element-citation></ref><ref id="B61-pharmaceuticals-16-01054"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dolan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jahagirdar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.-C.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pili</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Immunization with short peptide particles reveals a functional CD8<sup>+</sup> T-cell neoepitope in a murine renal carcinoma model</article-title><source>J. Immunother. Cancer</source><year>2021</year><volume>9</volume><fpage>e003101</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-003101</pub-id><pub-id pub-id-type="pmid">34862254</pub-id><pub-id pub-id-type="pmcid">PMC8647534</pub-id></element-citation></ref><ref id="B62-pharmaceuticals-16-01054"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>M.</given-names></name><name name-style="western"><surname>Finch</surname><given-names>W.</given-names></name><name name-style="western"><surname>Coombs</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>76516</fpage><lpage>76524</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.20407</pub-id><pub-id pub-id-type="pmid">29100330</pub-id><pub-id pub-id-type="pmcid">PMC5652724</pub-id></element-citation></ref><ref id="B63-pharmaceuticals-16-01054"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahdevar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Safavi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abiri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kefayat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hejazi</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Miresmaeili</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mobarakeh</surname><given-names>V.I.</given-names></name></person-group><article-title>Exploring the cancer-testis antigen BORIS to design a novel multi-epitope vaccine against breast cancer based on immunoinformatics approaches</article-title><source>J. Biomol. Struct. Dyn.</source><year>2021</year><volume>40</volume><fpage>6363</fpage><lpage>6380</lpage><pub-id pub-id-type="doi">10.1080/07391102.2021.1883111</pub-id><pub-id pub-id-type="pmid">33599191</pub-id></element-citation></ref><ref id="B64-pharmaceuticals-16-01054"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahdevar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kefayat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Safavi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Behnia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hejazi</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Javid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghahremani</surname><given-names>F.</given-names></name></person-group><article-title>Immunoprotective effect of an in silico designed multiepitope cancer vaccine with BORIS cancer-testis antigen target in a murine mammary carcinoma model</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/s41598-021-01770-w</pub-id><pub-id pub-id-type="pmid">34848739</pub-id><pub-id pub-id-type="pmcid">PMC8632969</pub-id></element-citation></ref><ref id="B65-pharmaceuticals-16-01054"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slamon</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Levin</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Ullrich</surname><given-names>A.</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>W.L.</given-names></name></person-group><article-title>Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene</article-title><source>Science</source><year>1987</year><volume>235</volume><fpage>182</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1126/science.3798106</pub-id><pub-id pub-id-type="pmid">3798106</pub-id></element-citation></ref><ref id="B66-pharmaceuticals-16-01054"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burstein</surname><given-names>H.J.</given-names></name></person-group><article-title>The Distinctive Nature of HER2-Positive Breast Cancers</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>353</volume><fpage>1652</fpage><lpage>1654</lpage><pub-id pub-id-type="doi">10.1056/NEJMp058197</pub-id><pub-id pub-id-type="pmid">16236735</pub-id></element-citation></ref><ref id="B67-pharmaceuticals-16-01054"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Modi</surname><given-names>S.</given-names></name></person-group><article-title>HER2 breast cancer therapies: A review</article-title><source>Biologics</source><year>2009</year><volume>3</volume><fpage>289</fpage><pub-id pub-id-type="doi">10.2147/BTT.S3479</pub-id><pub-id pub-id-type="pmid">19707416</pub-id><pub-id pub-id-type="pmcid">PMC2726059</pub-id></element-citation></ref><ref id="B68-pharmaceuticals-16-01054"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvajal-Hausdorf</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Schalper</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Black</surname><given-names>J.</given-names></name><name name-style="western"><surname>Santin</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Rimm</surname><given-names>D.L.</given-names></name></person-group><article-title>Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance</article-title><source>Gynecol. Oncol.</source><year>2017</year><volume>145</volume><fpage>154</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2017.02.002</pub-id><pub-id pub-id-type="pmid">28196634</pub-id><pub-id pub-id-type="pmcid">PMC5941302</pub-id></element-citation></ref><ref id="B69-pharmaceuticals-16-01054"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slamon</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Godolphin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Keith</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Levin</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Udove</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ullrich</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer</article-title><source>Science</source><year>1989</year><volume>244</volume><fpage>707</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1126/science.2470152</pub-id><pub-id pub-id-type="pmid">2470152</pub-id></element-citation></ref><ref id="B70-pharmaceuticals-16-01054"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buza</surname><given-names>N.</given-names></name><name name-style="western"><surname>English</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Santin</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>P.</given-names></name></person-group><article-title>Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice</article-title><source>Mod. Pathol.</source><year>2013</year><volume>26</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2013.113</pub-id><pub-id pub-id-type="pmid">23765245</pub-id></element-citation></ref><ref id="B71-pharmaceuticals-16-01054"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iqbal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>N.</given-names></name></person-group><article-title>Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications</article-title><source>Mol. Biol. Int.</source><year>2014</year><volume>2014</volume><fpage>852748</fpage><pub-id pub-id-type="doi">10.1155/2014/852748</pub-id><pub-id pub-id-type="pmid">25276427</pub-id><pub-id pub-id-type="pmcid">PMC4170925</pub-id></element-citation></ref><ref id="B72-pharmaceuticals-16-01054"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnamurti</surname><given-names>U.</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>J.F.</given-names></name></person-group><article-title>HER2 in Breast Cancer: A review and update</article-title><source>Adv. Anat. Pathol.</source><year>2014</year><volume>21</volume><fpage>100</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1097/PAP.0000000000000015</pub-id><pub-id pub-id-type="pmid">24508693</pub-id></element-citation></ref><ref id="B73-pharmaceuticals-16-01054"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Baruch</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Bose</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kavuri</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>M.J.</given-names></name></person-group><article-title><italic toggle="yes">HER2</italic>-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor</article-title><source>J. Natl. Compr. Cancer Netw.</source><year>2015</year><volume>13</volume><fpage>1061</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2015.0131</pub-id><pub-id pub-id-type="pmcid">PMC4701428</pub-id><pub-id pub-id-type="pmid">26358790</pub-id></element-citation></ref><ref id="B74-pharmaceuticals-16-01054"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>M.-C.</given-names></name><name name-style="western"><surname>Marks</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Mandell</surname><given-names>J.B.</given-names></name></person-group><article-title>Breast and Ovarian Cancer Risks Due to Inherited Mutations in <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic></article-title><source>Science</source><year>2003</year><volume>302</volume><fpage>643</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1126/science.1088759</pub-id><pub-id pub-id-type="pmid">14576434</pub-id></element-citation></ref><ref id="B75-pharmaceuticals-16-01054"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>van Overeem Hansen</surname><given-names>T.</given-names></name><name name-style="western"><surname>S&#248;rensen</surname><given-names>C.S.</given-names></name></person-group><article-title>Hereditary breast and ovarian cancer: New genes in confined pathways</article-title><source>Nat. Rev. Cancer</source><year>2016</year><volume>16</volume><fpage>599</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.72</pub-id><pub-id pub-id-type="pmid">27515922</pub-id></element-citation></ref><ref id="B76-pharmaceuticals-16-01054"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuusisto</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Bebel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vihinen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schleutker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sallinen</surname><given-names>S.L.</given-names></name></person-group><article-title>Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals</article-title><source>Breast Cancer Res.</source><year>2011</year><volume>13</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1186/bcr2832</pub-id><pub-id pub-id-type="pmcid">PMC3109589</pub-id><pub-id pub-id-type="pmid">21356067</pub-id></element-citation></ref><ref id="B77-pharmaceuticals-16-01054"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>G.</given-names></name></person-group><article-title>The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy</article-title><source>Semin. Oncol.</source><year>2001</year><volume>28</volume><fpage>125</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/S0093-7754(01)90290-8</pub-id><pub-id pub-id-type="pmid">11706404</pub-id></element-citation></ref><ref id="B78-pharmaceuticals-16-01054"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsukita</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nomoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kitajima</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Irimura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yonezawa</surname><given-names>S.</given-names></name></person-group><article-title>Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma of the breast: Comparison with invasive ductal carcinoma</article-title><source>Histopathology</source><year>2003</year><volume>42</volume><fpage>26</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2559.2003.01530.x</pub-id><pub-id pub-id-type="pmid">12493022</pub-id></element-citation></ref><ref id="B79-pharmaceuticals-16-01054"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Ro</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.-W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.S.</given-names></name></person-group><article-title>The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma</article-title><source>Cancer</source><year>2005</year><volume>104</volume><fpage>251</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1002/cncr.21162</pub-id><pub-id pub-id-type="pmid">15937912</pub-id></element-citation></ref><ref id="B80-pharmaceuticals-16-01054"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayyoub</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scarlata</surname><given-names>C.-M.</given-names></name><name name-style="western"><surname>Hama&#239;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pignon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Valmori</surname><given-names>D.</given-names></name></person-group><article-title>Expression of MAGE-A3/6 in Primary Breast Cancer is Associated With Hormone Receptor Negative Status, High Histologic Grade, and Poor Survival</article-title><source>J. Immunother.</source><year>2014</year><volume>37</volume><fpage>73</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1097/CJI.0000000000000013</pub-id><pub-id pub-id-type="pmid">24509169</pub-id></element-citation></ref><ref id="B81-pharmaceuticals-16-01054"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tobias</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garner-Spitzer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Drini&#263;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wiedermann</surname><given-names>U.</given-names></name></person-group><article-title>Vaccination against Her-2/neu, with focus on peptide-based vaccines</article-title><source>ESMO Open</source><year>2022</year><volume>7</volume><fpage>100361</fpage><pub-id pub-id-type="doi">10.1016/j.esmoop.2021.100361</pub-id><pub-id pub-id-type="pmid">35026721</pub-id><pub-id pub-id-type="pmcid">PMC8760406</pub-id></element-citation></ref><ref id="B82-pharmaceuticals-16-01054"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Disis</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Goodell</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schiffman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Knutson</surname><given-names>K.L.</given-names></name></person-group><article-title>Humoral Epitope-Spreading Following Immunization with a HER-2/neu Peptide Based Vaccine in Cancer Patients</article-title><source>J Clin Immunol.</source><year>2004</year><volume>24</volume><fpage>571</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1023/B:JOCI.0000040928.67495.52</pub-id><pub-id pub-id-type="pmid">15359116</pub-id></element-citation></ref><ref id="B83-pharmaceuticals-16-01054"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peoples</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Gurney</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Hueman</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Woll</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Storrer</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shriver</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Ioannides</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Ponniah</surname><given-names>S.</given-names></name></person-group><article-title>Clinical Trial Results of a HER2/<italic toggle="yes">neu</italic> (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients</article-title><source>J. Clin. Oncol.</source><year>2005</year><volume>23</volume><fpage>7536</fpage><lpage>7545</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.03.047</pub-id><pub-id pub-id-type="pmid">16157940</pub-id></element-citation></ref><ref id="B84-pharmaceuticals-16-01054"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmichael</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Benavides</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Gates</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Mittendorf</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ponniah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peoples</surname><given-names>G.E.</given-names></name></person-group><article-title>Results of the first phase 1 clinical trial of the HER-2/neupeptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04</article-title><source>Cancer</source><year>2010</year><volume>116</volume><fpage>292</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1002/cncr.24756</pub-id><pub-id pub-id-type="pmid">19924797</pub-id></element-citation></ref><ref id="B85-pharmaceuticals-16-01054"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Toh</surname><given-names>U.</given-names></name><name name-style="western"><surname>Iwakuma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takenaka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Otsuka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Furukawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>T.</given-names></name><name name-style="western"><surname>Seki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kawahara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kage</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients</article-title><source>Breast Cancer Res.</source><year>2014</year><volume>16</volume><fpage>R70</fpage><pub-id pub-id-type="doi">10.1186/bcr3685</pub-id><pub-id pub-id-type="pmid">24992895</pub-id><pub-id pub-id-type="pmcid">PMC4227005</pub-id></element-citation></ref><ref id="B86-pharmaceuticals-16-01054"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonilli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rahimi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Visconti</surname><given-names>V.</given-names></name><name name-style="western"><surname>Napoletano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ruscito</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zizzari</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Caponnetto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barchiesi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Iadarola</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pierelli</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial</article-title><source>Int. J. Oncol.</source><year>2016</year><volume>48</volume><fpage>1369</fpage><lpage>1378</lpage><pub-id pub-id-type="doi">10.3892/ijo.2016.3386</pub-id><pub-id pub-id-type="pmid">26892612</pub-id><pub-id pub-id-type="pmcid">PMC4777599</pub-id></element-citation></ref><ref id="B87-pharmaceuticals-16-01054"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dillon</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Petroni</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Smolkin</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Brenin</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Chianese-Bullock</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Fanous</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Nail</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Brenin</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer</article-title><source>J. Immunother. Cancer</source><year>2017</year><volume>5</volume><fpage>92</fpage><pub-id pub-id-type="doi">10.1186/s40425-017-0295-5</pub-id><pub-id pub-id-type="pmid">29157306</pub-id><pub-id pub-id-type="pmcid">PMC5697108</pub-id></element-citation></ref><ref id="B88-pharmaceuticals-16-01054"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Mittendorf</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Hale</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Peace</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>D.O.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Vreeland</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Clifton</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Ardavanis</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence</article-title><source>Breast Cancer Res. Treat.</source><year>2020</year><volume>181</volume><fpage>391</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1007/s10549-020-05638-x</pub-id><pub-id pub-id-type="pmid">32323103</pub-id><pub-id pub-id-type="pmcid">PMC7188712</pub-id></element-citation></ref><ref id="B89-pharmaceuticals-16-01054"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toh</surname><given-names>U.</given-names></name><name name-style="western"><surname>Sakurai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saku</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okabe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iwakuma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shichijo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Akagi</surname><given-names>Y.</given-names></name></person-group><article-title>Early phase II study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancer</article-title><source>Cancer Sci.</source><year>2020</year><volume>111</volume><fpage>2760</fpage><lpage>2769</lpage><pub-id pub-id-type="doi">10.1111/cas.14510</pub-id><pub-id pub-id-type="pmid">32495455</pub-id><pub-id pub-id-type="pmcid">PMC7419019</pub-id></element-citation></ref><ref id="B90-pharmaceuticals-16-01054"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barati</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nikpoor</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Mosaffa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Razazan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Badiee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Motavallihaghi</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Behravan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jaafari</surname><given-names>M.R.</given-names></name></person-group><article-title>AE36 HER2/neu-derived peptide linked to positively charged liposomes with CpG-ODN as an effective therapeutic and prophylactic vaccine for breast cancer</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2021</year><volume>67</volume><fpage>102904</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2021.102904</pub-id></element-citation></ref><ref id="B91-pharmaceuticals-16-01054"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chamani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ranji</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hadji</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nahvijou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Esmati</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alizadeh</surname><given-names>A.M.</given-names></name></person-group><article-title>Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis</article-title><source>Eur. J. Pharmacol.</source><year>2018</year><volume>831</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2018.05.010</pub-id><pub-id pub-id-type="pmid">29753042</pub-id></element-citation></ref><ref id="B92-pharmaceuticals-16-01054"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>F.</given-names></name></person-group><article-title>Application of HER2 peptide vaccines in patients with breast cancer: A systematic review and meta-analysis</article-title><source>Cancer Cell Int.</source><year>2021</year><volume>21</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/s12935-021-02187-1</pub-id><pub-id pub-id-type="pmid">34526020</pub-id><pub-id pub-id-type="pmcid">PMC8442296</pub-id></element-citation></ref><ref id="B93-pharmaceuticals-16-01054"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erickson</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Zeybek</surname><given-names>B.</given-names></name><name name-style="western"><surname>Santin</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Fader</surname><given-names>A.N.</given-names></name></person-group><article-title>Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies</article-title><source>Curr. Opin. Obstet. Gynecol.</source><year>2020</year><volume>32</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1097/GCO.0000000000000599</pub-id><pub-id pub-id-type="pmid">31833974</pub-id><pub-id pub-id-type="pmcid">PMC7307693</pub-id></element-citation></ref><ref id="B94-pharmaceuticals-16-01054"><label>94.</label><element-citation publication-type="gov"><article-title>Generation of Immunity to the HER-2/neu Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-Based Vaccine-PubMed</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/10389911/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/10389911/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-07">(accessed on 7 April 2023)</date-in-citation></element-citation></ref><ref id="B95-pharmaceuticals-16-01054"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brossart</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wirths</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stuhler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reichardt</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Kanz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brugger</surname><given-names>W.</given-names></name></person-group><article-title>Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells</article-title><source>Blood</source><year>2000</year><volume>96</volume><fpage>3102</fpage><lpage>3108</lpage><pub-id pub-id-type="doi">10.1182/blood.V96.9.3102</pub-id><pub-id pub-id-type="pmid">11049990</pub-id></element-citation></ref><ref id="B96-pharmaceuticals-16-01054"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albert</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Sauter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>N.</given-names></name></person-group><article-title>Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs</article-title><source>Nature</source><year>1998</year><volume>392</volume><fpage>86</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1038/32183</pub-id><pub-id pub-id-type="pmid">9510252</pub-id></element-citation></ref><ref id="B97-pharmaceuticals-16-01054"><label>97.</label><element-citation publication-type="gov"><article-title>Immunization of Cancer Patients with a HER-2/neu, HLA-A2 Peptide, p369-377, Results in Short-Lived Peptide-Specific Immunity-PubMed</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12006513/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/12006513/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-07">(accessed on 7 April 2023)</date-in-citation></element-citation></ref><ref id="B98-pharmaceuticals-16-01054"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chianese-Bullock</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Irvin</surname><given-names>W.P.J.</given-names></name><name name-style="western"><surname>Petroni</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Smolkin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Boerner</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Nail</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Neese</surname><given-names>P.Y.</given-names></name><etal/></person-group><article-title>A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer</article-title><source>J. Immunother.</source><year>2008</year><volume>31</volume><fpage>420</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e31816dad10</pub-id><pub-id pub-id-type="pmid">18391753</pub-id></element-citation></ref><ref id="B99-pharmaceuticals-16-01054"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fulk</surname><given-names>K.</given-names></name><name name-style="western"><surname>Milam</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yussuf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Black</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>LaDuca</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stany</surname><given-names>M.P.</given-names></name></person-group><article-title>Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing</article-title><source>Gynecol. Oncol.</source><year>2019</year><volume>152</volume><fpage>612</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2018.12.021</pub-id><pub-id pub-id-type="pmid">30612783</pub-id></element-citation></ref><ref id="B100-pharmaceuticals-16-01054"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackenzie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kommoss</surname><given-names>S.</given-names></name><name name-style="western"><surname>Winterhoff</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Kipp</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Voss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Halling</surname><given-names>K.</given-names></name><name name-style="western"><surname>Karnezis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Senz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms</article-title><source>BMC Cancer</source><year>2015</year><volume>15</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12885-015-1421-8</pub-id><pub-id pub-id-type="pmid">25986173</pub-id><pub-id pub-id-type="pmcid">PMC4494777</pub-id></element-citation></ref><ref id="B101-pharmaceuticals-16-01054"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Ginardi</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Tinder</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>F.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>B.</given-names></name><name name-style="western"><surname>Longenecker</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Gendler</surname><given-names>S.J.</given-names></name></person-group><article-title>Mucin 1-Specific Immunotherapy in a Mouse Model of Spontaneous Breast Cancer</article-title><source>J. Immunother.</source><year>2003</year><volume>26</volume><fpage>47</fpage><lpage>62</lpage><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.lww.com/immunotherapy-journal/fulltext/2003/01000/mucin_1_specific_immunotherapy_in_a_mouse_model_of.6.aspx" ext-link-type="uri">https://journals.lww.com/immunotherapy-journal/fulltext/2003/01000/mucin_1_specific_immunotherapy_in_a_mouse_model_of.6.aspx</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-07">(accessed on 7 April 2023)</date-in-citation><pub-id pub-id-type="doi">10.1097/00002371-200301000-00006</pub-id><pub-id pub-id-type="pmid">12514429</pub-id></element-citation></ref><ref id="B102-pharmaceuticals-16-01054"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leffers</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lambeck</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Gooden</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Hoogeboom</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hamming</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Hepkema</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Willemse</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Molmans</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Hollema</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial</article-title><source>Int. J. Cancer</source><year>2009</year><volume>125</volume><fpage>2104</fpage><lpage>2113</lpage><pub-id pub-id-type="doi">10.1002/ijc.24597</pub-id><pub-id pub-id-type="pmid">19621448</pub-id></element-citation></ref><ref id="B103-pharmaceuticals-16-01054"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermeij</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leffers</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hoogeboom</surname><given-names>B.-N.</given-names></name><name name-style="western"><surname>Hamming</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reyners</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Molmans</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Hollema</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Drijfhout</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study</article-title><source>Int. J. Cancer</source><year>2012</year><volume>131</volume><fpage>E670</fpage><lpage>E680</lpage><pub-id pub-id-type="doi">10.1002/ijc.27388</pub-id><pub-id pub-id-type="pmid">22139992</pub-id></element-citation></ref><ref id="B104-pharmaceuticals-16-01054"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabbatini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ferran</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ritter</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sedrak</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tuballes</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jungbluth</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Ritter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aghajanian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bell-McGuinn</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients</article-title><source>Clin. Cancer Res.</source><year>2012</year><volume>18</volume><fpage>6497</fpage><lpage>6508</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-2189</pub-id><pub-id pub-id-type="pmid">23032745</pub-id></element-citation></ref><ref id="B105-pharmaceuticals-16-01054"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leffers</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vermeij</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hoogeboom</surname><given-names>B.-N.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>U.R.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hamming</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>van der Zee</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Melief</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>van der Burg</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Daemen</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Long-term clinical and immunological effects of p53-SLP<sup>&#174;</sup> vaccine in patients with ovarian cancer</article-title><source>Int. J. Cancer</source><year>2012</year><volume>130</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1002/ijc.25980</pub-id><pub-id pub-id-type="pmid">21328579</pub-id></element-citation></ref><ref id="B106-pharmaceuticals-16-01054"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahma</surname><given-names>O.E.</given-names></name><name name-style="western"><surname>Ashtar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Czystowska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Szajnik</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Wieckowski</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Herrin</surname><given-names>V.E.</given-names></name><name name-style="western"><surname>Shams</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Merino</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients</article-title><source>Cancer Immunol. Immunother.</source><year>2012</year><volume>61</volume><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1007/s00262-011-1100-9</pub-id><pub-id pub-id-type="pmid">21927947</pub-id><pub-id pub-id-type="pmcid">PMC3708463</pub-id></element-citation></ref><ref id="B107-pharmaceuticals-16-01054"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyatake</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Morimoto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Enomoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shirakata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tsuboi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oji</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hosen</surname><given-names>N.</given-names></name><etal/></person-group><article-title>WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: A phase II trial</article-title><source>J. Cancer Res. Clin. Oncol.</source><year>2013</year><volume>139</volume><fpage>457</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1007/s00432-012-1348-2</pub-id><pub-id pub-id-type="pmid">23160854</pub-id><pub-id pub-id-type="pmcid">PMC11824617</pub-id></element-citation></ref><ref id="B108-pharmaceuticals-16-01054"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujita</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Koshikawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nagura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>K.</given-names></name><name name-style="western"><surname>Miyoshi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamauchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Phase I clinical trial of multi-antigen peptide vaccines therapy using cancer-testis antigens for patients with advanced or recurrent breast cancer</article-title><source>J. Clin. Oncol.</source><year>2012</year><volume>30</volume><issue>(Suppl. 15)</issue><fpage>e13037</fpage><pub-id pub-id-type="doi">10.1200/jco.2012.30.15_suppl.e13037</pub-id></element-citation></ref><ref id="B109-pharmaceuticals-16-01054"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsuda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Matsueda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sasada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ushijima</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yokomine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients</article-title><source>Immunopharmacol. Immunotoxicol.</source><year>2014</year><volume>36</volume><fpage>224</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.3109/08923973.2014.913617</pub-id><pub-id pub-id-type="pmid">24773550</pub-id></element-citation></ref><ref id="B110-pharmaceuticals-16-01054"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chiba</surname><given-names>A.</given-names></name><name name-style="western"><surname>Izawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yanagida</surname><given-names>E.</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shimodaira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yonemitsu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shibamoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nagaya</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer</article-title><source>J. Ovarian Res.</source><year>2014</year><volume>7</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/1757-2215-7-48</pub-id><pub-id pub-id-type="pmid">25298213</pub-id><pub-id pub-id-type="pmcid">PMC4108140</pub-id></element-citation></ref><ref id="B111-pharmaceuticals-16-01054"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murahashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hijikata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kishimoto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>H.</given-names></name><name name-style="western"><surname>Marumoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Okazaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors</article-title><source>Clin. Immunol.</source><year>2016</year><volume>166&#8211;167</volume><fpage>48</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2016.03.015</pub-id><pub-id pub-id-type="pmid">27072896</pub-id></element-citation></ref><ref id="B112-pharmaceuticals-16-01054"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalli</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Block</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kasi</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Erskine</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Hobday</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Dietz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Padley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gustafson</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Shreeder</surname><given-names>B.</given-names></name><name name-style="western"><surname>Puglisi-Knutson</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients</article-title><source>Clin. Cancer Res.</source><year>2018</year><volume>24</volume><fpage>3014</fpage><lpage>3025</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-2499</pub-id><pub-id pub-id-type="pmid">29545464</pub-id><pub-id pub-id-type="pmcid">PMC6030477</pub-id></element-citation></ref><ref id="B113-pharmaceuticals-16-01054"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>McKay</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pett</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schorlemer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gohl</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sungsuwan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramadan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baniel</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice</article-title><source>J. Am. Chem. Soc.</source><year>2018</year><volume>140</volume><fpage>16596</fpage><lpage>16609</lpage><pub-id pub-id-type="doi">10.1021/jacs.8b08473</pub-id><pub-id pub-id-type="pmid">30398345</pub-id><pub-id pub-id-type="pmcid">PMC6470043</pub-id></element-citation></ref><ref id="B114-pharmaceuticals-16-01054"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hijikata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okazaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Murahashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kishimoto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0187878</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0187878</pub-id><pub-id pub-id-type="pmid">29293510</pub-id><pub-id pub-id-type="pmcid">PMC5749706</pub-id></element-citation></ref><ref id="B115-pharmaceuticals-16-01054"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasegawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kunugi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kurosaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Imai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kohyama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nagao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kozawa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsunoda</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer</article-title><source>J. Immunother.</source><year>2018</year><volume>41</volume><fpage>201</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1097/CJI.0000000000000214</pub-id><pub-id pub-id-type="pmid">29432282</pub-id></element-citation></ref><ref id="B116-pharmaceuticals-16-01054"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarivalasis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boudousqui&#233;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Balint</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Gannon</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Iancu</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Rossier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lluesma</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mathevet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sempoux</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma</article-title><source>J. Transl. Med.</source><year>2019</year><volume>17</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12967-019-02133-w</pub-id><pub-id pub-id-type="pmid">31771601</pub-id><pub-id pub-id-type="pmcid">PMC6880492</pub-id></element-citation></ref><ref id="B117-pharmaceuticals-16-01054"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Byrd</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vreeland</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Clifton</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>D.O.</given-names></name><name name-style="western"><surname>Hale</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Herbert</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients</article-title><source>Cancer Med.</source><year>2019</year><volume>8</volume><fpage>4678</fpage><lpage>4687</lpage><pub-id pub-id-type="doi">10.1002/cam4.2378</pub-id><pub-id pub-id-type="pmid">31274231</pub-id><pub-id pub-id-type="pmcid">PMC6712444</pub-id></element-citation></ref><ref id="B118-pharmaceuticals-16-01054"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Diao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Synthetic MUC1 breast cancer vaccine containing a Toll-like receptor 7 agonist exerts antitumor effects</article-title><source>Oncol. Lett.</source><year>2020</year><volume>20</volume><fpage>2369</fpage><lpage>2377</lpage><pub-id pub-id-type="doi">10.3892/ol.2020.11762</pub-id><pub-id pub-id-type="pmid">32782554</pub-id><pub-id pub-id-type="pmcid">PMC7400475</pub-id></element-citation></ref><ref id="B119-pharmaceuticals-16-01054"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morisaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hikichi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Onishi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Morisaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kubo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hirano</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshimura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kiyotani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>Y.</given-names></name></person-group><article-title>Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites</article-title><source>Immunol. Investig.</source><year>2020</year><volume>50</volume><fpage>562</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1080/08820139.2020.1778721</pub-id><pub-id pub-id-type="pmid">32660279</pub-id></element-citation></ref><ref id="B120-pharmaceuticals-16-01054"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Disis</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Gim</surname><given-names>J.-A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.H.</given-names></name></person-group><article-title>Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+ breast cancer murine model</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e004702</fpage><pub-id pub-id-type="doi">10.1136/jitc-2022-004702</pub-id><pub-id pub-id-type="pmid">36109084</pub-id><pub-id pub-id-type="pmcid">PMC9478831</pub-id></element-citation></ref><ref id="B121-pharmaceuticals-16-01054"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dzobo</surname><given-names>K.</given-names></name></person-group><article-title>The Role of Viruses in Carcinogenesis and Molecular Targeting: From Infection to Being a Component of the Tumor Microenvironment</article-title><source>OMICS A J. Integr. Biol.</source><year>2021</year><volume>25</volume><fpage>358</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1089/omi.2021.0052</pub-id><pub-id pub-id-type="pmid">34037476</pub-id></element-citation></ref><ref id="B122-pharmaceuticals-16-01054"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hausen</surname><given-names>H.Z.</given-names></name></person-group><article-title>Viruses in Human Cancers</article-title><source>Science</source><year>1991</year><volume>254</volume><fpage>1167</fpage><lpage>1173</lpage><pub-id pub-id-type="doi">10.1126/science.1659743</pub-id><pub-id pub-id-type="pmid">1659743</pub-id></element-citation></ref><ref id="B123-pharmaceuticals-16-01054"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawson</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Heng</surname><given-names>B.</given-names></name></person-group><article-title>Viruses and Breast Cancer</article-title><source>Cancers</source><year>2010</year><volume>2</volume><fpage>752</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.3390/cancers2020752</pub-id><pub-id pub-id-type="pmid">24281093</pub-id><pub-id pub-id-type="pmcid">PMC3835103</pub-id></element-citation></ref><ref id="B124-pharmaceuticals-16-01054"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burk</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Harari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>Human papillomavirus genome variants</article-title><source>Virology</source><year>2013</year><volume>445</volume><fpage>232</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2013.07.018</pub-id><pub-id pub-id-type="pmid">23998342</pub-id><pub-id pub-id-type="pmcid">PMC3979972</pub-id></element-citation></ref><ref id="B125-pharmaceuticals-16-01054"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garbuglia</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Lapa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sias</surname><given-names>C.</given-names></name><name name-style="western"><surname>Capobianchi</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Del Porto</surname><given-names>P.</given-names></name></person-group><article-title>The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>188</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.00188</pub-id><pub-id pub-id-type="pmid">32133000</pub-id><pub-id pub-id-type="pmcid">PMC7040023</pub-id></element-citation></ref><ref id="B126-pharmaceuticals-16-01054"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazzeroni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>D.</given-names></name></person-group><article-title>Potential Use of Vaccines in the Primary Prevention of Breast Cancer in High-Risk Patients</article-title><source>Breast Care</source><year>2012</year><volume>7</volume><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1159/000342167</pub-id><pub-id pub-id-type="pmid">23904830</pub-id><pub-id pub-id-type="pmcid">PMC3515785</pub-id></element-citation></ref><ref id="B127-pharmaceuticals-16-01054"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kundu</surname><given-names>R.</given-names></name></person-group><article-title>Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy</article-title><source>Front. Microbiol.</source><year>2020</year><volume>10</volume><fpage>3116</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.03116</pub-id><pub-id pub-id-type="pmid">32038557</pub-id><pub-id pub-id-type="pmcid">PMC6985034</pub-id></element-citation></ref><ref id="B128-pharmaceuticals-16-01054"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enokida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>N.</given-names></name></person-group><article-title>Vaccines for immunoprevention of cancer</article-title><source>J. Clin. Investig.</source><year>2021</year><volume>131</volume><fpage>6956</fpage><pub-id pub-id-type="doi">10.1172/JCI146956</pub-id><pub-id pub-id-type="pmid">33938446</pub-id><pub-id pub-id-type="pmcid">PMC8087198</pub-id></element-citation></ref><ref id="B129-pharmaceuticals-16-01054"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirnbauer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Booy</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lowy</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Schiller</surname><given-names>J.T.</given-names></name></person-group><article-title>Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1992</year><volume>89</volume><fpage>12180</fpage><lpage>12184</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.24.12180</pub-id><pub-id pub-id-type="pmid">1334560</pub-id><pub-id pub-id-type="pmcid">PMC50722</pub-id></element-citation></ref><ref id="B130-pharmaceuticals-16-01054"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chabeda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yanez</surname><given-names>R.J.R.</given-names></name><name name-style="western"><surname>Lamprecht</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meyers</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Rybicki</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Hitzeroth</surname><given-names>I.I.</given-names></name></person-group><article-title>Therapeutic vaccines for high-risk HPV-associated diseases</article-title><source>Papillomavirus Res.</source><year>2018</year><volume>5</volume><fpage>46</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.pvr.2017.12.006</pub-id><pub-id pub-id-type="pmid">29277575</pub-id><pub-id pub-id-type="pmcid">PMC5887015</pub-id></element-citation></ref><ref id="B131-pharmaceuticals-16-01054"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name></person-group><article-title>Human Papillomavirus Vaccines: An Updated Review</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>391</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8030391</pub-id><pub-id pub-id-type="pmid">32708759</pub-id><pub-id pub-id-type="pmcid">PMC7565290</pub-id></element-citation></ref><ref id="B132-pharmaceuticals-16-01054"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanna</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>G.</given-names></name></person-group><article-title>HPV vaccination with Gardasil<sup>&#174;</sup>: A breakthrough in women&#8217;s health</article-title><source>Expert Opin. Biol. Ther.</source><year>2006</year><volume>6</volume><fpage>1223</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1517/14712598.6.11.1223</pub-id><pub-id pub-id-type="pmid">17049018</pub-id></element-citation></ref><ref id="B133-pharmaceuticals-16-01054"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crosbie</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Kitchener</surname><given-names>H.C.</given-names></name></person-group><article-title>Cervarix&#8482;&#8212;A bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer</article-title><source>Expert Opin. Biol. Ther.</source><year>2007</year><volume>7</volume><fpage>391</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1517/14712598.7.3.391</pub-id><pub-id pub-id-type="pmid">17309330</pub-id></element-citation></ref><ref id="B134-pharmaceuticals-16-01054"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Joura</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Kothari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Luxembourg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Walia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Khoury</surname><given-names>H.</given-names></name><name name-style="western"><surname>Badgley</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>2214</fpage><lpage>2223</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.01.060</pub-id><pub-id pub-id-type="pmid">33658126</pub-id></element-citation></ref><ref id="B135-pharmaceuticals-16-01054"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zur Hausen</surname><given-names>H.</given-names></name></person-group><article-title>Papillomaviruses and cancer: From basic studies to clinical application</article-title><source>Nat. Rev. Cancer</source><year>2002</year><volume>2</volume><fpage>342</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1038/nrc798</pub-id><pub-id pub-id-type="pmid">12044010</pub-id></element-citation></ref><ref id="B136-pharmaceuticals-16-01054"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luckett</surname><given-names>R.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>S.</given-names></name></person-group><article-title>Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer</article-title><source>Hum. Vaccines Immunother.</source><year>2015</year><volume>12</volume><fpage>1332</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1108500</pub-id><pub-id pub-id-type="pmcid">PMC4964711</pub-id><pub-id pub-id-type="pmid">26588179</pub-id></element-citation></ref><ref id="B137-pharmaceuticals-16-01054"><label>137.</label><element-citation publication-type="gov"><article-title>Highlights of Prescribing Information</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.vaers.hhs.gov" ext-link-type="uri">www.vaers.hhs.gov</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-07">(accessed on 7 April 2023)</date-in-citation></element-citation></ref><ref id="B138-pharmaceuticals-16-01054"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Roden</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.-C.</given-names></name></person-group><article-title>Cervarix&#8482;: A vaccine for the prevention of HPV 16, 18-associated cervical cancer</article-title><source>Biologics</source><year>2008</year><volume>2</volume><fpage>107</fpage><pub-id pub-id-type="doi">10.2147/btt.s1877</pub-id><pub-id pub-id-type="pmcid">PMC2727782</pub-id><pub-id pub-id-type="pmid">19707432</pub-id></element-citation></ref><ref id="B139-pharmaceuticals-16-01054"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asif</surname><given-names>M.</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>C.M.</given-names></name></person-group><article-title>ADIS DRUG PROFILE Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil <sup>&#174;</sup>)</article-title><source>Drugs</source><year>2006</year><volume>66</volume><page-range>1263&#8211;1271; discussion 1272&#8211;1273</page-range><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003495-200666090-00008</pub-id><pub-id pub-id-type="pmid">16827602</pub-id></element-citation></ref><ref id="B140-pharmaceuticals-16-01054"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roden</surname><given-names>R.B.S.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>P.L.</given-names></name></person-group><article-title>Opportunities and challenges for human papillomavirus vaccination in cancer</article-title><source>Nat. Rev. Cancer</source><year>2018</year><volume>18</volume><fpage>240</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/nrc.2018.13</pub-id><pub-id pub-id-type="pmid">29497146</pub-id><pub-id pub-id-type="pmcid">PMC6454884</pub-id></element-citation></ref><ref id="B141-pharmaceuticals-16-01054"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Illah</surname><given-names>O.</given-names></name><name name-style="western"><surname>Olaitan</surname><given-names>A.</given-names></name></person-group><article-title>Updates on HPV Vaccination</article-title><source>Diagnostics</source><year>2023</year><volume>13</volume><elocation-id>243</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics13020243</pub-id><pub-id pub-id-type="pmid">36673053</pub-id><pub-id pub-id-type="pmcid">PMC9857409</pub-id></element-citation></ref><ref id="B142-pharmaceuticals-16-01054"><label>142.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Glaxosmithkline</collab></person-group><article-title>Cervarix, Suspension for Intramuscular Injection</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.vaers.hhs.gov" ext-link-type="uri">www.vaers.hhs.gov</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-07">(accessed on 7 April 2023)</date-in-citation></element-citation></ref><ref id="B143-pharmaceuticals-16-01054"><label>143.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Fda</surname><given-names>C.</given-names></name></person-group><article-title>Package Insert-Gardasil 9</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/vaccines-blood-biologics/vaccines/gardasil-9" ext-link-type="uri">https://www.fda.gov/vaccines-blood-biologics/vaccines/gardasil-9</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-07">(accessed on 7 April 2023)</date-in-citation></element-citation></ref><ref id="B144-pharmaceuticals-16-01054"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markowitz</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Schiller</surname><given-names>J.T.</given-names></name></person-group><article-title>Human Papillomavirus Vaccines</article-title><source>J. Infect. Dis.</source><year>2021</year><volume>224</volume><issue>(Suppl. 5)</issue><fpage>S367</fpage><lpage>S378</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiaa621</pub-id><pub-id pub-id-type="pmid">34590141</pub-id><pub-id pub-id-type="pmcid">PMC8577198</pub-id></element-citation></ref><ref id="B145-pharmaceuticals-16-01054"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akhatova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Azizan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Atageldiyeva</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ashimkhanova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iztleuov</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suleimenova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shamkeeva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aimagambetova</surname><given-names>G.</given-names></name></person-group><article-title>Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1912</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10111912</pub-id><pub-id pub-id-type="pmid">36423008</pub-id><pub-id pub-id-type="pmcid">PMC9696339</pub-id></element-citation></ref><ref id="B146-pharmaceuticals-16-01054"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fairley</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Hocking</surname><given-names>J.</given-names></name><name name-style="western"><surname>Canfell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>E.P.F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>G.</given-names></name></person-group><article-title>Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: A cost-effectiveness analysis</article-title><source>Lancet Glob. Health</source><year>2020</year><volume>8</volume><fpage>e1335</fpage><lpage>e1344</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(20)30277-1</pub-id><pub-id pub-id-type="pmid">32971056</pub-id></element-citation></ref><ref id="B147-pharmaceuticals-16-01054"><label>147.</label><element-citation publication-type="webpage"><article-title>Cecolin&#174;|WHO-Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://extranet.who.int/pqweb/content/cecolin%C2%AE" ext-link-type="uri">https://extranet.who.int/pqweb/content/cecolin%C2%AE</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-26">(accessed on 26 March 2023)</date-in-citation></element-citation></ref><ref id="B148-pharmaceuticals-16-01054"><label>148.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Inc</surname><given-names>E.</given-names></name></person-group><article-title>EG-HPV: Human Papillomavirus Vaccine Based on Virus-Like Particle (VLP) Technology (HPV 16 &amp; 18 L1 VLP) and a Novel Proprietary Immune Adjuvant EGvac (Adjuvant System CIA05+Alum) that Enhances the Immune Response against HPV through Both B Cell (Humoral) and T Cell (Cellular) Immune Stimulation</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.vaers.hhs.gov/" ext-link-type="uri">http://www.vaers.hhs.gov/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-07">(accessed on 7 April 2023)</date-in-citation></element-citation></ref><ref id="B149-pharmaceuticals-16-01054"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>K.-N.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y.J.</given-names></name></person-group><article-title>Current status of human papillomavirus vaccines</article-title><source>Clin. Exp. Vaccine Res.</source><year>2014</year><volume>13</volume><fpage>271</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.7774/cevr.2014.3.2.168</pub-id><pub-id pub-id-type="pmcid">PMC4083069</pub-id><pub-id pub-id-type="pmid">25003090</pub-id></element-citation></ref><ref id="B150-pharmaceuticals-16-01054"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negahdaripour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eslami</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nezafat</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hajighahramani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ghoshoon</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Shoolian</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dehshahri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Erfani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Morowvat</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Ghasemi</surname><given-names>Y.</given-names></name></person-group><article-title>A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches</article-title><source>Infect. Genet. Evol.</source><year>2017</year><volume>54</volume><fpage>402</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2017.08.002</pub-id><pub-id pub-id-type="pmid">28780192</pub-id></element-citation></ref><ref id="B151-pharmaceuticals-16-01054"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negahdaripour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nezafat</surname><given-names>N.</given-names></name><name name-style="western"><surname>Heidari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Erfani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hajighahramani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ghoshoon</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Shoolian</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rahbar</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Najafipour</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dehshahri</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Production and Preliminary In Vivo Evaluations of a Novel in silico-designed L2-based Potential HPV Vaccine</article-title><source>Curr. Pharm. Biotechnol.</source><year>2020</year><volume>21</volume><fpage>316</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.2174/1389201020666191114104850</pub-id><pub-id pub-id-type="pmid">31729940</pub-id></element-citation></ref><ref id="B152-pharmaceuticals-16-01054"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hollingsworth</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>K.</given-names></name></person-group><article-title>Turning the corner on therapeutic cancer vaccines</article-title><source>NPJ Vaccines</source><year>2019</year><volume>4</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1038/s41541-019-0103-y</pub-id><pub-id pub-id-type="pmid">30774998</pub-id><pub-id pub-id-type="pmcid">PMC6368616</pub-id></element-citation></ref><ref id="B153-pharmaceuticals-16-01054"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>C.</given-names></name></person-group><article-title>Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2022</year><volume>12</volume><fpage>901</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2022.909223</pub-id><pub-id pub-id-type="pmid">35860379</pub-id><pub-id pub-id-type="pmcid">PMC9289603</pub-id></element-citation></ref><ref id="B154-pharmaceuticals-16-01054"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welters</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kenter</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Piersma</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Vloon</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Lowik</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>der Meer</surname><given-names>D.M.B.-V.</given-names></name><name name-style="western"><surname>Drijfhout</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Valentijn</surname><given-names>A.R.P.</given-names></name><name name-style="western"><surname>Wafelman</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Oostendorp</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>178</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1880</pub-id><pub-id pub-id-type="pmid">18172269</pub-id></element-citation></ref><ref id="B155-pharmaceuticals-16-01054"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenter</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Welters</surname><given-names>M.J.P.</given-names></name><name name-style="western"><surname>Valentijn</surname><given-names>A.R.P.M.</given-names></name><name name-style="western"><surname>Lowik</surname><given-names>M.J.G.</given-names></name><name name-style="western"><surname>Berends-van der Meer</surname><given-names>D.M.A.</given-names></name><name name-style="western"><surname>Vloon</surname><given-names>A.P.G.</given-names></name><name name-style="western"><surname>Essahsah</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fathers</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Offringa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Drijfhout</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>361</volume><fpage>1838</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0810097</pub-id><pub-id pub-id-type="pmid">19890126</pub-id></element-citation></ref><ref id="B156-pharmaceuticals-16-01054"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Heat shock protein 110 improves the anti-tumor effects of the cytotoxic T lymphocyte epitope E7 in mice</article-title><source>Cancer Biol. Ther.</source><year>2010</year><volume>9</volume><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.4161/cbt.9.2.10391</pub-id><pub-id pub-id-type="pmid">19901562</pub-id></element-citation></ref><ref id="B157-pharmaceuticals-16-01054"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melief</surname><given-names>C.J.</given-names></name></person-group><article-title>Synthetic Vaccine for the Treatment of Lesions Caused by High Risk Human Papilloma Virus</article-title><source>Cancer J.</source><year>2011</year><volume>17</volume><fpage>300</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1097/PPO.0b013e318235e0fe</pub-id><pub-id pub-id-type="pmid">21952279</pub-id></element-citation></ref><ref id="B158-pharmaceuticals-16-01054"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melief</surname><given-names>C.J.M.</given-names></name></person-group><article-title>Treatment of Established Lesions Caused by High-risk Human Papilloma Virus Using a Synthetic Vaccine</article-title><source>J. Immunother.</source><year>2012</year><volume>35</volume><fpage>215</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e318248f17f</pub-id><pub-id pub-id-type="pmid">22421938</pub-id></element-citation></ref><ref id="B159-pharmaceuticals-16-01054"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Che</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo</article-title><source>Int. Immunopharmacol.</source><year>2019</year><volume>69</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2019.01.024</pub-id><pub-id pub-id-type="pmid">30743204</pub-id></element-citation></ref><ref id="B160-pharmaceuticals-16-01054"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>W.</given-names></name><name name-style="western"><surname>Su</surname><given-names>T.</given-names></name><name name-style="western"><surname>Che</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice</article-title><source>Int. J. Nanomed.</source><year>2020</year><volume>15</volume><fpage>9571</fpage><lpage>9586</lpage><pub-id pub-id-type="doi">10.2147/IJN.S275670</pub-id><pub-id pub-id-type="pmcid">PMC7718974</pub-id><pub-id pub-id-type="pmid">33293808</pub-id></element-citation></ref><ref id="B161-pharmaceuticals-16-01054"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berzofsky</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Vos van Steenwijk</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Ramwadhdoebe</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>L&#246;wik</surname><given-names>M.J.G.</given-names></name><name name-style="western"><surname>van der Minne</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Berends-van der Meer</surname><given-names>D.M.A.</given-names></name><name name-style="western"><surname>Fathers</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Valentijn</surname><given-names>R.P.M.</given-names></name><name name-style="western"><surname>Oostendorp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fleuren</surname><given-names>G.J.</given-names></name><etal/></person-group><article-title>Faculty Opinions recommendation of A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions</article-title><source>Cancer Immunol. Immunother.</source><year>2012</year><volume>61</volume><fpage>1485</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.3410/f.720882163.793559557</pub-id><pub-id pub-id-type="pmid">22684521</pub-id><pub-id pub-id-type="pmcid">PMC3427705</pub-id></element-citation></ref><ref id="B162-pharmaceuticals-16-01054"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welters</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>van der Sluis</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>van Meir</surname><given-names>H.</given-names></name><name name-style="western"><surname>Loof</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>van Ham</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>van Duikeren</surname><given-names>S.</given-names></name><name name-style="western"><surname>Santegoets</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Arens</surname><given-names>R.</given-names></name><name name-style="western"><surname>de Kam</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>A.F.</given-names></name><etal/></person-group><article-title>Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses</article-title><source>Sci. Transl. Med.</source><year>2016</year><volume>8</volume><fpage>334ra52</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aad8307</pub-id><pub-id pub-id-type="pmid">27075626</pub-id></element-citation></ref><ref id="B163-pharmaceuticals-16-01054"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domingos-Pereira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Galliverti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hanahan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nardelli-Haefliger</surname><given-names>D.</given-names></name></person-group><article-title>Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors</article-title><source>J. Immunother. Cancer</source><year>2019</year><volume>7</volume><fpage>122</fpage><pub-id pub-id-type="doi">10.1186/s40425-019-0593-1</pub-id><pub-id pub-id-type="pmid">31060612</pub-id><pub-id pub-id-type="pmcid">PMC6503370</pub-id></element-citation></ref><ref id="B164-pharmaceuticals-16-01054"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melief</surname><given-names>C.J.M.</given-names></name><name name-style="western"><surname>Welters</surname><given-names>M.J.P.</given-names></name><name name-style="western"><surname>Vergote</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kroep</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Kenter</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Ottevanger</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Tjalma</surname><given-names>W.A.A.</given-names></name><name name-style="western"><surname>Denys</surname><given-names>H.</given-names></name><name name-style="western"><surname>van Poelgeest</surname><given-names>M.I.E.</given-names></name><name name-style="western"><surname>Nijman</surname><given-names>H.W.</given-names></name><etal/></person-group><article-title>Strong vaccine responses during chemotherapy are associated with prolonged cancer survival</article-title><source>Sci. Transl. Med.</source><year>2020</year><volume>12</volume><fpage>aaz8235</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaz8235</pub-id><pub-id pub-id-type="pmid">32188726</pub-id></element-citation></ref><ref id="B165-pharmaceuticals-16-01054"><label>165.</label><element-citation publication-type="gov"><article-title>Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer-Full Text View-ClinicalTrials.gov</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02128126" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT02128126</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-07">(accessed on 7 April 2023)</date-in-citation></element-citation></ref><ref id="B166-pharmaceuticals-16-01054"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Greenfield</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Stratton</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Vaughn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kieber</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moerman-Herzog</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Hitt</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Quick</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Hutchins</surname><given-names>L.F.</given-names></name><etal/></person-group><article-title>Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination</article-title><source>Cancer Immunol. Immunother.</source><year>2016</year><volume>65</volume><fpage>563</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1007/s00262-016-1821-x</pub-id><pub-id pub-id-type="pmid">26980480</pub-id><pub-id pub-id-type="pmcid">PMC4841729</pub-id></element-citation></ref><ref id="B167-pharmaceuticals-16-01054"><label>167.</label><element-citation publication-type="gov"><article-title>A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions-Full Text View-ClinicalTrials.gov</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02481414" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT02481414</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-07">(accessed on 7 April 2023)</date-in-citation></element-citation></ref><ref id="B168-pharmaceuticals-16-01054"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arribillaga</surname><given-names>L.</given-names></name><name name-style="western"><surname>Echeverria</surname><given-names>I.</given-names></name><name name-style="western"><surname>Belsue</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lozano</surname><given-names>T.</given-names></name><name name-style="western"><surname>Casares</surname><given-names>N.</given-names></name><name name-style="western"><surname>Villanueva</surname><given-names>L.</given-names></name><name name-style="western"><surname>Domingos-Pereira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Nardelli-Haefliger</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens</article-title><source>J. Immunother. Cancer</source><year>2020</year><volume>8</volume><fpage>e000704</fpage><pub-id pub-id-type="doi">10.1136/jitc-2020-000704</pub-id><pub-id pub-id-type="pmid">32581060</pub-id><pub-id pub-id-type="pmcid">PMC7319778</pub-id></element-citation></ref><ref id="B169-pharmaceuticals-16-01054"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Speetjens</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Welters</surname><given-names>M.J.P.</given-names></name><name name-style="western"><surname>Slingerland</surname><given-names>M.</given-names></name><name name-style="western"><surname>van Poelgeest</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>van Steenwijk</surname><given-names>P.J.d.V.</given-names></name><name name-style="western"><surname>Roozen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Boekestijn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loof</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Zom</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Valentijn</surname><given-names>A.R.P.M.</given-names></name><etal/></person-group><article-title>Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e005016</fpage><pub-id pub-id-type="doi">10.1136/jitc-2022-005016</pub-id><pub-id pub-id-type="pmid">36261215</pub-id><pub-id pub-id-type="pmcid">PMC9582304</pub-id></element-citation></ref><ref id="B170-pharmaceuticals-16-01054"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>D.-R.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.-J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.-N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.-F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.-F.</given-names></name><etal/></person-group><article-title>HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo</article-title><source>J. Huazhong Univ. Sci. Technol.</source><year>2013</year><volume>33</volume><fpage>735</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1007/s11596-013-1189-5</pub-id><pub-id pub-id-type="pmid">24142729</pub-id></element-citation></ref><ref id="B171-pharmaceuticals-16-01054"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Namvar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Panahi</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Agi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bolhassani</surname><given-names>A.</given-names></name></person-group><article-title>Development of HPV16,18,31,45 E5 and E7 peptides-based vaccines predicted by immunoinformatics tools</article-title><source>Biotechnol. Lett.</source><year>2020</year><volume>42</volume><fpage>403</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1007/s10529-020-02792-6</pub-id><pub-id pub-id-type="pmid">31915962</pub-id><pub-id pub-id-type="pmcid">PMC7087594</pub-id></element-citation></ref><ref id="B172-pharmaceuticals-16-01054"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qingfeng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Maolin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhihui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shanli</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pengfei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lifang</surname><given-names>Z.</given-names></name></person-group><article-title>A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>7693</fpage><lpage>7702</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.10.069</pub-id><pub-id pub-id-type="pmid">36376215</pub-id></element-citation></ref><ref id="B173-pharmaceuticals-16-01054"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maynard</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>MacGill</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cann</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Cayatte</surname><given-names>C.</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>S.H.</given-names></name></person-group><article-title>Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication</article-title><source>BMC Cancer</source><year>2019</year><volume>19</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/s12885-019-5725-y</pub-id><pub-id pub-id-type="pmid">31170937</pub-id><pub-id pub-id-type="pmcid">PMC6555006</pub-id></element-citation></ref><ref id="B174-pharmaceuticals-16-01054"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>B.</given-names></name></person-group><article-title>A novel self-assembled nanoparticle vaccine with HIV-1 Tat49-57/HPV16 E749-57 fusion peptide and GM-CSF DNA elicits potent and prolonged CD8+ T cell-dependent anti-tumor immunity in mice</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>1071</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.12.029</pub-id><pub-id pub-id-type="pmid">22178528</pub-id></element-citation></ref><ref id="B175-pharmaceuticals-16-01054"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahimian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fransen</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Kleinovink</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Amidi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hennink</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Ossendorp</surname><given-names>F.</given-names></name></person-group><article-title>Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation</article-title><source>J. Control. Release</source><year>2015</year><volume>203</volume><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.02.006</pub-id><pub-id pub-id-type="pmid">25660830</pub-id></element-citation></ref><ref id="B176-pharmaceuticals-16-01054"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Employing ATP as a New Adjuvant Promotes the Induction of Robust Antitumor Cellular Immunity by a PLGA Nanoparticle Vaccine</article-title><source>ACS Appl. Mater. Interfaces</source><year>2020</year><volume>12</volume><fpage>54399</fpage><lpage>54414</lpage><pub-id pub-id-type="doi">10.1021/acsami.0c15522</pub-id><pub-id pub-id-type="pmid">33215918</pub-id></element-citation></ref><ref id="B177-pharmaceuticals-16-01054"><label>177.</label><element-citation publication-type="gov"><article-title>A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial-Full Text View-ClinicalTrials.gov</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04580771" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT04580771</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-06-10">(accessed on 10 June 2023)</date-in-citation></element-citation></ref><ref id="B178-pharmaceuticals-16-01054"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dudley</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Golovkina</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>S.R.</given-names></name></person-group><article-title>Lessons Learned from Mouse Mammary Tumor Virus in Animal Models</article-title><source>ILAR J.</source><year>2016</year><volume>57</volume><fpage>12</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1093/ilar/ilv044</pub-id><pub-id pub-id-type="pmid">27034391</pub-id><pub-id pub-id-type="pmcid">PMC5007637</pub-id></element-citation></ref><ref id="B179-pharmaceuticals-16-01054"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawson</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>W.K.</given-names></name></person-group><article-title>Mouse Mammary Tumour Virus (MMTV) in Human Breast Cancer&#8212;The Value of Bradford Hill Criteria</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>721</elocation-id><pub-id pub-id-type="doi">10.3390/v14040721</pub-id><pub-id pub-id-type="pmid">35458452</pub-id><pub-id pub-id-type="pmcid">PMC9028876</pub-id></element-citation></ref><ref id="B180-pharmaceuticals-16-01054"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>T.H.M.</given-names></name><name name-style="western"><surname>Sage</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>A.F.R.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>D.W.</given-names></name></person-group><article-title>Breast cancer incidence highest in the range of one species of house mouse, Mus domesticus</article-title><source>Br. J. Cancer</source><year>2000</year><volume>82</volume><fpage>446</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1054/bjoc.1999.0941</pub-id><pub-id pub-id-type="pmid">10646903</pub-id><pub-id pub-id-type="pmcid">PMC2363264</pub-id></element-citation></ref><ref id="B181-pharmaceuticals-16-01054"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>A.F.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.-H.</given-names></name></person-group><article-title>Revisiting the MMTV Zoonotic Hypothesis to Account for Geographic Variation in Breast Cancer Incidence</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>559</elocation-id><pub-id pub-id-type="doi">10.3390/v14030559</pub-id><pub-id pub-id-type="pmid">35336966</pub-id><pub-id pub-id-type="pmcid">PMC8955943</pub-id></element-citation></ref><ref id="B182-pharmaceuticals-16-01054"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanton</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Gad</surname><given-names>E.</given-names></name><name name-style="western"><surname>Corulli</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Disis</surname><given-names>M.L.</given-names></name></person-group><article-title>Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>3552</fpage><lpage>3561</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.05.024</pub-id><pub-id pub-id-type="pmid">31126858</pub-id><pub-id pub-id-type="pmcid">PMC7087478</pub-id></element-citation></ref><ref id="B183-pharmaceuticals-16-01054"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braitbard</surname><given-names>O.</given-names></name><name name-style="western"><surname>Roniger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bar-Sinai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rajchman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>T.</given-names></name><name name-style="western"><surname>Abramovitch</surname><given-names>H.</given-names></name><name name-style="western"><surname>La Ferla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Franceschi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lessi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Naccarato</surname><given-names>A.G.</given-names></name><etal/></person-group><article-title>A new immunization and treatment strategy for mouse mammary tumor virus (MMTV) associated cancers</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>21168</fpage><lpage>21180</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7762</pub-id><pub-id pub-id-type="pmid">26934560</pub-id><pub-id pub-id-type="pmcid">PMC5008276</pub-id></element-citation></ref><ref id="B184-pharmaceuticals-16-01054"><label>184.</label><element-citation publication-type="webpage"><article-title>Abstract #367: Use of MMTV-p14 as a vaccine against MMTV-Bearing Tumors|Cancer Research|American Association for Cancer Research</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://aacrjournals.org/cancerres/article/69/9_Supplement/367/556331/Abstract-367-Use-of-MMTV-p14-as-a-vaccine-against" ext-link-type="uri">https://aacrjournals.org/cancerres/article/69/9_Supplement/367/556331/Abstract-367-Use-of-MMTV-p14-as-a-vaccine-against</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-07">(accessed on 7 April 2023)</date-in-citation></element-citation></ref><ref id="B185-pharmaceuticals-16-01054"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melana</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Nepomnaschy</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hasa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Djougarian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Djougarian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Pogo</surname><given-names>B.G.</given-names></name></person-group><article-title>Detection of human mammary tumor virus proteins in human breast cancer cells</article-title><source>J. Virol. Methods</source><year>2010</year><volume>163</volume><fpage>157</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2009.09.015</pub-id><pub-id pub-id-type="pmid">19781575</pub-id></element-citation></ref><ref id="B186-pharmaceuticals-16-01054"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dion</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Knittel</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Morneweck</surname><given-names>S.T.</given-names></name></person-group><article-title>Virus envelope-based peptide vaccines against virus-induced mammary tumors</article-title><source>Virology</source><year>1990</year><volume>179</volume><fpage>474</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(90)90318-L</pub-id><pub-id pub-id-type="pmid">2171218</pub-id></element-citation></ref><ref id="B187-pharmaceuticals-16-01054"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arias-Calvachi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Calaf</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Aguayo</surname><given-names>F.</given-names></name></person-group><article-title>Epstein&#8211;Barr Virus Association with Breast Cancer: Evidence and Perspectives</article-title><source>Biology</source><year>2022</year><volume>11</volume><elocation-id>799</elocation-id><pub-id pub-id-type="doi">10.3390/biology11060799</pub-id><pub-id pub-id-type="pmid">35741320</pub-id><pub-id pub-id-type="pmcid">PMC9220417</pub-id></element-citation></ref><ref id="B188-pharmaceuticals-16-01054"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonnet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guinebretiere</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Kremmer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Grunewald</surname><given-names>V.</given-names></name><name name-style="western"><surname>Benhamou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Contesso</surname><given-names>G.</given-names></name><name name-style="western"><surname>Joab</surname><given-names>I.</given-names></name></person-group><article-title>Detection of Epstein-Barr Virus in Invasive Breast Cancers</article-title><source>Gynecol. Oncol.</source><year>1999</year><volume>91</volume><fpage>1376</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1093/jnci/91.16.1376</pub-id><pub-id pub-id-type="pmid">10451442</pub-id></element-citation></ref><ref id="B189-pharmaceuticals-16-01054"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Takada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shew</surname><given-names>J.-Y.</given-names></name></person-group><article-title>Dysregulation of HER2/HER3 Signaling Axis in Epstein-Barr Virus-Infected Breast Carcinoma Cells</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>5705</fpage><lpage>5713</lpage><pub-id pub-id-type="doi">10.1128/JVI.00076-07</pub-id><pub-id pub-id-type="pmid">17376931</pub-id><pub-id pub-id-type="pmcid">PMC1900270</pub-id></element-citation></ref><ref id="B190-pharmaceuticals-16-01054"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name></person-group><article-title>Epstein-Barr Virus Infection and Sporadic Breast Cancer Risk: A Meta-Analysis</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e31656</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0031656</pub-id><pub-id pub-id-type="pmid">22363698</pub-id><pub-id pub-id-type="pmcid">PMC3283657</pub-id></element-citation></ref><ref id="B191-pharmaceuticals-16-01054"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>J.-R.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.-Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.-D.</given-names></name><name name-style="western"><surname>Su</surname><given-names>F.-X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>E.-W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.-M.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>G.-C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.-Q.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Z.-F.</given-names></name></person-group><article-title>Epstein-Barr virus and breast cancer: Serological study in a high-incidence area of nasopharyngeal carcinoma</article-title><source>Cancer Lett.</source><year>2011</year><volume>309</volume><fpage>128</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2011.05.012</pub-id><pub-id pub-id-type="pmid">21724319</pub-id></element-citation></ref><ref id="B192-pharmaceuticals-16-01054"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Immune response of mice to a latency membrane protein 2 multiepitope antigen of Epstein-Barr virus applied as DNA vaccine and/or peptide vaccine</article-title><source>Acta Virol.</source><year>2013</year><volume>57</volume><fpage>51</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.4149/av_2013_01_51</pub-id><pub-id pub-id-type="pmid">23530824</pub-id></element-citation></ref><ref id="B193-pharmaceuticals-16-01054"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>M.-C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.-T.</given-names></name><name name-style="western"><surname>Young</surname><given-names>T.-H.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>P.-J.</given-names></name></person-group><article-title>Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo</article-title><source>BMC Cancer</source><year>2017</year><volume>17</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/s12885-016-3027-1</pub-id><pub-id pub-id-type="pmid">28056887</pub-id><pub-id pub-id-type="pmcid">PMC5216543</pub-id></element-citation></ref><ref id="B194-pharmaceuticals-16-01054"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salih</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Higgo</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Khalifa</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Eed</surname><given-names>E.M.</given-names></name></person-group><article-title>Incidence of Epstein-Barr Virus Among Women With Breast Cancer Using Monoclonal Antibodies for Latent Membrane Protein 1 (LMP1)</article-title><source>Vivo</source><year>2022</year><volume>36</volume><fpage>1513</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.21873/invivo.12860</pub-id><pub-id pub-id-type="pmcid">PMC9087060</pub-id><pub-id pub-id-type="pmid">35478129</pub-id></element-citation></ref><ref id="B195-pharmaceuticals-16-01054"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olotu</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>M.E.</given-names></name></person-group><article-title>Immunoinformatics prediction of potential B-cell and T-cell epitopes as effective vaccine candidates for eliciting immunogenic responses against Epstein&#8211;Barr virus</article-title><source>Biomed. J.</source><year>2021</year><volume>44</volume><fpage>317</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.bj.2020.01.002</pub-id><pub-id pub-id-type="pmid">34154948</pub-id><pub-id pub-id-type="pmcid">PMC8358216</pub-id></element-citation></ref><ref id="B196-pharmaceuticals-16-01054"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Junaid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saleem</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>W.C.S.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>D.-Q.</given-names></name></person-group><article-title>Immunoinformatic and systems biology approaches to predict and validate peptide vaccines against Epstein&#8211;Barr virus (EBV)</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41598-018-37070-z</pub-id><pub-id pub-id-type="pmid">30679646</pub-id><pub-id pub-id-type="pmcid">PMC6346095</pub-id></element-citation></ref><ref id="B197-pharmaceuticals-16-01054"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omoboyede</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>O.</given-names></name><name name-style="western"><surname>Umar</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Bello</surname><given-names>T.</given-names></name><name name-style="western"><surname>Adedeji</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Khalid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fayojegbe</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Ayomide</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Chukwuemeka</surname><given-names>P.O.</given-names></name></person-group><article-title>Designing a vaccine-based therapy against Epstein-Barr virus-associated tumors using immunoinformatics approach</article-title><source>Comput. Biol. Med.</source><year>2022</year><volume>150</volume><fpage>106128</fpage><pub-id pub-id-type="doi">10.1016/j.compbiomed.2022.106128</pub-id><pub-id pub-id-type="pmid">36179514</pub-id></element-citation></ref><ref id="B198-pharmaceuticals-16-01054"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Takeshima</surname><given-names>S.-N.</given-names></name></person-group><article-title>Mechanisms of pathogenesis induced by bovine leukemia virus as a model for human T-cell leukemia virus</article-title><source>Front. Microbiol.</source><year>2013</year><volume>4</volume><fpage>328</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2013.00328</pub-id><pub-id pub-id-type="pmid">24265629</pub-id><pub-id pub-id-type="pmcid">PMC3820957</pub-id></element-citation></ref><ref id="B199-pharmaceuticals-16-01054"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buehring</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Hudes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Block</surname><given-names>G.</given-names></name></person-group><article-title>Exposure to Bovine Leukemia Virus Is Associated with Breast Cancer: A Case-Control Study</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0134304</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0134304</pub-id><pub-id pub-id-type="pmid">26332838</pub-id><pub-id pub-id-type="pmcid">PMC4557937</pub-id></element-citation></ref><ref id="B200-pharmaceuticals-16-01054"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabeya</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohishi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Amanuma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Onuma</surname><given-names>M.</given-names></name></person-group><article-title>An effective peptide vaccine to eliminate bovine leukaemia virus (BLV) infected cells in carrier sheep</article-title><source>Vaccine</source><year>1996</year><volume>14</volume><fpage>1118</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(96)00047-3</pub-id><pub-id pub-id-type="pmid">8911007</pub-id></element-citation></ref><ref id="B201-pharmaceuticals-16-01054"><label>201.</label><element-citation publication-type="gov"><article-title>Peptide-Based Bovine Leukemia Virus (BLV) Vaccine that Induces BLV-Env Specific Th-1 Type Immunity-PubMed</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/9209348/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/9209348/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-07">(accessed on 7 April 2023)</date-in-citation><pub-id pub-id-type="pmid">9209348</pub-id></element-citation></ref><ref id="B202-pharmaceuticals-16-01054"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chugh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Swenson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yuzbasiyan-Gurkan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name></person-group><article-title>Design and Synthesis of Bovine Leukemia Virus-Associated Peptide-Based Q&#946; Conjugate Eliciting Long-Lasting Neutralizing Antibodies in Mice</article-title><source>ACS Infect. Dis.</source><year>2022</year><volume>8</volume><fpage>1031</fpage><lpage>1040</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.2c00001</pub-id><pub-id pub-id-type="pmid">35482583</pub-id><pub-id pub-id-type="pmcid">PMC9112674</pub-id></element-citation></ref><ref id="B203-pharmaceuticals-16-01054"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meghla</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Nain</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Karpi&#324;ski</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>S.</given-names></name></person-group><article-title>Immune epitopes identification and designing of a multi-epitope vaccine against bovine leukemia virus: A molecular dynamics and immune simulation approaches</article-title><source>Cancer Immunol. Immunother.</source><year>2022</year><volume>71</volume><fpage>2535</fpage><lpage>2548</lpage><pub-id pub-id-type="doi">10.1007/s00262-022-03181-w</pub-id><pub-id pub-id-type="pmid">35294591</pub-id><pub-id pub-id-type="pmcid">PMC8924353</pub-id></element-citation></ref><ref id="B204-pharmaceuticals-16-01054"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hooshmand</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fayazi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tabatabaei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Behbahan</surname><given-names>N.G.G.</given-names></name></person-group><article-title>Prediction of B cell and T-helper cell epitopes candidates of bovine leukaemia virus (BLV) by in silico approach</article-title><source>Veter.- Med. Sci.</source><year>2020</year><volume>6</volume><fpage>730</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1002/vms3.307</pub-id><pub-id pub-id-type="pmcid">PMC7738742</pub-id><pub-id pub-id-type="pmid">32592322</pub-id></element-citation></ref><ref id="B205-pharmaceuticals-16-01054"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fadilah</surname><given-names>F.</given-names></name><name name-style="western"><surname>Linda</surname><given-names>E.</given-names></name><name name-style="western"><surname>Indah</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Anbar</surname><given-names>I.K.</given-names></name></person-group><article-title>Immunoinformatics studies and design of breast cancer multiepitope peptide vaccines: Diversity analysis approach</article-title><source>J. Appl. Pharm. Sci.</source><year>2021</year><volume>11</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.7324/JAPS.2021.110604</pub-id></element-citation></ref><ref id="B206-pharmaceuticals-16-01054"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prawiningrum</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Paramita</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Panigoro</surname><given-names>S.S.</given-names></name></person-group><article-title>Immunoinformatics Approach for Epitope-Based Vaccine Design: Key Steps for Breast Cancer Vaccine</article-title><source>Diagnostics</source><year>2022</year><volume>12</volume><elocation-id>2981</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics12122981</pub-id><pub-id pub-id-type="pmid">36552988</pub-id><pub-id pub-id-type="pmcid">PMC9777080</pub-id></element-citation></ref><ref id="B207-pharmaceuticals-16-01054"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curigliano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bagnardi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ghioni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Louahed</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brichard</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Marra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trapani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Criscitiello</surname><given-names>C.</given-names></name><name name-style="western"><surname>Viale</surname><given-names>G.</given-names></name></person-group><article-title>Expression of tumor-associated antigens in breast cancer subtypes</article-title><source>Breast</source><year>2020</year><volume>49</volume><fpage>202</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.breast.2019.12.002</pub-id><pub-id pub-id-type="pmid">31869767</pub-id><pub-id pub-id-type="pmcid">PMC7375652</pub-id></element-citation></ref><ref id="B208-pharmaceuticals-16-01054"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rafieian-Kopaei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dehkordi</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Pazoki-Toroudi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Azadegan-Dehkordi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mobini</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Alizadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nezhad</surname><given-names>M.</given-names></name></person-group><article-title>In silico design of a multi-epitope vaccine against HPV16/18</article-title><source>BMC Bioinform.</source><year>2022</year><volume>23</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1186/s12859-022-04784-x</pub-id><pub-id pub-id-type="pmcid">PMC9344258</pub-id><pub-id pub-id-type="pmid">35918631</pub-id></element-citation></ref><ref id="B209-pharmaceuticals-16-01054"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jabbar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rafique</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salo-Ahen</surname><given-names>O.M.H.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Munir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Idrees</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>M.U.</given-names></name><name name-style="western"><surname>Vanmeert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>S.Z.</given-names></name><name name-style="western"><surname>Jabbar</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>3000</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.03000</pub-id><pub-id pub-id-type="pmid">30619353</pub-id><pub-id pub-id-type="pmcid">PMC6305797</pub-id></element-citation></ref><ref id="B210-pharmaceuticals-16-01054"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robles-Oteiza</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.J.</given-names></name></person-group><article-title>Reinvigorating therapeutic cancer vaccines</article-title><source>Curr. Opin. Immunol.</source><year>2022</year><volume>76</volume><fpage>102176</fpage><pub-id pub-id-type="doi">10.1016/j.coi.2022.102176</pub-id><pub-id pub-id-type="pmid">35429774</pub-id><pub-id pub-id-type="pmcid">PMC9612210</pub-id></element-citation></ref><ref id="B211-pharmaceuticals-16-01054"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Azadegan-Dehkordi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rafieian-Kopaei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Salehi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ghasemi-Dehnoo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mahooti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alizadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bagheri</surname><given-names>N.</given-names></name></person-group><article-title>Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s41598-021-91997-4</pub-id><pub-id pub-id-type="pmid">34117331</pub-id><pub-id pub-id-type="pmcid">PMC8196015</pub-id></element-citation></ref><ref id="B212-pharmaceuticals-16-01054"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>T.-Y.</given-names></name><name name-style="western"><surname>Hussein</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name><name name-style="western"><surname>Skwarczynski</surname><given-names>M.</given-names></name></person-group><article-title>Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines</article-title><source>Curr. Top. Med. Chem.</source><year>2012</year><volume>12</volume><fpage>1581</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.2174/156802612802652402</pub-id><pub-id pub-id-type="pmid">22827526</pub-id></element-citation></ref><ref id="B213-pharmaceuticals-16-01054"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#246;len</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gileadi</surname><given-names>U.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Valente</surname><given-names>M.</given-names></name><name name-style="western"><surname>Creemers</surname><given-names>J.H.A.</given-names></name><name name-style="western"><surname>Van Dinther</surname><given-names>E.A.W.</given-names></name><name name-style="western"><surname>van Riessen</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hruby</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cerundolo</surname><given-names>V.</given-names></name><etal/></person-group><article-title>PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>641703</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.641703</pub-id><pub-id pub-id-type="pmid">33717196</pub-id><pub-id pub-id-type="pmcid">PMC7947615</pub-id></element-citation></ref><ref id="B214-pharmaceuticals-16-01054"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Katti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Hills</surname><given-names>T.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Shenton</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Carlisle</surname><given-names>R.C.</given-names></name></person-group><article-title>A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response</article-title><source>Eur. J. Pharm. Sci.</source><year>2020</year><volume>152</volume><fpage>105456</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2020.105456</pub-id><pub-id pub-id-type="pmid">32653563</pub-id></element-citation></ref><ref id="B215-pharmaceuticals-16-01054"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tornesello</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Tagliamonte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tornesello</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Buonaguro</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Buonaguro</surname><given-names>L.</given-names></name></person-group><article-title>Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines</article-title><source>Cancers</source><year>2020</year><volume>12</volume><elocation-id>1049</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12041049</pub-id><pub-id pub-id-type="pmid">32340356</pub-id><pub-id pub-id-type="pmcid">PMC7226445</pub-id></element-citation></ref><ref id="B216-pharmaceuticals-16-01054"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duinkerken</surname><given-names>S.</given-names></name><name name-style="western"><surname>Horrevorts</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Kalay</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ambrosini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rutte</surname><given-names>L.</given-names></name><name name-style="western"><surname>De Gruijl</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Garcia-Vallejo</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Van Kooyk</surname><given-names>Y.</given-names></name></person-group><article-title>Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>5797</fpage><lpage>5809</lpage><pub-id pub-id-type="doi">10.7150/thno.35059</pub-id><pub-id pub-id-type="pmid">31534520</pub-id><pub-id pub-id-type="pmcid">PMC6735376</pub-id></element-citation></ref><ref id="B217-pharmaceuticals-16-01054"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrizzo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Conte</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tagliamonte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Napolitano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bifulco</surname><given-names>K.</given-names></name><name name-style="western"><surname>Carriero</surname><given-names>V.</given-names></name><name name-style="western"><surname>De Stradis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tornesello</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Buonaguro</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Quaglia</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Functional characterization of biodegradable nanoparticles as antigen delivery system</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2015</year><volume>34</volume><fpage>114</fpage><pub-id pub-id-type="doi">10.1186/s13046-015-0231-9</pub-id><pub-id pub-id-type="pmid">26444005</pub-id><pub-id pub-id-type="pmcid">PMC4596393</pub-id></element-citation></ref><ref id="B218-pharmaceuticals-16-01054"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gujrati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>E.-C.</given-names></name><name name-style="western"><surname>Jon</surname><given-names>S.</given-names></name></person-group><article-title>Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses</article-title><source>J. Control. Release</source><year>2017</year><volume>256</volume><fpage>56</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.04.024</pub-id><pub-id pub-id-type="pmid">28428066</pub-id></element-citation></ref><ref id="B219-pharmaceuticals-16-01054"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujita</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Taguchi</surname><given-names>H.</given-names></name></person-group><article-title>Nanoparticle-Based Peptide Vaccines</article-title><source>Micro Nanotechnol. Vaccine Dev.</source><year>2017</year><fpage>149</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/b978-0-323-39981-4.00008-7</pub-id></element-citation></ref><ref id="B220-pharmaceuticals-16-01054"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Firdaus</surname><given-names>F.Z.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hussein</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nahar</surname><given-names>U.J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khongkow</surname><given-names>M.</given-names></name><name name-style="western"><surname>Veitch</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Liposomal Formulations of a Polyleucine&#8211;Antigen Conjugate as Therapeutic Vaccines against Cervical Cancer</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>602</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15020602</pub-id><pub-id pub-id-type="pmid">36839923</pub-id><pub-id pub-id-type="pmcid">PMC9965676</pub-id></element-citation></ref><ref id="B221-pharmaceuticals-16-01054"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buonaguro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tagliamonte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tornesello</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Buonaguro</surname><given-names>F.M.</given-names></name></person-group><article-title>Developments in virus-like particle-based vaccines for infectious diseases and cancer</article-title><source>Expert Rev. Vaccines</source><year>2014</year><volume>10</volume><fpage>1569</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1586/erv.11.135</pub-id><pub-id pub-id-type="pmid">22043956</pub-id></element-citation></ref><ref id="B222-pharmaceuticals-16-01054"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Besson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Laurin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Manches</surname><given-names>O.</given-names></name><name name-style="western"><surname>Aspord</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hannani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fender</surname><given-names>P.</given-names></name></person-group><article-title>Stimulation of the immune system by a tumor antigen-bearing adenovirus-inspired VLP allows control of melanoma growth</article-title><source>Mol. Ther.-Methods Clin. Dev.</source><year>2022</year><volume>28</volume><fpage>76</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2022.12.003</pub-id><pub-id pub-id-type="pmid">36620074</pub-id><pub-id pub-id-type="pmcid">PMC9798141</pub-id></element-citation></ref><ref id="B223-pharmaceuticals-16-01054"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartmaier</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Charo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fabrizio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Albacker</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Pao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chmielecki</surname><given-names>J.</given-names></name></person-group><article-title>Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies</article-title><source>Genome Med.</source><year>2017</year><volume>9</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/s13073-017-0408-2</pub-id><pub-id pub-id-type="pmid">28231819</pub-id><pub-id pub-id-type="pmcid">PMC5324279</pub-id></element-citation></ref><ref id="B224-pharmaceuticals-16-01054"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desrichard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>T.A.</given-names></name></person-group><article-title>Cancer Neoantigens and Applications for Immunotherapy</article-title><source>Clin. Cancer Res.</source><year>2016</year><volume>22</volume><fpage>807</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-3175</pub-id><pub-id pub-id-type="pmid">26515495</pub-id></element-citation></ref><ref id="B225-pharmaceuticals-16-01054"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slingluff</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Slingluff</surname><given-names>C.L.</given-names><suffix>Jr.</suffix></name></person-group><article-title>The Present and Future of Peptide Vaccines for Cancer</article-title><source>Cancer J.</source><year>2011</year><volume>17</volume><fpage>343</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1097/PPO.0b013e318233e5b2</pub-id><pub-id pub-id-type="pmid">21952285</pub-id><pub-id pub-id-type="pmcid">PMC3204371</pub-id></element-citation></ref><ref id="B226-pharmaceuticals-16-01054"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bijker</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Eeden</surname><given-names>S.J.F.v.D.</given-names></name><name name-style="western"><surname>Franken</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Melief</surname><given-names>C.J.M.</given-names></name><name name-style="western"><surname>van der Burg</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Offringa</surname><given-names>R.</given-names></name></person-group><article-title>Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation</article-title><source>Eur. J. Immunol.</source><year>2008</year><volume>38</volume><fpage>1033</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1002/eji.200737995</pub-id><pub-id pub-id-type="pmid">18350546</pub-id></element-citation></ref><ref id="B227-pharmaceuticals-16-01054"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dalvi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iyer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jyothi</surname><given-names>V.G.S.S.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>H.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>S.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>J.</given-names></name></person-group><article-title>Armamentarium of Cryoprotectants in Peptide Vaccines: Mechanistic Insight, Challenges, Opportunities and Future Prospects</article-title><source>Int. J. Pept. Res. Ther.</source><year>2021</year><volume>27</volume><fpage>2965</fpage><lpage>2982</lpage><pub-id pub-id-type="doi">10.1007/s10989-021-10303-y</pub-id><pub-id pub-id-type="pmid">34690621</pub-id><pub-id pub-id-type="pmcid">PMC8524217</pub-id></element-citation></ref><ref id="B228-pharmaceuticals-16-01054"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moldovan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Targoni</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sundararaman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>P.V.</given-names></name></person-group><article-title>How frequently are predicted peptides actually recognized by CD8 cells?</article-title><source>Cancer Immunol. Immunother.</source><year>2016</year><volume>65</volume><fpage>847</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1007/s00262-016-1840-7</pub-id><pub-id pub-id-type="pmid">27108305</pub-id><pub-id pub-id-type="pmcid">PMC4917593</pub-id></element-citation></ref><ref id="B229-pharmaceuticals-16-01054"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tay</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Toh</surname><given-names>H.C.</given-names></name></person-group><article-title>Revisiting the role of CD4+ T cells in cancer immunotherapy&#8212;New insights into old paradigms</article-title><source>Cancer Gene Ther.</source><year>2020</year><volume>28</volume><fpage>5</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/s41417-020-0183-x</pub-id><pub-id pub-id-type="pmid">32457487</pub-id><pub-id pub-id-type="pmcid">PMC7886651</pub-id></element-citation></ref><ref id="B230-pharmaceuticals-16-01054"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdala</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Brossel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Calvinho</surname><given-names>L.</given-names></name><name name-style="western"><surname>Carignano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gazon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gillissen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hamaidia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hoyos</surname><given-names>C.</given-names></name><etal/></person-group><article-title>BLV: Lessons on vaccine development</article-title><source>Retrovirology</source><year>2019</year><volume>16</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1186/s12977-019-0488-8</pub-id><pub-id pub-id-type="pmid">31590667</pub-id><pub-id pub-id-type="pmcid">PMC6781361</pub-id></element-citation></ref><ref id="B231-pharmaceuticals-16-01054"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Diao</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.-M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>S.</given-names></name></person-group><article-title>The progress of peptide vaccine clinical trials in gynecologic oncology</article-title><source>Hum. Vaccines Immunother.</source><year>2022</year><volume>18</volume><fpage>2062982</fpage><pub-id pub-id-type="doi">10.1080/21645515.2022.2062982</pub-id><pub-id pub-id-type="pmcid">PMC9450897</pub-id><pub-id pub-id-type="pmid">35687860</pub-id></element-citation></ref><ref id="B232-pharmaceuticals-16-01054"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skwarczynski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name></person-group><article-title>Peptide-based synthetic vaccines</article-title><source>Chem. Sci.</source><year>2016</year><volume>7</volume><fpage>842</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1039/C5SC03892H</pub-id><pub-id pub-id-type="pmid">28791117</pub-id><pub-id pub-id-type="pmcid">PMC5529997</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-16-01054-f001" orientation="portrait"><label>Figure 1</label><caption><p>Different types of vaccines against female-specific cancers. TSAs (Tumor specific antigens) and TAAs (Tumor associated antigens) are exploited for the development of various types of vaccines such as Cell-based, Nucleic acid-based, Vector-based and Peptide/Protein-based vaccines.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-16-01054-g001.jpg"/></fig><fig position="float" id="pharmaceuticals-16-01054-f002" orientation="portrait"><label>Figure 2</label><caption><p>General features of Peptide vaccines. CCL&#8212;Chemokine (C-C motif) ligand; CXCL&#8212;Chemokine (C-X-C motif) ligand; E1&#8212;Epitope 1, E2&#8212;Epitope 2, E3&#8212;Epitope 3, IL&#8212;Interleukin; IFN&#8212;Interferon; NK&#8212;Natural killer; TGF&#8212;Tumor growth factor; Th&#8212;helper T cells; TNF&#8212;Tumor necrosis factor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-16-01054-g002.jpg"/></fig><fig position="float" id="pharmaceuticals-16-01054-f003" orientation="portrait"><label>Figure 3</label><caption><p>Study design for development of peptide vaccine. MD&#8212;Molecular dynamics, NP&#8212;Nanoparticle, VLP&#8212;Virus like particles.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-16-01054-g003.jpg"/></fig><table-wrap position="float" id="pharmaceuticals-16-01054-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceuticals-16-01054-t001_Table 1</object-id><label>Table 1</label><caption><p>Various aspects of female-specific cancers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Type of Cancer</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Incidence Rate *** [<xref rid="B18-pharmaceuticals-16-01054" ref-type="bibr">18</xref>]<break/>(%)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Mortality Rate *** [<xref rid="B18-pharmaceuticals-16-01054" ref-type="bibr">18</xref>]<break/>(%)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Causative Factor/Agent</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Treatment Strategy ** [<xref rid="B19-pharmaceuticals-16-01054" ref-type="bibr">19</xref>]</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Post Treatment 5-Year Survival Rate. [<xref rid="B20-pharmaceuticals-16-01054" ref-type="bibr">20</xref>]</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pathogen</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gene Mutation</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Localized Disease * (%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Regional Spread * (%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Distant Metastasis * (%)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human Papilloma virus (HPV), Mouse Mammary Tumour Virus(MMTV) Epstein-Barr virus (EBV) [<xref rid="B21-pharmaceuticals-16-01054" ref-type="bibr">21</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA1, BRCA2, TP53, PTEN, STK11, CDH1, PALB2, CHECK2, ATM, NBN, and NF1. [<xref rid="B22-pharmaceuticals-16-01054" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceuticals-16-01054" ref-type="bibr">23</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surgery, Radiation therapy, Endocrine therapy Chemotherapy, Targeted therapy, Immunotherapy.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cervical Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sneathia, Pseudomonas, Ureaplasma urealyticum, Ureaplasma parvum, Chlamydia trachomatis, Trichomonas vaginalis, Atopobium HPV [<xref rid="B24-pharmaceuticals-16-01054" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGFR, KRAS and PIK3CA [<xref rid="B25-pharmaceuticals-16-01054" ref-type="bibr">25</xref>] CASP8, TMS1/ASC [<xref rid="B26-pharmaceuticals-16-01054" ref-type="bibr">26</xref>]<break/>ERBB3 [<xref rid="B27-pharmaceuticals-16-01054" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surgery, Chemotherapy, Targeted therapy, Immunotherapy.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endometrial Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Porphyromonas, Atopobium vaginae, Pelomonas, Prevotella. [<xref rid="B24-pharmaceuticals-16-01054" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PIK3CA, PIK3R1, PTEN, KRAS, FGFR2, ARID1A (BAF250a), and CTNNB1 (&#946;-catenin), MLH1, TP53 (p53), PPP2R1A, HER-2/ERBB2, PIK3CA, and PTEN [<xref rid="B24-pharmaceuticals-16-01054" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surgery, Chemotherapy, Targeted therapy, Hormone therapy, Radiation therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proteobacteria/Firmicutes., HPV [<xref rid="B24-pharmaceuticals-16-01054" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TP53, BARD1, CHEK2, RAD51, and PALB2, BRCA1 and BRCA2 [<xref rid="B28-pharmaceuticals-16-01054" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surgery, Chemotherapy, Targeted therapy, Immunotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaginal cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proteobacteria and Firmicutes, HPV [<xref rid="B24-pharmaceuticals-16-01054" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TP53, KRAS, RASA1, KMT2D, and JAK2 [<xref rid="B29-pharmaceuticals-16-01054" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surgery, Chemotherapy, Radiation therapy.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vulvar cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV [<xref rid="B30-pharmaceuticals-16-01054" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PIK3CA, FBXW7, HRAS, FGFR3, STK11, AKT1, SMAD4, FLT3, JAK3, GNAQ, and PTEN [<xref rid="B31-pharmaceuticals-16-01054" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surgery, Chemotherapy, Radiation therapy, Targeted drug therapy, Immunotherapy.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td></tr></tbody></table><table-wrap-foot><fn><p>*** GLOBOCAN 2020 crude rate in percentage (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://gco.iarc.fr/today/home">https://gco.iarc.fr/today/home</uri> (accessed on 7 April 2023)).** Treatment strategies as per <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.mayoclinic.org">www.mayoclinic.org</uri> (accessed on 7 April 2023) <bold>* Localized disease:</bold> The cancer is only in a specific part, without spreading to lymph nodes or nearby tissues. This includes stage I cancers, <bold>Regional spread:</bold> The cancer has spread to nearby lymph nodes or tissues, but has not spread to distant organs. This includes mainly stage II, III and IVA cancers, <bold>Distant metastasis:</bold> The cancer has spread to distant parts of the body such as the lungs, liver or bones. This includes stage IVB cancers. (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cancer.org">https://www.cancer.org</uri> (accessed on 7 April 2023)).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-16-01054-t002" orientation="portrait"><object-id pub-id-type="pii">pharmaceuticals-16-01054-t002_Table 2</object-id><label>Table 2</label><caption><p>HER2 based peptide vaccines for breast cancer HER2/neu-derived GP2 and GP2&#8211;P4.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Peptide</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mode of Administration</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapeutic Strategy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immune Response</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase of Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase of Clinical Trial</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Sample</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three peptides of HER2/neu-(i) ECD; p42, p98 and p328 (ii) ICD p776, p927 and p1166 (iii) Peptides from both domains; p369, p688 and p971</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GM-CSF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intradermal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed vaccine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER-2/neu IgG specific antibody responses &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage III breast and ovarian cancer<break/>N = 38,<break/>Sub group: <list list-type="simple"><list-item><label>-</label><p>breast cancer Stage III (n = 13) or IV(n = 18), ovarian (n = 5), or non small cell lung cancer (n = 2).</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-pharmaceuticals-16-01054" ref-type="bibr">82</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E75 peptide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GM-CSF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intradermal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clonal expansion of E75-specific CD8+ T cells &#8593;<break/>NPBC recurrence&#8595;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two-Stage Safety Trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-palpable breast cancer (NPBC)<break/>N = 53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-pharmaceuticals-16-01054" ref-type="bibr">83</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GP2 peptide (HER2/neu, 654&#8211;662)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GM-CSF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intradermal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">in vivo and ex vitro immune responses specific to GP2 &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disease free lymph node-negative, (HLA)-A2+ breast cancer<break/>N = 18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-pharmaceuticals-16-01054" ref-type="bibr">84</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31 pooled peptide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Incomplete Freund&#8217;s adjuvant (Montanide ISA51)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In combination with chemotherapy, hormonal therapy and radiotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTL and/or IgG responses &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trials</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Triple-negative breast cancer (TNBC)<break/>N = 79<break/>Sub group: <list list-type="simple"><list-item><label>-</label><p>mrTNBC group (n&#8201; = &#8201;18), HER2-negative group (n&#8201; = &#8201;41) and HER2-positive group (n&#8201; = &#8201;18)</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B85-pharmaceuticals-16-01054" ref-type="bibr">85</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Triple peptide-MUC1 (159&#8211;167),CEA (605&#8211;613) and ErbB2 (368&#8211;377)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Montanide ISA 51</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multi peptide vaccine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN-&#947; producing CD8+ T cell response &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I/II</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High-risk disease-free ovarian and breast cancer<break/>N = 14<break/>Sub group: <list list-type="simple"><list-item><label>-</label><p>(ovarian n = 7 and breast n= 7).</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B86-pharmaceuticals-16-01054" ref-type="bibr">86</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 MHC class I-restricted peptides from MAGE-A1, &#8722;A3, and -A10, CEA, NY-ESO-1, and HER2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLR3 agonist, poly-ICLC and peptide derived from tetanus toxoid</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular and intradermal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptide specific CD8+ T cell response &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pilot study</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer patients with stage IB-IV resected.<break/>N = 12<break/>Sub group: <list list-type="simple"><list-item><label>-</label><p>(Estrogen receptor positive disease, n = 5 and HER2 amplified n = 5)</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B87-pharmaceuticals-16-01054" ref-type="bibr">87</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AE37 and GP2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GM-CSF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intradermal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AE37 specific CD4+ T cell response and GP2 specific CD8+ T cell response &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer with disease-free node positive and high-risk node negative patients<break/>N= 456</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-pharmaceuticals-16-01054" ref-type="bibr">88</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed 19-peptide vaccine derived from 11 different TAAs including EGFR</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Freund&#8217;s adjuvant (Montanide ISA-51VG; Seppic)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptide specific Ig &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced metastatic triple-negative breast cancer (mTNBC)<break/>N = 14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-pharmaceuticals-16-01054" ref-type="bibr">89</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2/neu-derived GP2<break/>and<break/>GP2&#8211;P4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KLH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">monotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Humoral immune response&#8212; IFN-&#947;, IL-2, IL-4 and Th1 and Th2 &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical study</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TUBO breast cancer model of BALB/c mice, overexpressing HER2/neu oncogene.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-pharmaceuticals-16-01054" ref-type="bibr">45</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2/neu-derived peptide AE36</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CpG-ODN</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synthesis of cytokines &#8593;<break/>CD8+ and CD4+ T cell responses &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical study</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TUBO breast cancer model of BALB/c mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-pharmaceuticals-16-01054" ref-type="bibr">90</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>AE37, AE36, E75 and GP2&#8212;immunogenic peptides from the HER2/neu; CpG-ODN&#8212;Oligodeoxynucleotides of cytosine and guanine; CTL&#8212;Cytotoxic T lymphocyte; ECD&#8212;Extracellular domain; EGFR&#8212;Epidermal growth factor receptor; GM-CSF&#8212;Granulocyte macrophage colony stimulating factor; ICD&#8212;Intracellular domain; IFN-&#947;&#8212;Interferon gamma; IgG&#8212;Immunoglobulin G; IL- Interleukins; KLH&#8212;keyhole limpet hemocyanin; MHC&#8212;Major histocompatibility complex; NPBC&#8212;Node-positive breast cancer; Poly-ICLC&#8212;Polyinosinic-polycytidylic acid; TAAs&#8212;Tumor-associated antigens; Th&#8212;T helper cells; TLR&#8212;Toll-like receptor; TNBC&#8212;Triple-negative breast cancer; TUBO&#8212;cells lines cloned from a BALB/c mouse mammary carcinoma. (&#8216;N&#8217; represents the size of the study sample and the &#8216;n&#8217; represents the size of the subgroup within the main study group). &#8593;: increased; &#8595;: decreased.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-16-01054-t003" orientation="portrait"><object-id pub-id-type="pii">pharmaceuticals-16-01054-t003_Table 3</object-id><label>Table 3</label><caption><p>Non-HER2 based peptide vaccines for female-specific cancers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Peptide</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mode of Administration</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapeutic Strategy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immune Response</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase of Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase of Clinical Trial</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Sample</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER-2/neu-derived E75/MUC1-derived M1.2 peptide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Autologous DCs pulsed with HER-2/neu&#8211; or MUC1-derived peptides</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CEA- and MAGE-3 peptide-specific T-cell response &#8593;<break/>MUC1-specific T lymphocytes &#8593;<break/>MAGE-3- and CEA- peptide specific CD8+ T cell response &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I/II</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic breast cancer expressing HLA-A2 and HER-2/neu or MUC1<break/>N = 7 breast cancer and<break/>N = 3<break/>ovarian cancers </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-pharmaceuticals-16-01054" ref-type="bibr">95</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MUC1 lipopeptide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MUC1-specific CTL response&#8593;<break/>T cells expressing intracellular IFN-&#947; &#8593;<break/>T cells reactive with H-2Db/MUC1 tetramer &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MUC1 Transgenic mice </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B101-pharmaceuticals-16-01054" ref-type="bibr">101</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p53- synthetic long peptide (SLP)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Montanide ISA51</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN-&#947; producing T-cells &#8593;<break/>p53-specific Th1 and Th2 CD4+ T-cell responses &#8593;<break/>Th1 and Th2 cytokines &#8593;<break/>Circulating p53-specific T-cells &#8595;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epithelial ovarian cancer<break/>N = 18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-pharmaceuticals-16-01054" ref-type="bibr">102</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p53 SLP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Montanide ISA51</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunization preceded by Cyclophosphamide administration </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p53-specific T cells &#8593;<break/>Th1 and Th2 cytokines &#8593;<break/>p53-specific IFN-&#947;-producing T cells &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epithelial ovarian cancer<break/>N = 19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-pharmaceuticals-16-01054" ref-type="bibr">103</xref>]<break/></td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Overlapping long peptides (OLP) from cancer-testis antigen NY-ESO-1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Montanide-ISA-51 in Poly-polyinosinic-polycytidylic acid (ICLC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NY-ESO-1&#8211;specific antibody &#8593; <break/>NY-ESO-1&#8211;specific CD8+ T cells &#8593;<break/>NY-ESO-1&#8211;specific CD4+ T cells &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced ovarian cancer<break/>N = 11 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-pharmaceuticals-16-01054" ref-type="bibr">104</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p53-SLP<sup>&#174;</sup> vaccine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Montanide ISA51, </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccination followed by chemotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p53-specific IFN-&#947; &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epithelial ovarian cancer<break/>N = 17 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-pharmaceuticals-16-01054" ref-type="bibr">105</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p53 peptide </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Montanide and GM-CSF </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous<break/>Intravenous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptide admixed with Montanide and GM-CSF<break/>Peptide-pulsed dendritic cells</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p53 specific immune response &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian cancer<break/>N = 13 (Subcutaneous administration)<break/>N = 6 (Intravenous administration)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B106-pharmaceuticals-16-01054" ref-type="bibr">106</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wilms&#8217; tumor 1 (WT1) peptide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Montanide ISA 51 </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intradermal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WT1 peptide-specific delayed-type hypersensitivity (DTH) reaction &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian carcinoma N = 24<break/>Cervical carcinoma N = 11<break/>Uterine sarcoma <break/>N = 5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B107-pharmaceuticals-16-01054" ref-type="bibr">107</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer-testis (CT) peptide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination with 5 CT peptides</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT peptide- specific CTLs &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HLA-A24-positive patients with metastatic and advanced breast cancer.<break/>N = 9 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B108-pharmaceuticals-16-01054" ref-type="bibr">108</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Personalized peptide vaccine (PPV) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Montanide ISA51VG</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PPV monotherapy/PPV in combination with chemotherapy </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptide specific IgG responses &#8593;<break/>Peptide specific CTL response &#8593;<break/>Interleukin (IL)-6, C Reactive Protein (CRP) and Serum amyloid A (SAA) levels &#8593; </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recurrent ovarian cancer <break/>N = 42 <break/>Sub group:<break/>(Platinum-sensitive n = 17 and platinum resistant n = 25)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B109-pharmaceuticals-16-01054" ref-type="bibr">109</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WT1 peptide/MUC1 long peptide/</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OK-432, </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Intradermal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chemotherapy followed by DC-based immunotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WT1-specific CTL &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recurrent ovarian cancer (ROC)<break/>N = 56 <break/>Sub-group: (Serous cystadeno carcinoma n = 37, Endometrioid adenocarcinoma n = 6, clear cell adenocarcinoma n = 5, other cancers n = 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B110-pharmaceuticals-16-01054" ref-type="bibr">110</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Five HLA-A2402-restricted epitope peptides from KOC1, TTK, URLC10, DEPDC1 and MPHOSPH1 </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Incomplete Freund&#8217;s.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Subcutaneous </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination therapy with Cyclophosphamide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T cell response &#8593;<break/>Overall survival &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cervical cancer and other solid tumors <break/>N = 18 <break/>Subgroup: (cervical cancer n = 1, other solid tumors n = 17)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B111-pharmaceuticals-16-01054" ref-type="bibr">111</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Folate receptor alpha </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GM-CSF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">intradermal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination therapy with low-dose Cyclophosphamide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T cell response &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage II-III breast or stage II-IV ovarian cancer<break/>N = 22 <break/>Subgroup: (breast cancer n = 8 ovarian cancer n = 14)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B112-pharmaceuticals-16-01054" ref-type="bibr">112</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Q&#946;-MUC1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Incomplete Freund&#8217;s adjuvant</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IgG antibodies &#8593;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical study</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MUC1.Tg mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B113-pharmaceuticals-16-01054" ref-type="bibr">113</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RNF43 peptide pulsed DCs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination therapy with low-dose Cyclophosphamide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum IL-6 level &#8593;<break/>IFN&#947;-producing, tumor-reactive CD8+ T cells &#8593;<break/>Treg Cells &#8595;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cervical cancer and other solid tumors<break/>N = 10<break/>Subgroup: (cervical cancer n = 1 other solid tumors n = 9).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B114-pharmaceuticals-16-01054" ref-type="bibr">114</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptides derived from FOXM1, MELK, Holiday Junction Recognition protein VEGF receptors 1 and 2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Incomplete Freund&#8217;s adjuvant </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FOXM1 and MELK specific T-cell responses &#8593; </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recurrent or persistent cervical cancer<break/>N = 21 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B115-pharmaceuticals-16-01054" ref-type="bibr">115</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DC vaccine pulsed with personalized peptides (PEP-DC) or with tumor lysate (OC-DC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranodal </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carboplatin/Paclitaxel adjuvant chemotherapy; Immunomodulation with low dose Cyclophosphamide </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proposed epitope spreading, increase in pre-existing NeoAgs-specific T cell clones and immune response against patient-specific antigens</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I/II</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced high-grade ovarian serous carcinoma<break/>N = 16 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-pharmaceuticals-16-01054" ref-type="bibr">116</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Folate-binding protein- derived E39 peptide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GM-CSF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intradermal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disease free survival&#8593; </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I/IIa</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian, endometria, fallopian, or peritoneal cancer<break/>N = 51 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B117-pharmaceuticals-16-01054" ref-type="bibr">117</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MUC1 </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLR7 agonists </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intraperitoneal </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Monotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytokine production &#8593;<break/>CD3+/CD8+ T-cells &#8593;<break/>Antibody titre &#8593;<break/>Tumor weight &#8595;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical study</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4T1 mouse breast cancer cells, MCF-7 human breast cancer cells, MB231 human breast cancer cells<break/>BALB/c mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-pharmaceuticals-16-01054" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MHC class I restricted neoantigen peptide-loaded DC vaccine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranodal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neoantigen-specific T cell responses &#8593;<break/>CA-125 levels &#8595;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chemorefractory ovarian cancer and malignant ascites<break/>N = 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B119-pharmaceuticals-16-01054" ref-type="bibr">119</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSP90 derived MHC class II epitopes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complete Freund&#8217;s adjuvant </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combined with STING agonist and/or anti CTLA-4 antibody</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSP90-specific IgG responses &#8593; <break/>Th1 immune response &#8593;<break/>CD8+ T cells response &#8593;<break/>T reg cells &#8593; </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical study</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer murine model </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B120-pharmaceuticals-16-01054" ref-type="bibr">120</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>CA-125&#8212;Cancer antigen 125; CEA&#8212;carcinoembryonic antigen peptide; CRP&#8212;C-reactive protein; CTLA-4&#8212;cytotoxic T lymphocyte-associated antigen-4; CTLs&#8212;cytotoxic T lymphocytes; DC&#8212;Dendritic cell; DTH&#8212;Delayed type hypersensitivity; ER&#8212;Estrogen receptor; E75 and GP2&#8212;immunogenic peptides from the HER2/neu; GM-CSF&#8212;Granulocyte macrophage colony stimulating factor; HER-2&#8212;human epidermal growth factor receptor 2; HLA&#8212;Human leukocyte antigen; HSP&#8212;Heat shock protein; IFN&#947;&#8212;Interferon gamma; Ig&#8212;Immunoglobulin; IL&#8212;Interleukins; MAGE&#8212;Melanoma Antigen Gene; MUC1&#8212;Mucin short variant S1; OLP&#8212;Overlapping peptide; PEP-DC&#8212;DCs pulsed with up to ten peptides; RNF&#8212;Ring finger protein; ROC&#8212;recurrent ovarian cancer; SLP&#8212;synthetic long peptide; STING&#8212;stimulator of interferon genes; Th&#8212;T helper cells; TLR&#8212;Toll-like receptor; wt p53&#8212;Wild type p53; WT1&#8212;Wilms&#8217; tumor 1. &#8593;: increased; &#8595;: decreased.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-16-01054-t004" orientation="portrait"><object-id pub-id-type="pii">pharmaceuticals-16-01054-t004_Table 4</object-id><label>Table 4</label><caption><p>HPV prophylactic peptide vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Commercial Name of Vaccine</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Vaccine Composition</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Effective against Which Type of Cancer</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Acts against Which Strain</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Dosage</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Current Status of the Vaccine</th></tr><tr><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptides</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other Components</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gardasil</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV&#8212;6L1, 11L1, 16L1, 18 L1 [<xref rid="B137-pharmaceuticals-16-01054" ref-type="bibr">137</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminum (Amorphous Aluminum Hydroxyphosphate Sulfate), [<xref rid="B137-pharmaceuticals-16-01054" ref-type="bibr">137</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium chloride, L-histidine, polysorbate 80, sodium borate [<xref rid="B137-pharmaceuticals-16-01054" ref-type="bibr">137</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cervical, vulval, vaginal, and anal cancers and their associated precursor lesions (and a subset of head and neck cancers) Genital warts and laryngeal papillomas [<xref rid="B138-pharmaceuticals-16-01054" ref-type="bibr">138</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV types 6, 11, 16, 18 [<xref rid="B139-pharmaceuticals-16-01054" ref-type="bibr">139</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 doses of 0.5-mL: intramuscularly at 0, 2 months, 6 months [<xref rid="B139-pharmaceuticals-16-01054" ref-type="bibr">139</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Licensed, Merck and Co. [<xref rid="B137-pharmaceuticals-16-01054" ref-type="bibr">137</xref>,<xref rid="B140-pharmaceuticals-16-01054" ref-type="bibr">140</xref>,<xref rid="B141-pharmaceuticals-16-01054" ref-type="bibr">141</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cervarix</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV&#8212;16 L1, 18 L1. [<xref rid="B142-pharmaceuticals-16-01054" ref-type="bibr">142</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AlSO4 (aluminium salt + MPL (3-O-desacyl-4&#8242;-monophosphoryl lipid A) [<xref rid="B142-pharmaceuticals-16-01054" ref-type="bibr">142</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium chloride and sodium dihydrogen phosphate dihydrate [<xref rid="B142-pharmaceuticals-16-01054" ref-type="bibr">142</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cervical, vulval, vaginal, and anal cancers and their associated precursor lesions (and a subset of head and neck cancers) [<xref rid="B138-pharmaceuticals-16-01054" ref-type="bibr">138</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV 16 and 18 [<xref rid="B142-pharmaceuticals-16-01054" ref-type="bibr">142</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 doses of 0.5 mL, intramuscular injections at 0, 1, and 6 [<xref rid="B138-pharmaceuticals-16-01054" ref-type="bibr">138</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Licensed, GlaxoSmithKline [<xref rid="B140-pharmaceuticals-16-01054" ref-type="bibr">140</xref>,<xref rid="B141-pharmaceuticals-16-01054" ref-type="bibr">141</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gardasil 9</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV&#8212;6 L1, 11 L1, 16 L1, 18 L1, 31 L1, 33 L1, 45 L1, 52 L1, 58 L1 [<xref rid="B143-pharmaceuticals-16-01054" ref-type="bibr">143</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminum (provided as AAHS), [<xref rid="B143-pharmaceuticals-16-01054" ref-type="bibr">143</xref>] </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium chloride, L-histidine, polysorbate 80, sodium borate [<xref rid="B143-pharmaceuticals-16-01054" ref-type="bibr">143</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cervical, vulvar, vaginal, anal, oropharyngeal and Genital warts (condyloma acuminata) [<xref rid="B143-pharmaceuticals-16-01054" ref-type="bibr">143</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV-6, 11,16,18,31, 33,45,52, 58 [<xref rid="B144-pharmaceuticals-16-01054" ref-type="bibr">144</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 or 3 doses Intramuscularly, depending on age at initiation [<xref rid="B144-pharmaceuticals-16-01054" ref-type="bibr">144</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Licensed Merck and Co. [<xref rid="B140-pharmaceuticals-16-01054" ref-type="bibr">140</xref>,<xref rid="B141-pharmaceuticals-16-01054" ref-type="bibr">141</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cecolin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV&#8212;16 L1 18 L1 [<xref rid="B145-pharmaceuticals-16-01054" ref-type="bibr">145</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminum hydroxide [<xref rid="B145-pharmaceuticals-16-01054" ref-type="bibr">145</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phosphate buffered saline. [<xref rid="B145-pharmaceuticals-16-01054" ref-type="bibr">145</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cervical cancer, CIN grade I-III and adenocarcinoma in situ (AIS). [<xref rid="B145-pharmaceuticals-16-01054" ref-type="bibr">145</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV 16/18 [<xref rid="B140-pharmaceuticals-16-01054" ref-type="bibr">140</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-dose Intramuscularly for girls aged 9&#8211;14 years, 3-dose Intramuscularly for young women [<xref rid="B146-pharmaceuticals-16-01054" ref-type="bibr">146</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Licensed in China. WHO prequalification Status: Current [<xref rid="B141-pharmaceuticals-16-01054" ref-type="bibr">141</xref>,<xref rid="B144-pharmaceuticals-16-01054" ref-type="bibr">144</xref>,<xref rid="B147-pharmaceuticals-16-01054" ref-type="bibr">147</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EG-HPV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV&#8212;16 L1,18L1 [<xref rid="B148-pharmaceuticals-16-01054" ref-type="bibr">148</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CIA06 (Aluminum hydroxide + dLOS (CIA05) [<xref rid="B148-pharmaceuticals-16-01054" ref-type="bibr">148</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cervical cancer [<xref rid="B148-pharmaceuticals-16-01054" ref-type="bibr">148</xref>,<xref rid="B149-pharmaceuticals-16-01054" ref-type="bibr">149</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV type 16 and type 18 [<xref rid="B148-pharmaceuticals-16-01054" ref-type="bibr">148</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 doses at 0, 1, 6 [<xref rid="B148-pharmaceuticals-16-01054" ref-type="bibr">148</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical phase I trial, Eyegene Inc. Korea [<xref rid="B149-pharmaceuticals-16-01054" ref-type="bibr">149</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>AAHS&#8212;Amorphous aluminum hydroxyphosphate sulfate; CIN&#8212;cervical squamous intraepithelial neoplasia; dLOS (CIA06)&#8212;A novel proprietary immune adjuvant; EG-HPV&#8212;Combination of HPV 16 and 18 L1 VLP; HPV&#8212;Human papillomavirus; L1&#8212;Major capsid protein. Immunoinformatics and structural vaccinology approaches have led to the designing of a prophylactic HPV vaccine for protection against cervical cancer. The vaccine construct consisted of two immunodominant epitopes from L2 proteins of HPV, flagellin (TLR5 agonist), a short synthetic TLR4 agonist and T-helper agonists (PADRE and TpD) joined by appropriate linkers. The designed vaccine was suggested to elicit humoral and cellular immune responses and offer protection against HPV [<xref rid="B150-pharmaceuticals-16-01054" ref-type="bibr">150</xref>]. Efficacy of the vaccine was further established by in vivo experiments which demonstrated induction of IgG, Th1 (IFN-&#947;, IL-2) and Th2 (IL-4, IL-5, IL-10) type cytokines and elevated levels of IL-2 and IL-5 in vaccinated mice [<xref rid="B151-pharmaceuticals-16-01054" ref-type="bibr">151</xref>].</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>